Regulation of gene expression and survival in cellular stress. by Janjua, S.
REFERENCE ONLY 
U N IV ERSITY  O F LO N D O N  T H E S IS
Degree fW o  Year Name of Author 4
COPYRIGHT
This is a thesis accepted for a Higher Degree of the University of London. It is an 
unpublished typescript and the copyright is held by the author. All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
LOANS
Theses may not be lent to individuals, but the Senate House Library may lend a copy 
to approved libraries within the United Kingdom, for consultation solely on the 
premises of those libraries. Application should be made to: Inter-Library Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University of London theses may not be reproduced without explicit written 
permission from the Senate House Library. Enquiries should be addressed to the 
Theses Section of the Library. Regulations concerning reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A. Before 1962. Permission granted only upon the prior written consent of the
author. (The Senate House Library will provide addresses where possible).
B. 1962- 1974. In many cases the author has agreed to permit copying upon
completion of a Copyright Declaration.
C. 1975 - 1988. Most theses may be copied upon completion of a Copyright
Declaration.
D. 1989 onwards. Most theses may be copied.
This thesis comes within category D.
t ) c
n This copy has been deposited in the Library of _____
□ This copy has been deposited in the Senate House Library, Senate House, Malet Street, London WC1E 7HU.
C:\Documents and Settings\lproctor\Local SettingsNTemporary Internet Files\OLK8\Copyright - thesis (2).doc

Regulation of Gene Expression and Survival in 
Cellular Stress
A thesis submitted to the University of London
By Sadia Janjua
Institute of Child Health 
University College London
In fulfdment of the requirements for the degree of Doctor of Philosophy
September 2005
UMI Number: U592065
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592065
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
All organisms have developed regulated mechanisms to maintain homeostasis. At 
the cellular level, this normal functioning of cells is regulated by expression of 
regulatory genes that are required for normal cell function. Most cells in 
multicellular organisms are capable of altering gene expression in response to 
extracellular signals such as elevated temperature, ischaemia/reperfusion, 
inflammation, infection, cytokines, and amino acid analogues.
In this thesis the effects of cellular stresses in the form of elevated temperature or 
simulated ischaemia have been investigated. Previous studies show that elevated 
temperature or simulated ischaemia can induce expression of heat shock proteins 
(Hsps) in order to prevent misfolding of cellular proteins. Moreover, it has been 
shown that the stress responsive transcription factor heat shock factor-1 (HSF-1) is 
phosphorylated and translocates to the nucleus to bind to heat shock elements 
within hsp gene promoters. In addition, HSF-1 can interact with other 
transcription factors such as the signal transducer and activator of transcription-1 
(STAT-1), which is a latent cytoplasmic transcription factor activated in response 
to regulatory cytokines such as interferon y (IFNy).
Preliminary data shows that elevated temperature can induce expression of Hsp90 
in the STAT-1 deficient cell line (U3A) treated with IFNa (activates STAT-1 and 
STAT-2), but reduces the levels of Hsp90 expression in the U3A cell line treated 
with IFNa and IFNyin combination. These findings suggest that there may be 
competition between STAT-1 homodimers and STAT-l/STAT-2 heterodimers 
and will require further investigation
The STAT-1 transcription factor has previously been demonstrated to play a role in 
stress- induced apoptosis. In this study, STAT-1 is shown to be required for 
stress-induced apoptosis using the STAT-1 deficient U3A cell line. Cells lacking 
STAT-1 show reduced cell death/apoptosis in response to elevated temperature or 
simulated ischaemia. However, expression of STAT-1 in these cells restores
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sensitivity to stress-induced death. The C-terminal domain alone o f STAT-1 is 
also able to enhance stress-induced cell death, and may be acting via a novel co­
activator-type mechanism.
Many protective agents have been identified that are able to reduce cell death due 
to ischaemic injury. Cardiotrophin-1 (CT-1), a member of the IL-6 family of 
cytokines, has been shown to protect rat neonatal cardiomyocytes subjected to 
simulated ischaemia via the p42/p44 MAPkinase and PI-3 Kinase pathways. In 
addition, the unrelated peptide urocortin (Ucn) also protects cardiomyocytes via 
the same pathway as CT-1 in response to simulated ischaemia and both CT-1 and 
Ucn induce Hsp expression. In this study, Ucn has been shown to be able to 
induce enhanced expression of CT-1 at mRNA and protein levels in response to 
simulated ischaemia. Moreover, the effect is mediated by activation of the CT-1 
promoter and requires the transcription factor C/EBPp /NFIL-6. This finding 
indicates that a common pathway exists for these two protective agents with Ucn 
inducing CT-1 synthesis.
Overall, the work performed indicates that multiple interacting pathways modulate 
the cellular stress response with either protective or damaging effects.
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Aims
The aim of this thesis is to provide an insight into various mechanisms in different 
cell types in which protective or damaging effects are induced in response to 
stresses including heat shock, hypoxia, and ischaemia.
Firstly, the STAT-1 transcription factor will be investigated for its role in stress- 
induced apoptosis. This study will demonstrate that the C-terminal activation 
domain is required for stress-induced apoptosis. This would show that STAT-1 
can be targeted in order to protect cells from stress.
In the second study, STAT-1 will be investigated for its role in Hsp induction. 
This study will demonstrate that STAT-1 is able to activate the Hsp90 promoter in 
response to heat shock.
In the third study, the aim is to investigate whether the cardioprotective agent Ucn 
can induce the expression of CT-1 at the promoter and protein levels. Both these 
factors induce hsp expression. This study would demonstrate that Ucn is able to 
induce direct expression of CT-1 in response to hypoxic stress, and that activation 
of the CT-1 promoter is mediated in part by the C/EPBptranscription factor.
One of the purposes of the study is to investigate whether urocortin, a protective 
agent, can enhance the expression of the CT-1 promoter and the possible pathway 
of activation that may be involved since both these different molecules signal via a 
common pathway and protection by Ucn requires protein synthesis whereas CT-1 
does not.
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CHAPTER 1. 
INTRODUCTION
10
INTRODUCTION
1.0 Signal Transduction and Control of Gene Expression
The ability of organisms to respond to the extra-cellular environment requires highly 
sophisticated responses at the intracellular level, and is maintained by the control of gene 
expression as well as by signal transduction. Moreover, the control of gene expression, 
when it occurs, where and how, is critically dependent on signal transduction by extra­
cellular molecules and the intensity of the signal, which may tip the cell towards death or 
survival.
In eukaryotes, RNA polymerase II initiates the start of the transcription process to produce 
messenger RNAs (mRNAs). However, before RNA polymerase initiates, other proteins 
are recruited such as general transcription factors, co-activators, chromatin remodellers, 
histone acetylases, kinases, deacetylases and methylases (Malik and Roeder, 2000; Naar et 
al., 2001). These proteins are crucial components of the transcription initiation complex 
and are required in addition to RNA polymerase to produce the primary messenger RNA 
transcript.
Genes are expressed at widely varying levels. There are two modes of expression of a 
gene. Constitutively expressed genes (housekeeping genes) are expressed at all times and 
the corresponding protein is essential for all cells. Alternatively, some genes are expressed 
in specific tissues, or in response to a particular stimulus, and are not required by all cells.
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Regulation of these genes is highly dependent on a large number of proteins, known as 
transcription factors, which have a DNA binding domain to recognize and bind gene 
specific sequences directly, and a transcriptional activation domain. Transcription factors 
also control the transcription of house keeping genes also, but do not require regulation.
Subsequently, co-activator proteins are recruited by these site-specific transcription factors 
to initiate gene-specific transcription. As many as 2000 proteins may be involved in such 
transcriptional responses, and having such a large variety of proteins means that the 
activation of genes is specific and can be activated at the required time. It has been shown 
in various studies that more than six proteins can act in concert to activate specific 
transcription of a gene, and can act on one enhancer to regulate gene specific transcription 
(Grosschedl, 1995).
Transcription of a gene can be repressed by factors either indirectly or directly. Indirect 
repression involves an inhibitor interfering with the action of an activator. Inhibition of an 
activator can occur in several ways: (1) Inhibition of an activator can occur by the inhibitor 
masking the DNA binding site of the activator. The negatively acting factor effectively 
inhibits gene activation, which can be achieved by the negatively acting factor binding to 
the same site as the positively acting factor but failing to activate transcription.
The inhibitor can also act indirectly by reorganizing the nucleosome arrangement of the 
chromatin, therefore the binding site is masked by a nucleosome, which effectively 
represses gene activation; (2) Activator binding can also be inhibited by formation of a
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non-DNA-binding complex with the activating factor; (3) Inhibition of the activator can 
be achieved by quenching the activator. This involves the inhibitor interfering with 
transcriptional activation by a DNA bound factor and neutralizing the effect of the 
activator (4) The action of the repressor can promote the degradation of the activator 
following repressor binding.
An inhibitory effect of a repressor can also inhibit transcription directly by interacting with 
the basal transcription complex to reduce its activity. Some factors that are direct 
repressors have been shown to bind specific DNA binding sites within their target genes 
and reduce the activity of the basal transcriptional complex. Inhibitory factors can also 
bind to the basal complex itself by protein-protein interaction therefore interfering with its 
activity or assembly (Latchman, 1998; 2001).
A large group of positive-acting eukaryotic transcription factors have recently been 
identified and can be either constitutive nuclear factors or regulatory factors depending 
upon their function. A general tree diagram can be seen in figure 1.0
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Regulatory
Signal dependent
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Fitzure 1.0 Classification of Positive Acting Transcription Factors
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1.0.1 Constitutive Transcription Factors
The constitutively active nuclear factors for example, CCA AT binding protein, Spl, and 
NF1 are DNA binding proteins and are present in the nucleus all the time (Chodosh et al., 
1988; Briggs et al., 1986; Johnson and McKnight, 1989; Rosenfeld and Kelly, 1986) 
These factors are known to facilitate transcription of house keeping genes including actin, 
tubulin, ubiquitous metabolic enzymes and GAPDH (Brivanlou and Darnell, 2002). These 
binding proteins can also participate in enhancing transcription of genes by acting in 
concert with regulatory transcription factors (Johnson and McKnight, 1989; Rosenfeld and 
Kelly, 1986).
1.0.2 Regulatory Transcription Factors
Regulatory transcription factors encompass two classes of transcription factors: 
developmentally active and signal dependent transcription factors respectively. The 
developmental class of transcription factors includes MyoD (required for muscle 
differentiation) (Yun and Wold, 1996). These factors are normally expressed in a cell 
type-specific manner, and require extra-cellular signals to be activated themselves, after 
which they enter the nucleus without being post-translationally modified (Xanthopoulos et 
al., 1989; Johnson and Nusslein- Volhard, 1992).
The regulatory transcription factors play roles in development, or can be activated in a 
signal dependent manner. The signal dependent transcription factors are usually present in 
the cells in inactive or precursor forms until the cells are exposed to the required signal and
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consist of three major groups: (1) Transcription factors activated by cell surface receptor- 
ligand interactions; (2) Transcription factors activated by internal signals (3) Steroid 
receptor superfamily. These groups will be discussed in turn.
1.0.3 Transcription Factors activated bv cell surface-receotor ligand interactions
Cell surface receptor-ligand interactions can lead to two routes to the nucleus. Firstly, 
intracellular serine phosphorylation cascades that end at hundreds of resident nuclear 
protein substrates occurs. Secondly, a more limited number of latent cytoplasmic 
transcription factors are activated after cell surface receptor-ligand interaction and then 
accumulate in the nucleus to drive transcription (Brivanlou and Darnell, 2001).
1.0.3.1 Latent Cytoplasmic Factors
These transcription factors are inactive under normal conditions and are found in the 
cytoplasm. However, when a particular ligand binds to its cell surface receptor, 
dimerisation of the receptor leads to phosphorylation of the cytoplasmic tail of the 
receptor. Phosphorylation of the receptor creates docking sites for the latent factors, where 
they are also phosphorylated. The phosphorylated factors dissociate from the receptor to 
translocate to the nucleus to bind to promoters of ligand specific genes. Many 
transcription factors of this type have been identified and include SMADs, STATs, NFkB, 
NFAT and catenins (Masyuma et al., 1999; Darnell et al., 1994; Karin et al., 1999; 
Crabtree et al., 1999).
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L'hc STATs and SMADs are proteins that are activated at the cell surface receptor and both 
transcription factors require phosphorylation of serine and/or tyrosine residues. The STAT 
family of transcription factors will not be discussed any further in this section, but will be 
discussed in subsequent sections since they are relevant to this thesis.
Those factors that require serine phosphorylation and subsequent serine phosphorylation 
and proteolysis include NFkB /Rel family of transcription factors. This group is highly 
conserved in vertebrates (Baeuerle and Baltimore, 1996; Perkins, 2000). In mammals five 
proteins have been identified and are NFkBl, NFkB2, c-Rel, Rel-a and Rel-b. They are 
activated by various stimuli including oxidative stress, viral and bacterial infections, 
cytokines (Perkins, 2000). Two proteolytic events occur in the final translocation of NFkB 
to the nucleus. NFkB is a heterodimer, which is post-translationally activated. NFkB is 
bound to an inhibitor protein called IkB, which binds to NFkB and also binding to the actin 
cytoskeleton thus keeping NFkB in the cytoplasm. However, phosphorylation of IkB at 
two serine residues causes dissociation and proteosomal degradation of IkB and hence 
release of NFkB. NFkB then translocates to the nucleus (Karin, 1999).
Fluctuations in secondary messenger proteins also cause activation of latent transcription 
factors such as NFAT (nuclear factor of activated T cells) (Crabtree, 1999; Rao et al., 
1997). In resting cells, NFAT is phosphorylated. However, when immunoglobulins bind 
to their receptors, the internal concentration of Ca2+ ions is increased, which leads to 
activation of calcineurin (a phosphatase) and activation of NFAT. De-phosphorylated
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NFAT moves to the nucleus to bind to proteins such as AP-1 which is necessary since 
NFAT binds weakly to DNA (Rao et al., 1997; Okamura et al., 2000).
1.0.3.2 Resident nuclear factors
This group of factors is constitutively expressed and is activated by serine phosphorylation. 
Phosphorylation occurs when peptides such as thyroid stimulating hormone or molecules 
such as epinephrine bind to their cognate G-protein coupled receptors (GPCRs) leading to 
the increase of secondary messengers such as cyclic AMP, calcium ions, and 
phosphoinositides. Increases in secondary messengers triggers serine kinase cascades and 
ultimately phosphorylation of resident nuclear factors such as CREB, Jun-Fos. The target 
proteins in the nucleus are already bound to DNA (Gille et al., 1995; Janknecht, 1995). 
Resident factors are also phosphorylated through receptor tyrosine kinases (RTKs) as a 
result of ligands binding to cell surface receptors containing intrinsic tyrosine kinases 
(Pawson, 1997). Serine phosphorylation of resident factors also allows their binding to co­
activators such as CBP/p300 and is catalysed by multiple MAPKinases (Janknecht, 1993).
1.0.4 Transcription factors activated bv internal signals
Various internal signalling molecules regulate the activation of pre-existing transcription 
factors in response to intracellular signals. For example, DNA damage causes an increase 
in activation of the p53 transcription factor (Levine, 1997).
In yeast, internal fatty acid concentration leads to cleavage of precursor molecules Spt23 
and MGA2, which on release are able to translocate to the nucleus to regulate genes for
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fatly acid synthesis (Foreman et al., 1995). This group is not relevant to this thesis 
therefore it will not be discussed any further.
1.0.5 Steroid receptor superfamilv
Steroid molecules enter cells by diffusing through the lipid bilayer. Once inside the cell, 
steroids can bind to various receptors, which are activated and then participate in activating 
transcription of responsive genes (Manglesdorf et al., 1995). All steroid receptors are in the 
nucleus before being activated by their appropriate hormone except for the glucocorticoid 
receptor (GR), which is in the cytoplasm as a complex with heat shock protein (Hsp) 90, 
and is released when glucocorticoids bind, allowing GR dimers to enter the nucleus (Htun 
et al., 1996; Mackem et al., 2001).
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1.1 l i ie  Signal Transducers and Activators of Transcription
1.1.1 Introduction
Cytokines and interferons are molecules that play roles in the regulation of a variety of 
cellular functions in the lympho-haematopoietic system and stimulate proliferation, 
differentiation, and survival signals as well as specialized functions in host resistance to 
pathogens. Cytokines are known to activate many signaling pathways, of which the JAK- 
STAT pathway is one. This pathway is activated in response to cytokines and interferons. 
It allows the activation of latent cytoplasmic transcription factors known as the Signal 
Transducers and Activators of Transcription (STATs), which can modulate expression of 
specific genes. These transcription factors are also known to display specific functions that 
are vital to mammals. In this section, an overview of the signaling pathways, structure, 
activation and roles of the STATs will be given.
1.1.2 The STAT Proteins
There are seven mammalian STATs that have been identified and are denoted as STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 (Darnell, 1997). They are a 
group of transcription factors that are approximately 750 to 800 amino acids in length. 
Splice variant forms also exist, which lack a portion of the C-terminal domain. These 
variants are natural dominant negative forms since they bind DNA but are unable to 
activate gene transcription.
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The genes encoding STATs exist in clusters. STAT1 and STAT4 genes are found on 
mouse chromosome 1 and STAT2 and STAT6 genes are found on mouse chromosome 11 
(Copeland et al., 1995). Such clustering suggests that a primordial ancestral gene 
duplication event occurred. STAT genes are structurally conserved therefore suggesting 
essential roles in multiple cellular functions.
1.1.3 Biological Roles of STATs
Although the first STATs were identified on the basis of their activation by interferons 
(IFNs), much more important roles have been deciphered from mouse knockout models of 
each of the STATs and are shown in table 1.1
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Table 1.1 Features of STAT Proteins Required for Gene Regulation
STAT Knockout
Delect
Phenotype Phosphorylation 
Site (serine (S) 
or tyrosine (Y))
Transcriptional
Activation
Domain
Interaction With Other 
Proteins in 
Transcription
1 Type I and II IFN 
Signalling
No response 
to Viral or 
bacterial 
infection
Y701, S727 Aa 711-750 CBP/p300, SP1, 
TFII-I, Nmi-1, 
MCM5, BRCA1
2 Type I IFN 
Signalling
Early
embryonic
lethal
Y689 Human: 736-851 
Murine: 699-749
CBP, p48, STAT-1
3 Unknown Early
embryonic
lethal
Y705, S727 716-770 TF-II-1, c-Jun, 
Nmi-1, CBP
4 IL-12 Signalling No Th 1 cell 
function
Y694, S722 699-749 Nmi-1
5a Prolactin
Signalling
No breast 
development 
or Lactation
Y694, S726 722-794 GR, Nmi-1
5b Growth Hormone 
Signalling
No breast 
development 
or lactation
Y699, S731 727-787 GR, Nmi-1
6 IL-4 Signalling No Th2 cell 
function
Y641 661-847 C/EBPP, Nmi-1
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1.1.3.1 STAT-1
STAT1 is activated by various cytokines and growth factors. STAT1 knockout mice 
display selective signaling defects in their response to both type I IFNs (IFNot/p) and type 
II IFNs (IFNy) (Meraz et al., 1996; Durbin et ah, 1996). These mice are highly sensitive to 
bacterial and viral infection. In addition, expression of the major histocompatibility 
complex II (MHC class II) protein, complement protein C3, IFN-regulatory factor-1 (IRF- 
1) and guanylate binding protein 1 (GBP-1) was also diminished in these mice. STAT1 
knockout mice respond normally to other cytokines, which shows that STAT1 is necessary 
for mediating IFN-dependent responses but not for other responses.
1.1.3.2 STAT-2
STAT2 is activated in response to IFNa and IFNp and is unique in that it is the only STAT 
protein that has not been found to bind to GAS element DNA as a homodimer. Instead, 
after IFN activation STAT-2 forms a heterodimer with STAT-1, which must associate with 
p48 to form the interferon-a-induced interferon-stimulated gene factor-3(ISGF-3) 
transcription factor complex (Horvath et ah, 1996). Mice that lack STAT-2 are viable and 
develop normally. However, STAT-2 null mice are susceptible to viral infections, and 
cells from these mice are unresponsive to IFNo/p. In addition, the absence of STAT-2 
results in reduced tyrosine phosphorylation and reduced activation of STAT-1 (Park et ah, 
2000).
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1.1.3.3 STAT-3
SIAT3 is activated in response to the IL-6 family of cytokines, which mediate their signal 
via the gpl30  transmembrane receptor subunit. STAT3 activity is detected during early 
embryonic development in the mouse (Duncan et al., 1997; Takeda et al., 1997). Mice 
deficient for STAT3 die early in embryogenesis prior to gastrulation and the phenotype is 
unknown (Takeda et al., 1997). In myeloid M l cells, dominant negative STAT3 
overexpression abolishes any differentiating response to IL-6 or LIF therefore, STAT3 is 
required for IL-6 mediated growth arrest and differentiation of Ml cells (Minami et al., 
1996).
1.1.3.4 STAT-4
STAT-4 plays an important role in immune responses. STAT4 expression is restricted to 
myeloid cells, thymus and testes and it is phosphorylated in response to IL -12 (Jacobson et 
al., 1995). Knockout mice lacking STAT4 are viable, but are impaired in their response to 
IL-12. Moreover, an increase in Th2 cells is also observed (Kaplan et al., 1996).
1.1.3.5 STAT-5a and STAT-5b
STAT5 function was originally identified in mammary gland tissue by gene targeting and 
was called a prolactin-induced transcription factor (MGF) (Wakao et al., 1994). This 
transcription factor was activated by a variety of cytokines including IL-2, IL-3, IL-5, IL-7, 
IL-9, IL-15 and GM-CSF, erythropoietin, and growth hormone.
STAT5 consists of two highly related genes encoding STAT5a and STAT5b proteins. 
These proteins display 96% similarity at the amino acid level (Lui et al., 1998), and differ
24
mainly at their C-terminal domains. A single amino acid difference in the DNA binding 
domain results in distinct DNA binding specificities of STAT5a and STAT5b (Boucheron 
et al., 1998).
STAT5a knockout mice displayed normal development and were indistinguishable from 
the wild type mice. However, female mice failed to lactate, and mammary lobuloalveolar 
out growth was inhibited (Lui et al., 1997). These mice are also defective in GM-CSF 
induced proliferation of macrophages (Feldman et al., 1997)
Disruption of the STAT5b gene led to the loss of multiple responses linked to the sexually 
dimorphic pattern of pituitary growth hormone secretion. Body growth rate and male 
specific liver gene expression were decreased to levels observed in wild type female mice, 
whereas female specific liver gene expression was increased to levels observed in wild 
type male mice (Udy et al., 1997). STAT5b knockout mice were also defective in 
augmentation of natural killer (NK) cytotoxic activity mediated by IL-2 or IL-15 and 
proliferation of these cells was also stunted (Imada et al., 1998). In a double knockout of 
both STAT5a and STAT5b, female mice were found to be infertile (Teglund et al., 1998).
1.1.3.6 STAT-6
STAT6 is activated in response to IL-4, and knockout mice have defects in IL-4 mediated 
functions including MHC II expression, induction of CD23, immunoglobulin class 
switching to IgE, B and T cell differentiation, and Th2 development (Takeda et al., 1996;
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Shimoda et al., 1996; Kaplan et al., 1996). These knockout mice have also shown that 
STAT6 is involved in allergy induced airway inflammation (Kuperman et al., 1998).
1.1.4 STAT Signalling and the JAK-STAT Pathway
Investigations into the transcriptional response to interferons have led to the identification 
of the Janus Kinases (JAKs) as being required for cytokine mediated STAT activation 
(Darnell et al., 1994; Darnell JE Jr., 1997; Ihle, 1996). Thus the common pathway 
activating the STATs is known as the JAK-STAT pathway, and is activated by a variety of 
other cytokines.
The JAK family currently consists of the proteins kinases JAK1, JAK2, JAK3 and TYK2, 
which vary in their size from 120-135 kDa. They are composed of Jak homology domains 
(JH), JH1 to JH7 (Figure 1.1). However, for the majority of these regions, a clear function 
has not been determined. JH1 is the most studied of all the domains. This region confers 
the catalytic activity of the kinase protein. Evidence shows that mutation in a single lysine 
residue renders the kinase inactive (Gushin et al., 1995). Structural studies of JH1 show 
that an activation loop is necessary for kinase activity, and mutations within the activation 
loop at a tyrosine residue have effects on catalytic activity ranging from reduced activity to 
abrogation of activity (Feng et al., 1997). The N-terminal domain of JAK2 has been found 
to be involved in binding to cytokine receptors (Frank et al., 1994).
The JAKs are essential for cytokine signaling as mutations in JAK3 lead to severe 
combined immunodeficiency (SCID) in humans (Machi et al., 1995). Similarly, knockout
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mice for JAK3 display defects in B lymphocyte maturation and T lymphocyte activation 
(Thomis et al., 1995).
Pseudokinase Kinase
Receptor Binding Domain Domain Domain
□  c
JH7 JH6 JH5 JH4 JH3 JH2 JH1
Figure 1.1 Structure of JAKs
JAKs are structurally unique in having tandem kinase and kinase-like 
domains. The C-terminal domain is the catalytic domain.
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Once IFNs (or other cytokines) are bound to cognate receptors, the receptor components 
dimerise, allowing phosphorylation by the JAKs at the cytoplasmic tail of the receptor at 
tyrosine residues. The tyrosine residues become docking sites for latent cytoplasmic 
STAT monomers by means of the Src Homology 2 (SH2) domains. Following recruitment 
to the receptor, STATs become phosphorylated at tyrosine residues in the C-terminus. 
Phosphorylated STATs dissociate from the receptor to form homo or hetero-dimers that 
can translocate to the nucleus to bind STAT responsive elements and subsequently activate 
transcription of STAT responsive genes (Darnell et al., 1994) (Figure 1.2)
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Figure 1.2 Cytokine Induced STA1 Activation and Transcriptional R e g u l a t i o n
Latent cytoplasmic STAT monomers are recruited and phosphorylated at the receptor 
upon cytokine interaction and dimerisation of the receptor. Phosphorylated STATs 
can form homo or heterodimers which translocate to the nucleus where they 
bind STAT binding motifs to activate transcription of STAT responsive genes.
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1.1.5 Structure and Activation of STATs
The SH2 domain of STATs is highly conserved and it is via this domain that STAT 
molecules dock at the receptor (Figure 1.2). The SH2 domains of STAT proteins differ in 
specificity. For example, in IFNa/p signaling, STAT-2 docks on the receptor whereas 
STAT1 docks on STAT2 when STAT2 is phosphorylated (Li et al., 1997). Interestingly, 
STAT6 binds to phosphotyrosine docking sites in the IL-4 receptor a chain. The N- 
terminus of STATs is required for protein-protein interactions, and the C-terminus is 
required for phosphorylation, activation and interaction with other proteins (Figure 1.3 and 
table 1.1).
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Figure 1.3 Structures of STATs, The figure shows domains common to 
the STAT proteins. DD: dimerisation domain; DB: DNA binding domain; 
SH2: Src Homology 2 domain; TAD: trans-activation domain.
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All STATs have conserved tyrosine residues at approximately 700 residues from the N 
terminus which become phosphorylated following receptor activation (Horvath and 
Darnell, 1997). STAT dimers are formed via interaction of the SH2 domain of one 
phosphorylated STAT molecule with the SH2 domain of another phosphorylated STAT 
molecule to give a stabilized dimer.
It is not clearly known how dimers of STAT activated molecules translocate to the nucleus 
and it is also not clear whether dimers translocate independently of helper chaperones or in 
a complex, but it is known that translocation of STAT dimers leads to direct binding of 
STAT dimers to the DNA. DNA binding of STAT1 and STAT2 hetero-dimers requires an 
additional protein p48, which is a DNA binding protein (Horvath and Darnell, 1997). The 
STATl/STAT2/p48 complex recognizes the motif AGTTNCNTTTC. However, the 
recognition of other consensus sequences or gamma-activated sequences (GAS) is 
dependent on the particular STAT dimer combination and the specificity of the DNA 
binding domain of STATs (Schindler et al., 1995). The loss and gain of specificity of 
DNA binding domains has been determined by creating STAT fusion proteins (chimaeric 
constructs) (Horvath et al., 1995).
Activation of STATs occurs at the C-terminus of all the proteins. Studies on STAT-1 for 
example, show that STAT-lp, the splice variant of STA T-la, lacks the terminal 38 amino 
acids and does not activate gene transcription in response to IFNy (Muller et al., 1993). In 
addition, the 38 amino acids at the C-terminus are essential for STAT-1 activation. STAT-
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la ,  3, 4, and 5a are about the same length, and the C-terminus of these proteins is required 
for full gene activation (Moriggl et al., 1996; Caldenhoven et al., 1996; Wang et al., 1996).
The C-terminal amino acids are not highly conserved in these proteins, except for Pro-met- 
ser-pro in the C-terminal domain. STAT-1 and STAT-3 are phosphorylated on a single 
serine residue (serine 727) and is one of the conserved amino acids in the C-terminal 
domain (Wen et al., 1995; Wen et al., 1997). Serine 727 phosphorylation is required for 
maximal gene activation by STAT-1 and STAT-3 in cells stimulated with IFNy. For 
transcriptional activation of STAT-1 and STAT-3, tyrosine phosphorylation is necessary 
and obligatory. However, serine phosphorylation is supplementary.
Tyrosine phosphorylation of STAT-1 is independent of serine phosphorylation and vice 
versa (Zhu et al., 1996), since mutant serine to alanine mutants can be phosphorylated on 
tyrosine, and a tyrosine to phenylalanine mutant can be phosphorylated on serine. 
Tyrosine phosphorylation induced by IFNy occurs within 5 minutes, whereas serine 
phosphorylation takes 10 minutes (Zhu et al., 1996). STAT-1 tyrosine phosphorylation 
occurs at the plasma membrane, whereas serine phosphorylation is likely to occur at the 
cytoplasmic tail of the receptor. Therefore, although tyrosine and serine phosphorylation 
is essential, it seems that they are controlled by distinct pathways (Darnell, 1997).
In addition to tyrosine phosphorylation and serine phosphorylation, physical interactions of 
STATs with other proteins have been identified. STAT1 can associate with the activator 
Sp-1 to bind to the ICAM-1 promoter (Look et al., 1995), and with CBP/p300, which
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interacts with the N-terminal domain of STAT-1 as well as the C-terminal domain via the 
E1A binding region of CBP/p300 (Zhang et al., 1996). The N-terminal domain of STAT1 
is also involved in interactions with N-terminal domains of other STATs to mediate 
dimerisation (Xu et al., 1996) and stabilization of DNA binding (Vinkemeir et al., 1996). 
Interestingly, STAT3P can associate with c-jun in a co-operative manner (Schaefer et al., 
1993).
1.1.6 Inhibition of STATs
Inactivation and subsequent loss of DNA binding occurs by de-phosphorylation of the 
tyrosine residues (Haspel et al., 1996). The N-terminal domain of STAT1 can bind a 
phosphatase (Shuai and Song, 1996) thus reversing tyrosine phosphorylation. However, 
there is not one single mechanism of deactivation. Thus, for example, it has been shown 
that STAT1 is degraded via the ubiquitin-proteasome pathway (Kim and Maniatis, 1996). 
Other mechanisms involve binding of STAT splice variants to DNA. For example, 
STATlp lacks 38 amino acids at the C-terminus, and does not activate gene transcription.
However, cytokine activated STATs are also negatively regulated by inhibitor proteins at 
various stages of the JAK-STAT pathway. These include protein inhibitor of activated 
STAT (PIAS) family (Liu et al., 1998; Shuai, 1999), the cytokine-inducible SH2 
containing protein (CIS) (Yoshimura et al., 1995), the suppressor of cytokine signaling 
(SOC) family, also known as JAB (JAK binding protein), and SSI-1 (STAT induced STAT 
inhibitor-1) (Endo et al., 1997; Starr et al., 1997; Naka et al., 1997). These groups will be 
described in turn.
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1.1.7 The PIAS family of proteins
PIAS was originally isolated as a partial cDNA clone encoding the C terminus of an 
unknown protein which was later termed as PIAS1 as it was able to interact with STA Tip 
(Liu et al., 1998; Shuai, 1999). Additional related proteins were identified subsequently: 
P1AS3, PIASy, PIASxa, PIASxP (Chung et al., 1997; Liu et al., 1998). The structure of 
all PIAS members consists of a conserved LXXLL motif in the N terminal domain, which 
is known as the nuclear receptor box (Heery et al., 1997) and mediates ligand-dependent 
co-activator-nuclear receptor interactions. Also present is a zinc-binding motif in the 
middle of the protein, and serine/threonine residues in the C-terminal region.
The potential functions of the PIAS proteins in signaling were identified by co- 
immunoprecipitations using antibodies to STAT1 and STAT3 (Chung et al., 1997; Liu et 
al., 1998). PIAS3 has been shown to associate with STAT-3 but not STAT-1, and inhibits 
signal transduction by suppressing STAT3 activity by blocking the DNA binding activity 
of STAT3. Furthermore, PIAS3 only associates with STAT3 when cells are stimulated 
with IL-6, CNTF or OM. PIAS3 also inhibits DNA binding of the STAT1/STAT3 
heterodimer (Chung et al., 1997). Deletion of amino acids 1-191 of STAT1 results in loss 
of PIAS1 association with STAT1 (Liao et al., 2000). The N terminal domain of STAT-3 
is also likely to be necessary for STAT3 and PIAS3 interaction.
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1.1,8 J h e  SQCs Family of Cytokine Inhibitors
The SOCS family consists of eight proteins, SOCS-1 to SOCS-7 and CIS (cytokine 
inducible SH2 containing protein), and they all have similar structures (Masuhara et al., 
1997; Minamoto et al., 1997).
The first member of this family was identified as an immediate early gene induced in 
response to cytokines and was named CIS (Yoshimura et al., 1995). This protein was able 
to bind to tyrosine- phosphorylated receptors and competes with STAT5 for binding to the 
receptor (Matsumoto et al., 1999; Yoshimura et al., 1995). CIS expression is induced by 
IL-3 and erythropoietin by activation of STAT-5. In addition, the CIS gene promoter 
contains STAT5 binding sites (Matsumoto et al, 1997). Mice over-expressing CIS display 
defects in growth hormone signaling as well as defects in mammary gland development, 
and similar defects are observed in STAT5 knockout mice (Matsumoto et al., 1999). 
Therefore, it is possible that cytokine induced STAT-5 activation leads to CIS expression, 
which in turn, binds to phosphorylated tyrosine within the receptor to prevent further 
STAT-5 recruitment in a negative feedback loop.
SOCS-1 was identified as an inhibitor of IL-6 induced differentiation of myeloid 
leukaemic Ml cells that was able to bind to JAKs (Endo et al., 1997; Starr et al., 1997; 
Naka et al., 1997) through its SH2 domain. SOCS-1 knockout mice were retarded in their 
growth and were not able to survive more than 3 weeks after birth (Naka et al., 1998). It 
was also shown that these mice had lost maturation function of B-lymphocytes in bone 
marrow, spleen and peripheral blood cells (Naka et al., 1998). Interestingly, embryonic 
fibroblasts lacking SOCS-1 were sensitive to TN F-a induced apoptosis (Morita et al.,
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20(H)). Other studies show that SOCS-1 may be involved in modulating responses to IFNy 
(Alexander et al., 1999).
SOCS (also known as JAB, SSI-1) factors function by binding JAK kinases. SOCS-1 
binds to the phosphorylated tyrosine residue in the activated JAK via its SH2 domain to 
inhibit JAK catalytic activity, thus preventing access of STAT and ATP to the catalytic 
pocket of JAKs. A kinase inhibitory region within the SH2 domain of SOCS-1 is required 
for high affinity binding of SOCS-1 to the kinase domain (Nicholson et al., 1999; 
Yasukawa et al., 1999). Mutation of 12 amino acids within the SH2 domain of SOCS-1 
prevents binding to phospho-tyrosine.
1.1.9 Other Roles of STATs
It is known that STATs are required for normal functioning of cells, primarily in response 
to cytokines to trigger growth or differentiation of cells. STATs are versatile since they 
can take part in early signaling in ligand binding and receptor dimerisation and activation, 
and they also execute the final steps by translocating to the nucleus to bind DNA and 
activate transcription of STAT responsive genes.
Recent studies have shown that STATs are part of a larger multi-step signaling pathway 
that results in programmed cell death. STAT-1 has been shown to be activated by the 
TNFa death ligand (Kumar et al., 1997). Although it is not clear at what stage in the 
apoptotic pathway STAT-1 is activated, Chin and colleagues have implicated STAT-1 in 
transcriptional activation of some caspases (Chin et al., 1997). Apoptosis is initiated by 
activation of a caspase cascade of caspase proteases that cleave cellular proteins (Fraser
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and Evans, 1995). Studies have shown that the serine 727residue is required for apoptotic 
activity after ischaemia/reperfusion (Stephanou et al., 2001) and mutation of serine 727 
reduces apoptotic activity of STAT-1.
It is important to further investigate the involvement of STAT-1 in apoptosis and that 
STAT-1 could be a potential target in minimizing cell death especially when cells are 
subjected to stress such as elevated temperature and ischaemia/reperfusion injury. In the 
following section, a background introduction to apoptosis will be given, and the role of 
STAT-1 in apoptosis will be addressed.
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1.2 Cell Death Pathways
1.2.1 Introduction
Cell death is a physiological process that is required for maintenance of cellular 
homeostasis and development in organisms. Death of a cell can occur when exposed to a 
serious physical or chemical insult (predominantly necrosis) or during development and 
other normal biological processes (predominantly apoptosis or programmed cell death). 
Features of necrosis and apoptosis can be seen in table 1.2.
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Table 1,2 Differential Features and Significance of Necrosis and Apoptosis
Features Necrosis Apoptosis
Morphology Loss o f  m em braine  intregrity M em brane  blebbing, no loss o f  integrity
Swelling  o f  cytoplasm  and 
m itochondria
Shrinking o f  cytoplasm
Total cell lysis Fragm entation  o f  cell into smaller bodies
N o vesicle formation, com plete lysis Form ation  o f  m em brane  bound  vesicles
D isintegration (swelling) o f  organelles M itochondria  becom e leaky due to 
pore formation
D N A  fragmentation
Nuclear envelope shows characteristic clustering 
o f  nuclear pores
Biochemistry Loss o f  regulation o f  ion homeostasis Tightly  regulated process involving 
activation and enzym atic  steps
No energy requirem ent 
(passive process)
Energy (ATP)-dependent
R andom  D N A  digestion N on-random  m ono and oligonucleosom al 
length fragmentation  o f  D N A
Post-lytic D N A  fragmentation 
(late event o f  death)
Prelytic D N A  fragmentation
Release o f  various factors into cytoplasm 
by mitochondria 
Activation o f  caspase cascade 
Alterations in m em brane asym m etry  
(ie, translocation o f  phosphatidyl serine 
from the cytoplasmic region to the 
extracellular side o f  the cell m embrane)
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P hvsio logv Affects  groups o f  contigious cells Affects individual cells
Evoked  by non-physiological 
d isturbances
Induced by physiological stimuli
Phagocytosis  by m acrophages Phagocytosis  by adjacent cells or 
macrophages
Significant inflammatory response N o inflam m atory  response
Necrosis involves uncontrolled bursting of cells caused by for example, stroke, trauma, 
heat, radiation, lack of oxygen, or toxins, leading to damaging immune responses (Valance 
et al., 1997). This mechanism is rapid and leads to leakage of cellular contents, as the 
integrity of the cell membrane is lost.
Cell death by apoptosis occurs in many physiological and pathological processes such as 
development, differentiation, tumorigenesis and infections (Kerr et al., 1972; Martins and 
Eamshaw, 1997; Thompson, 1995). Apoptosis is a slow process and can last up to 24 
hours (Collins et al., 1997). A diagrammatic representation of the apoptotic pathways are 
shown in figure 1.4
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Figure 1.4 Mammalian cell death pathways two major apoptotic pathways ensue in 
response to death signals: mitochondrial dysfunction leading to caspase-9 
activationand activation of death receptors such as Fas.
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1.2,2 Identification of a Regulated Pathway to Apoptosis
The term ‘apoptosis’ first appeared in the literature in 1972 and was defined as a distinct 
mode of cell death responsible for cell loss within living tissues (Kerr et al., 1972). 
Genetic pathways of cell death have been defined in C. elegans and the fruitfly D. 
melanogaster (Ellis et al., 1991; Abrams, 1999). A set of proteins were discovered that 
were evolutionarily conserved, widely represented by homologues in other species and 
were responsible for turning on or off the final commitment to death (Hengartner and 
Horvitz. 1994). Knockout studies have revealed many more proteins involved in apoptosis 
(table 1.3.).
1.3 Major phenotypes in Cell Death Pathway Knockout Mice
Death Pathway 
protein
Knockout Phenotype
Caspases 
Caspase 1
Caspase2
Caspase3
Caspase8
Caspase9 
Caspase 11 
Caspase 12 
Adaptors
Viable.resistant to lipopolysaccharide induced endotoxic shock; resistant to 
ischaemic brain injury.
Viable; excess oocytes  resistant to a variety o f  cytotoxic agents;defects 
in B cell apoptosis  by granzye B and perforin
Perinatal lethality (depending  on mouse strain), neuronal hyperplasia ,  
structural d isorganiza tion  and partial resistance o f  mature T  lym phocytes to 
activation-induced cell death
Em bryonic  lethality (E l  I-E12.5); impaired cardiac muscle developm ent; 
em bryonic  fibroblasts resistant to death receptor induced apoptosis
Perinatal lethality, neuronal hyperplasia
Viable; resistant to LPS  induced endotoxic shock; resistant to ischaemic brain 
injury
Viable; partially resistant to E R  stress inducers
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A pa I I E m bryonic  lethality ( E l 6.5); severe craniofacial abnormalities;  infertility in 
surviving males
Fadd Em bryonic  lethality (E9-E12.5); impaired card iom yogenesis  and 
abdom inal hemorrhage; impaired proliferation o f  thym ocytes
Bel 2 Death within few months o f  birth; renal failure; neuronal death in postnatal 
period
Be IX E m bryonic  lethality; extensive neuronal death; death o f  hem atopoietic  cells o f  
the liver
Mel 1 Peri-implantation em bryonic lethality
A l
BclW
Viable; accelerated neutrophil apoptosis
Viable; male infertility; no production o f  mature sperm
Pro-apoptotic
Bax Viable; male infertility; increased oocyte lifespan in females
Bak
Bax/Bak
Viable; fertile
A ccum ula tion  o f  neurons in the central nervous system ; adults resistant 
to anti-Eas-induced hepatocellular apoptosis; 90%  perinatal lethality
BH3 dom ain  onlv
Bid Viable; resistance to anti-Eas induced hepatocellular apoptosis
M itochondrial penes
Cytochrom e c Em bryonic  lethality (E8.5)
A if D efective em bryoid  body cavitation; Escells resistant to growth factor 
w ithdrawal
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1.2.3 The Cell Death Pathway and its Components
The identified proteins were called the cell death abnormal (ced) (Yuan et al., 1993). The 
proteins resulting from ced 3 and ced 4 genes were identified as the initiators of apoptosis. 
Ced 9 was found to prevent cell death. In addition, seven more genes were identified, and 
were involved in the recognition and phagocytosis of the cell.
Ced 3 protein is a protease that also resembles at least twelve mammalian proteases 
(Alnemri et al., 1996) called caspases (so called because of the obligatory cysteine in their 
active site and their tendency to cut adjacent to aspartate residues). The ced genes were 
found to be highly homologous to the human genes for interleukin-1 converting enzyme 
(ICE) (also known as caspase 1), which is a protease that cuts IL-1 from its precursor 
protein (Yuan et al., 1993).
Caspases can be divided into two functional subfamilies: initiator caspases, which are
involved in upstream regulatory events, and effector caspases, which are directly 
responsible for cell disassembly events.
Initiator pro-caspases 8 and 9 are capable of trans or auto activation after they are 
aggregated with the adaptor molecules Fadd and Apaf-1 (Li et al., 1997). The downstream 
effector caspases 3, 6 and 7 are substrates of the initiators, which result in a protease 
cascade that ensures widespread cleavage of multiple substrates, and ultimately death.
Caspase 3 carries out the final irreversible commitment to death in many situations. 
Cytoskeletal proteins such as actin and nuclear laminins, regulatory and chaperone-like
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proteins, are functionally altered by cleavage (Thomberry, 1997). One such example is 
cleavage of apoptotic nuclease which is thereby activated and is responsible for chromatin 
cleavage to oligonucleosome fragments (Ehari et al., 1998). Caspases are present in most 
cells in an inactive pro-enzyme form, which, when active, are able to cleave target 
substrates.
Ced4 was found predominantly in the mitochondria, and the mammalian equivalent was 
named Apaf-1 (Zou et al., 1997). Under conditions of cellular shutdown, Ced 4 was found 
to initiate apoptotic signals by changes in cellular energy metabolism. Thus, Ced 4 may 
play the linking role between mitochondrial injury associated agents such as calcium and 
reactive oxygen species in the initiation of apoptosis.
1.2.4 Death Ligands
Many death and survival signals stimulate extrinsic or intrinsic pathways composed of 
several adaptors, regulators, caspases and members of the Bcl-2 family. Extrinsic signals 
involve Fas and TN Fa, which induce apoptosis by means of their receptors. The 
intracellular domains of the death receptors TNF receptor 1 (TNFR1) and Fas/Apo-l/CD95 
receptors are known as the death domains (DD). Oligomerisation of Fas causes binding of 
a Fas associated death domain protein (FADD). Oligomerisation of TNFR1 requires a 
TNFR1 associated death domain (TRADD) to recruit FADD. Upon association to both 
receptors, FADD interacts with the death effector domain (DED) of the initiator 
procaspase-8 thereby causing proteolytic autoactivation to generate caspase-8 (Martin et 
al., 1998).
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In addition to activating the downstream effector caspase-3, caspase-8 also cleaves Bid 
(Budihardjo et al., 1999) to an active form, which translocates to the mitochondria to 
initiate cytochrome c release into the cytoplasm by Bcl2 family- mediated membrane 
permeabilisation (Li et ah, 1998) (see section 1.2.3.1). Cytochrome c is a component of the 
mitochondrial electron transport chain necessary for mitochondrial respiration and is a 
well- characterized component of the mitochondrial driven death pathway (Li et ah, 1997). 
In addition to cytochrome c release, Smac/Diablo (pro-apoptotic) and apoptosis inducing 
factor (AIF) are also released. The release of cytochrome c into the cytoplasm results in 
oligomerisation of the Apaf-1 adaptor protein by binding to procaspase 9. The binding of 
Apaf-1 to procaspase 9 leads to activation of caspase 9 without cleavage (Zou et ah, 1997). 
Caspase 9/cytochrome C/Apaf-1 complex promotes activation of the effector caspase 3 and 
mediate the final death signal (Li et ah, 1997).
1.2.4.1 Death regulation bv the Bcl-2 Family of Proteins
The Bcl-2 family of proteins is also involved in the regulation of mitochondrial outer
membrane permeabilisation (MOMP) (Martinou and Green, 2001). The Bcl-2 family
consists of anti-apoptotic, and pro-apoptotic proteins. The anti-apoptotic members include 
Bcl-2, BclXL, Mcl-1, Bcl-W and A l. Pro-apoptotic members include Bax, Bak and Bok. 
All members are BH (Bcl-2 Homology) 1, 2, 3 proteins. BH3 only proteins include Bid, 
Bim, Bik, Bmf, Bad, Hrk, BNIP3, Noxa, and Puma (Martinou and Green, 2001).
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Bel 2, BclXL, Bax, and Bid share 3D structures that resemble pore-forming chains of some 
bacterial toxins (Martinou and Green, 2001). Bcl-2 and B c I X l block mitochondrial outer 
membrane permeabilisation, while Bax and Bak promote it (Lindsten et al., 2000).
Pro-apoptotic Bax can oligomerise and migrate to the mitochondria (Eskes et al., 2000). 
Oligomerised Bax can then generate a pore, or can alter the integrity of the outer 
mitochondrial membrane. Bcl-2 can block Bax activity (Cheng et al., 2001).
1.2.5 STATs as Activators of Apoptosis
Increasing evidence suggests that STATs are not restricted to roles in modulating gene 
expression induced by cytokine stimulation, and that STATs can display specific roles in 
modulating gene expression in response to specific cellular processes such as apoptotic cell 
death.
Recent studies have shown that STAT-1 and STAT-3 have distinctively opposing effects 
on apoptotic cell death (Battle and Frank, 2002). For example, cell lacking STAT-1 are 
more resistant to apoptotic cell death induced by TN Fa (Kumar et al., 1998) whereas 
STAT-3 has been shown to have oncogenic properties and its activity is enhanced in 
several tumours ( Garcia and Jove, 1998). Anti-apoptotic effect for STAT-3 has also been 
demonstrated in breast cancer (Bromberg et al., 1999). In our laboratory, it has been 
shown that overexpression of STAT-1 in cardiac myocytes leads to enhanced apoptosis 
upon ischaemia reperfusion. In contrast, over-expression of STAT-3 leads to a reduction 
in apoptotic cell death induced by STAT-1 (Stephanou et al., 2000). In addition, ischaemia
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reperfusion or IFNy leads to induction of caspase-1, Fas, and FasL in a STAT-1 dependent 
manner. This effect is abolished with the presence of anti-sense STAT-1 (Stephanou et al., 
2000; Stephanou et al., 2001, Stephanou et al., 2002). STAT-1 is also able to inhibit the 
anti-apoptotic genes BclXcand Bcl-2 whereas STAT-3 enhances expression of BcIXl and 
Bcl-2 genes (Stephanou et al., 2000a).
STAT-1 pro-apoptotic activity is dependent upon phosphorylation of its serine 727 residue 
within the C-terminal domain, and this has been shown to be critical for its ability to 
interact with other regulatory proteins including MCM5 and BRCA1 (Da Fonesca et al., 
2001; Ouchi et al., 2000).
In these circumstances, STAT-1 can potentially be a therapeutic target in terms of reducing 
cell death after lethal stresses. However, it is vital that the biological activity of STAT-1 
in stress-induced apoptosis is understood, and at what stage of the apoptotic pathway 
STAT-1 is required. In a previous study by King and Goodboum, STAT-1 is shown to be 
cleaved at position 694 by caspase-3, therefore it is possible that STAT-1 may be involved 
in amplifying the apoptotic loop following caspase activation (King and Goodbourn, 
1998). It is equally important to understand how STAT-1 may interact with other proteins 
to exert its effects, and which genes are activated or repressed. For example, the heat 
shock proteins are commonly known for their cell protective roles in response to various 
stresses such as heat shock and ischaemia/reperfusion. Hsp70 and Hsp90 can bind to 
Apaf-1 thus inhibiting apoptosome formation (Saleh et al., 2000; Beere et al., 2000; 
Pandey et al., 2000). Hsp70 can also inhibit caspase-3 activity further downstream of the
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apoptotic pathway (Jaattela et al., 1998). In our laboratory, it has been shown that STAT-1 
can interact with heat shock factor 1 (HSF-1) (Stephanou et al., 1999). Therefore, it is 
important to determine whether this interaction between STAT-1 and HSF-1 is also 
required for Hsp inhibition in stress-induced apoptosis. The Hsps will be discussed in the 
next section.
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1.3 The Stress Response
1.3.1 Introduction
Cells are equipped to ensure correct folding of proteins. Under stressed conditions, 
proteins can become denatured, and as a result, can misfold, leading to proteins that fail to 
function and/or give rise to diseases. Molecular chaperones assist in the correct folding of 
other proteins so that they can fulfill their proper functions under normal conditions 
(Gething and Sambrook, 1992; Hightower et al., 1991; Lidquist and Craig, 1988; Welch,
1992). This function is essential for normal cells, but when cells are subjected to elevated 
temperature protein misfolding is enhanced and prevention of aggregation of other proteins 
with each other is of even more importance.
The stress response was first discovered by Ritossa (1962), who reported the formation of 
a new puffing pattern, in the salivary gland polytene chromosomes of the fruit fly 
Drosophila huskii on exposure to elevated temperature. It was subsequently found that the 
pattern of gene transcription had been reprogrammed (Ashbourner, 1970). The pattern 
observed was related to the rapid synthesis of a novel group of proteins known as the heat 
shock proteins (Hsps) (Tissiers et al., 1974), which were named simply because of their 
inducibility by elevated temperature. However, other stresses such as cytokines, microbial 
and viral infections, ischaemia, hypoxia, and amino acid analogues also enhanced the 
synthesis of the Hsps. The Hsps were found to be a phenomenon common to all 
prokaryotes and eukaryotes (Lindquist, 1986) and since the Hsps were found to constitute 
2% of total cellular proteins in the unstressed cell, this implied that these proteins play 
important roles in the general maintenance of the cell under normal conditions as well as
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stress conditions. For example, the 70 kilodalton stress protein has two forms, a 
constitutive and an inducible form. The constitutive form is present in the unstressed cell 
whereas inducible Hsp70 is expressed at high levels when the cell is stressed to refold 
misfolded proteins, and in addition, proteins that are damaged permanently as a result of 
stress and cannot be refolded are recognized and subsequently degraded.
The hsp family of proteins is a large family consisting of Hsp 110, 100, 90, 70, 65, 56, 47, 
and the small Hsps. All Hsps are classified according to their molecular weights and 
members of this family can be seen in table 1.4.
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Table 1.4 The Heat Shock Proteins in Eukaryotes and their Prokaryotic homologues
H S P Members Other Homologues Roles
H sp 110
- G lucose regulated , p redom inant in 
nucleoli
H sp 100 H sp 104, 
H s p 100
C lpA , C lpB G lucose regulated , p redom inant in 
G olgi
I Isp90 H sp90,
G rp94
TRA P1 (eukaryotic), C 62 .5(E . coli) 
H sp83(yeast, D rosophila) 
m itochondrial
K eeps steroid recep to rs inactive, 
a  and P form s from  distinct genes
H sp70 G rp78 (B iP ), 
H sp70
Hsc7()
D naK Involved in cell surv ival, protein 
F old ing  and unfolding, 
involved in therm oto lerance 
Involved in b ind ing  to nascent 
po lypeptide chains, keeping 
them  from  form ing m isfolded proteins
H sp60 H sp60 G roH L Involved in m itochondrial protein 
fo ld ing
H sp56 H sp56
(F K B P 59)
C an associa te  w ith Hsp7() and 
Hsp9() in steroid recep to r com plexes 
and is a target o f im m unosuppressive 
drugs
Hsp47 H sp47 Involved in co llagen  protein 
fo ld ing, hom ology  to protease 
inhibitors
Hsp27 H sp27,
H sp26, H sp25
H sp26(yeast)
H sp25(m ouse)
C an bind to actin  filam ents, 
involved in pro tein  fold ing, 
therm oto lerance and cell survival
U biquitin U biquitin H sp22 ,H sp23 ,H sp26 , 
H sp28 (D rosophila)
Involved in pro tein  degradation  
and can  associate w ith H 2A  
histone in nucleus
In this section, the roles of the Hsps will be discussed in detail individually, especially 
those Hsps that are directly relevant to this thesis.
1.3.2 H sp90
Hsp90 protein is constitutively expressed in unstressed cells and is one of the most 
abundant proteins in eukaryotic cells, constituting 1-2% of total cellular protein. Hsp90 is
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highly conserved since homologues are found in bacteria yeast and humans. Two 
cytoplasmic isoforms of the human Hsp90 protein have been identified: Hsp90a and 
Hsp90p (Gupta et al., 1995). These are encoded by separate genes and have resulted from a 
gene duplication event (Hickey et al., 1989). Hsp90a shares 76% amino acid homology 
with Hsp90p (Gupta et al., 1995). Hsp90a is more inducible than Hps90p (which is 
constitutively expressed).
For both isoforms dimerisation and phosphorylation are essential for chaperone activity 
(Minami et al., 1994). Hsp90p and Hsp90a are situated in the cytoplasm, and a large 
majority of these proteins is localized in the nuclear envelope region (Perdew et al., (1993). 
Hsp90 exists predominantly as phosphorylated homodimers and forms oligomers, with 2-3 
covalently bound phosphate molecules per monomer (Ianotti et al., 1988). In cases when 
cells are stressed due to elevated temperature, Hsp90 chaperone activity (Yonehara et al.,
1996) and hydrophobicity increases, thus enhancing binding to other unfolded proteins. 
Hsp90 protects the cell by associating with actin filaments (Kellemayer and Csemely, 
1995) as a result of lower levels of ATP in the cell (Kabakov and Gabai, 1997).
Hsp90 also contains a hinge-domain between the C and N termini, which is highly charged 
and another highly charged domain is located within the C-terminal domain, thus giving 
Hsp90 its binding activity to other proteins. The N-terminal domain of Hsp90 contains a 
binding site for ATP/ADP (Prodromou et al., 1997) and the antitumourigenic drug
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geldanamycin (Stebbins et al., 1997). This domain is also involved in target protein 
binding (Young et al., 1997).
The highly charged central domain is thought to have possible regulatory functions since 
putative phosphorylation sites are present in this domain, and can be phosphorylated by 
protein kinases (Dougherty et al., 1987). The C-terminal domain is the site at which 
dimerisation occurs (Minami, 1994) and is also the site for calmodulin binding (Mimami, 
1993). This domain is also involved in binding with actin filaments as the binding of the 
antiHsp90 antibody AC88 (which recognises an epitope in the C-terminal domain) to 
Hsp90 interferes with actin filament binding (Schlatter et al., 1992).
Functions of the Hsp90 family involve the prevention of aggregation of unstable proteins, 
as well as partially re-natured and heat denatured proteins since purified Hsp90 can prevent 
aggregation of unstable proteins. Hsp90 can bind protein kinases to enable proper function 
and correct cellular localization (table 1.5). The binding of Hsp90 with actin filaments 
suggests that Hsp90 plays a vital role in cell protection due to heat stress (Williams and 
Nelson, 1997).
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Table L5. Complex formation of Hsp90 with various protein kinases
Protein Kinases Examples Reference
Tyrosine Kinases VSrc, cSrc 
Insulin receptor
Brugge et al., 1981; 
Oppermann, 1981; 
Blakenship and Matsumura, 
1997
Serine/Threonine Kinases V-Raf, c-Raf, b-Raf Stancato et al., 1993; 
Wartmann and Davis, 1994; 
Jaiswal et al., 1996
MEK Stancato et al., 1997
EIF-2-a kinase Rose et al., 1987
Protein Kinase CK-II Dougherty et al., 1987
Roles of Hsp90 in modulation of transcription factors such as MyoDl and hypoxia induced 
factor l a  in the nucleus by conformational changes have been suggested as a low affinity 
complex formation of Hsp90 with these transcription factors enhances DNA binding 
(Shaknovich et al., 1992; Shue and Kohtz, 1994). In addition, an important role of Hsp90 
has been observed in regulation of the heat activated heat shock factor 1 (HSF1) 
transcription factor (See Section 1.3.6). The highly charged connecting loop of Hsp90 
resembles DNA and can be bound by many factors (Nadeau et al., 1993).
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Finally, one of the most studied roles of Hsp90 is the interaction with steroid hormone 
receptors and in vivo Hsp90 is essential for steroid action (Picard et al., 1990). Interaction 
with steroid receptors requires formation of a complex with other co-chaperones such as 
hsc70, Hop, p23. This complex keeps the receptor in a partially unfolded state and allows 
high affinity binding of the steroid. Steroid binding destabilizes the steroid receptor/Hsp90 
complex, leading to dissociation of Hsp90 followed by nuclear translocation of the 
receptor and gene activation.
1.3.3 Hsp70
The Hsp70 family of chaperones is one of the most studied protein families. This family 
of proteins is most abundant and highly conserved in eukaryotic cells compared to other 
Hsps (Tavaria et al., 1996). The Hsp70 family includes Hsc70 (constitutive form) (present 
in the cytoplasm and nucleus in the unstressed cell), Hsp70 (inducible form; produced in 
response to stress), Grp78 (present only in the endoplasmic reticulum), and mitochondrial 
Hsp70. The different isoforms are encoded by multiple gene copies in eukaryotes (Becker 
and Craig, 1994). In prokaryotes (E . coli) there is one copy of the dnaK gene (Hsp70 
homologue), whereas in yeast several hsp70 genes are present (Becker and Craig, 1994).
Hsp70 assists in folding of newly synthesized proteins and facilitates degradation of 
unstable proteins. Other roles involve guiding translocating proteins across organellar 
membranes, disassembly of oligomeric protein structures, controlling biological activity of 
folded regulatory proteins (such as transcription factors), and enabling proteolytic 
degradation of unstable proteins (Flynn et al., 1989; Riidger et al., 1997).
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Hsp70 proteins consist of a highly conserved N- terminal domain, which confers ATPase 
activity (44 kDa) and a C-terminal domain (25kDa), which is also highly conserved. The 
function of this domain is not known. Both termini are separated by a linker domain and 
substrate- binding domain. ATP binding to the N- terminal domain drives changes in the 
C-terminal substrate -binding domain. Thus, weak ATP binding affinity with Hsp70 is 
formed, which allows high affinity for the substrate as a binding pocket of Hsp70 opens 
(Palleros et al., 1993; Pierpaoli et al., 1997). Hsp70 in its ADP-bound state has high 
affinity binding and low substrate affinity, thus closing the binding pocket of Hsp70 
(Theyson et al., 1996). This two- step process for association/dissociation is extremely 
important for Hsp70 activity. Mutations in the substrate binding domain of Hsp70 result in 
failure to bind to its substrate (Ha et al., 1997).
1.3.4 Hsp47
Hsp47 is a collagen binding glycoprotein and displays characteristics of serine protease 
inhibitors. This protein is located in the endoplasmic reticulum (ER) and assists in protein 
folding and assembly. An ER retention signal is found in the C-terminal domain of the 
protein (Nakai et al., 1992).
Hsp47 plays a major role in the maturation of pro-collagen into collagen types I to IV 
(Nagata et al., 1996). Moreover, hsp47-/- mice clearly lack the ability to process pro­
collagen into mature collagen, and embryos only survive until day 11.7 (Nagai et al.,
2000). No other roles of Hsp47 have yet been identified.
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1.3.5 Hsp27
Hsp27 or the small Hsps (sHsps) consist of proteins upto 40kDa, which are less conserved 
compared to Hsp70 or Hsp90. The number of sHsps varies in different organisms. For 
example, in Drosophila, four small Hsps have been identified and in mammals three sHsps 
have been identified (aB-Crystallin, Hsp20 and Hsp27). In yeast, three sHsps have been 
identified (Hspl2, 26 and 42) (Wotton et al., 1996). Common to all sHsps is the highly 
conserved a-Crystallin core (100 amino acids in length) located at the C-terminal domain 
of the protein (Boelens et al., 1998). The N- terminal domain is variable in sequence and 
length. Under non- stressful conditions, the sHsps are located in the cytoplasm (Lavoie et 
al., 1993a) and also in the perinuclear zone (Preville et al., 1996). sHsps are also found in 
mitochondria as observed in Drosophila (Plesofsky Vig and Bramble, 1990). Under stress 
conditions, aggregates of sHsps translocate to the nucleus (Arrigo et al., 1988).
All sHsps have the ability to form oligomers or aggregates, with molecular weights of upto 
800kDa depending on the cell type and conditions (Seizen et al., 1978a). sHSps 
aggregates are also found in prion disease (Radford et al., 1999), and neurodegenerative 
diseases including Parkinson’s disease (Renkawek et al., 1999), Huntington’s disease 
(Reddy et al., 1999), Creutzfeld-Jakob disease and Alzheimer’s disease Like other Hsps, 
expression of the sHsps increases in response to elevated temperature (Landry et al., 1989). 
In vitro, sHsps display chaperone activity (Jakob et al., 1993) as they can induce re- 
naturation of denatured proteins in an ATP-independent manner. Non-native proteins 
interact with the large sHsp oligomers, which accumulate during heat shock, and may
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create a reservoir of folding intermediates that could prevent further aggregation of non­
native proteins (Ehrnsperger et al., 1997).
Both phosphorylation and oligomerisation are induced by stress, TN Fa, 11-6, IL-3, IL-1, 
and retinoic acid (Kim et al., 1984; Welch, 1985; Kaur and Satlatvala, 1988; Mehlen et al., 
1995b). The N- terminal domain contains MAPKAPK2 phosphorylation sites that are 
highly conserved (Stokoe et al., 1992). Human Hsp27 is phosphorylated at serine residues 
15, 78, and 82 (Landry et al., 1992), whereas murine Hsp25 is phosphorylated at serine 
residues 15 and 86 (Gaestel et al., 1991). Oligomerisation has been studied in 
unphosphorylatable mutants of human Hsp27 in which serine 15, 78 and 82 were replaced 
with alanine, glycine or aspartic acid. Different patterns of Hsp27 oligomers were 
observed with large aggregates being generated with alanine substitution, and small 
aggregates formed with glycine and aspartic acid substitutions (Mehlen et al., 1997a).
1.3.6 Mechanism of Hsp gene regulation
The mechanism of Hsp gene regulation in response to stress such as heat shock has been 
well documented. The response is regulated by transcription factors known as Heat shock 
factors (HSFs). The mammalian family of HSFs consists of four members: HSF-1, HSF-2, 
HSF-3 and HSF-4. HSF-1 and HSF-3 acquire DNA binding activity in response to heat 
shock, ischaemia/reperfusion, hypoxia, and exposure of cells to heavy metal and amino 
acid analogues (Bailer et al., 1993; Sarge et al., 1993). Moreover, cells in which HSF-1 is 
disrupted are not tolerant to mild stress and are not protected against heat-induced 
apoptosis (McMillan et al., 1998).
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HSF-2 is constitutively expressed in mouse embryonic stem cells (Murphy et al., 1994). 
HSF-3 has been cloned only from chicken cells (Nakai and Morimoto, 1993) and is 
activated by various stresses that activate HSF-1. However, the thresholds of HSF-1 and 
HSF-3 are dissimilar (Tanabe et al., 1997) as HSF-3 activation is slow, whereas HSF-1 
activation is rapid. HSF-3, however, is activated in conditions of severe stress.
HSF-4 is expressed in the heart, brain, pancreas and skeletal muscles. It lacks a carboxy 
terminal domain and is thought to be a negative regulator of the heat shock response, since 
it also lacks transactivation properties (Nakai et al., 1997).
The structure of HSFs is conserved. All HSFs have a DNA binding domain (DBD), which 
resembles the prokaryotic helix-tum-helix motif and is thought to be involved in 
intramolecular interactions (for sequestering monomers that are inactive) and 
intermolecular interactions (to form homotrimers that are capable of binding DNA) with 
high affinity. Further downstream is an oligomerisation domain, which forms a three- 
stranded a  helical coiled coil and controls protein-protein interactions (Sorger and Nelson,
1989). The C-terminal domain is required for transcriptional activation. Also within this 
domain is an internal repressive domain, which regulates the protein’s activity (Wu et al., 
1995). Phosphorylation of HSF-1 occurs in the cytoplasm when HSF-1 monomers form a 
homo-trimer that is active, which then translocates to the nucleus to bind heat shock 
elements (HSEs) within the promoter of Hsp genes (Figure 1.5).
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Il was first suggested from experiments in yeast that the products of HSF target genes 
within the Hsp90 chaperone complex were directly involved in the negative regulation of 
HSF, and deletion of Hsp70 showed that there was an increase in abundance of other Hsps 
under HSF control in non-stressful conditions. Such studies have shown that Hsp70 is not 
sufficient alone to negatively regulate HSF (Abravaya et al., 1992).
Hsp90 is also another component, which interacts with HSF1 and negatively regulates its 
activity. Depletion of Hsp90 from the complex results in activation of the monomer to the 
trimeric state (Ali et al., 1998) whereas depletion of other chaperone proteins including 
Hsp70 does not activate trimerization and this suggests that the most important contacts of 
HSF1 in the complex are with Hsp90 itself (Zou et al., 1998). Furthermore, under non- 
stressful conditions, the association of HSP90 and HSF1 keeps HSF1 in an inactive form, 
however, under stressed conditions trimerisation of HSF1 occurs as a result of loss of 
Hsp90 from the chaperone complex.
Other growth signals also promote activity of HSF1 through phosphorylation sites in the 
C-terminal trans-activation domain in response to MAPK (Chu et al., 1996). Serine to 
alanine mutations in the C-terminal domain results in lack of activation under normal 
conditions (Kline and Morimoto, 1997). HSF activity is also influenced by protein 
kinases at the trans-activation or DNA binding stages (see review by Morano and Thiele 
(1999)).
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Figure 1.5 Mechanism of HSF-1 Activation
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HSF-1 has been shown to be required for roles in functions other than stress. Over­
expression of cDNA of HSF-1 can block cell growth (Espinet et al., 1995) in yeast. In 
mammalian cells under non-stressful conditions, HSF can interact with c-Myb to stimulate 
the expression of hsp70 expression in cell proliferation and the cell cycle (Kanei-Ishii et 
al., 1997). C-Myb can form a complex with HSF-3 through DNA binding domains, 
stimulating HSF-3 nuclear entry in unstressed conditions (Kanei-lshii et al., 1997).
Other proteins have also been shown to regulate HSF. Stephanou et al (1998) have 
previously shown that STAT-3 can activate the Hsp90p promoter. It has been shown that 
NFIL-6 and STAT-3 interact differentially with HSF-1. Interaction of HSF-1 and NFIL-6 
in the presence of heat shock has a synergistic effect on the activity of Hsp90p promoter 
whereas HSF-1 interacting with STAT-3 and heat shock has an antagonistic effect on the 
Hsp90P promoter (Stephanou et al., 1998).
IFNyis able to activate expression of Hsps 70 and 90 by activating HSF-1. Over­
expression of STAT-1 has been shown to enhance the activity of Hsp70 and Hsp90p 
promoters in the human hepatoma HepG2 cells. In STAT-1 deficient cells (U3A) IFNy is 
unable to activate Hsp70 and 90P promoters. However, when STAT-1 is re-introduced 
into this cell line, activation of Hsp70 and 90p is re-established in response to IFNy. 
Interaction studies show that STAT-1 and HSF-1 co-operate in activating Hsp70 and 
Hsp90P promoters (Stephanou et al., 1999). Protein-protein interaction studies also show 
that HSF-1 interacts with STAT-1 but not with STAT-3.
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1.3.7 Thermotolerance and Cell Protection
One of the most important roles of the Hsps is observed in stressful conditions such as heat 
shock, when proteins misaggregate due to intolerance to high temperature. One such 
phenomenon in which cells confer greater tolerance to heat stress is known as 
thermotolerance and has been studied extensively.
A state of tolerance is achieved when cells are subjected to a mild heat stress, thereby 
inducing the synthesis of the Hsps and protecting against a more severe stress. 
Thermotolerance is also known as preconditioning (Gemer and Schneider, 1975) and has 
been observed in various conditions ranging from developmental stages of organisms to 
cultured cells, whole mice, and Drosophila adults, but is not observed in all organisms such 
as aged animals. Heat treatments, which induce Hsps can be replaced by other 
conditioning treatments including ethanol, hypoxia and ischaemia. Such conditioning is 
usually transient, lasting 24 hours in cultured cells. Examination of tissues and organs 
subjected to various metabolic insults such as ischaemia has revealed that Hsp synthesis is 
increased for example in rat heart (Delcayre et al., 1988). Moreover, rats that were 
subjected to whole body hypothermia were found to suffer less myocardial damage in 
response to a subsequent ischaemia/reperfusion treatment (Donnelly et al., 1992).
High levels of Hsps can also protect cells from apoptosis as has been observed with Hsp70. 
In transient transfections, Hsp70 has been shown to block caspase activation and suppress 
mitochondrial damage as well as nuclear fragmentation (Mosser et al., 1997; Buzzard et 
al., 1998). Hsp70 has also been shown to inhibit apoptosis at particular points in the 
apoptotic pathway by preventing the recruitment of pro-caspase 3 and 9, and also JNK
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activation (Beere et al., 2000; Merrin et al., 1999). Similarly, Hsp27 can also block 
apoptosis induced by heat shock, fas ligand, and anticancer drugs when overexpressed 
(Richards et al., 1996). However, this effect has not been observed in response to other 
stresses such as UV radiation (Trautinger et al., 1997).
It has been shown that Hsps can protect against ischaemic damage (Martin et al., 1997). 
For example, dorsal root ganglion (DRG) neurons can be protected against heat or 
ischaemic stress by overexpressing hsp70 and hsp90 using disabled herpes simplex viruses 
(Amin et al., 1996; Wyatt et al., 1996). In contrast, only Hsp27 has been shown to protect 
DRG neurons from apoptosis induced by nerve growth factor withdrawal (Wagstaff et al., 
1999).
The sHsps are thus negative regulators in apoptosis (Samali and Cotter, 1996). For 
example, many studies have shown that expression of Hsp27 interferes with apoptotic 
death mediated by staurosporine (Mehlen et al., 1996b) in vitro.
In cultured cardiomyoctyes Hsp70 and Hsp90 gene transcription is induced by heat shock 
or ischaemia (Nayeem et al., 1997). In the intact heart, cardiac function is improved after a 
whole body heat shock followed by a global ischaemic insult applied 24 hours later 
compared to hearts that are given an ischaemic insult alone (Currie et al., 1988). 
Overexpression of Hsp27 and Hsp70 in viral vectors can protect cardiac cells from heat 
shock or ischaemia since they are able to survive better compared to control cells (Brar et 
al., 1998b). Transgenic mice over-expressing hsp70 have also been shown to exhibit
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improved recovery of the myocardium after ischaemic injury (Marber et al., 1995; Plumier 
et al., 1995).
Hsps play a vital role in cell survival. Elucidation of new non-stressful Hsp inducers and 
their mechanisms are of importance since they could provide protection against stresses 
such as myocardial ischaemic injury. Cardiotrophin-1 (CT-1) and Urocortin (Ucn) are 
such inducers of Hsps that have been identified as protective factors which will be 
discussed in the next section.
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IA Cardiotrophin-1 (CT-1) -  A Member of The Interleukin-6 Family of Cytokines 
1.4.1 Introduction
Cytokines are essential mediators of normal and pathological responses such as tissue 
injury and infection. Cytokines mediate signals into the cell via different cytokine 
receptors and intracellular signalling pathways. Responses to infection lead to activation 
of inflammatory and immune derived cytokine genes that also act on various organs in the 
body to maintain homeostasis (Dinarello, 1996). Cytokines show a wide variety of 
biological functions on various tissues and cells, and several different cytokines can exert 
similar and overlapping functions on a certain cell type. The IL-6 family of cytokines 
display overlapping functions and include interleukin 6 (IL-6), leukaemia inhibitory factor 
(LIF), oncostatin M (OM), interleukin 11 (IL-11), ciliary neurotrophic factor(CNTF) and 
cardiotrophin-1 (CT-1) (Gearing et al., 1992; Pennica et al., 1995b). This section will 
commence with a brief introduction about the IL-6 family of cytokines, followed by a 
detailed discussion about CT-1 signalling pathways, and finally, sections on CT-1- induced 
hypertrophy and cell protection. The final part of this introduction will discuss urocortin, 
signalling pathways activated by Ucn, and Ucn in cell protection.
1.4.2 The IL-6 Family of Cytokines
The IL-6 family of cytokines is pleiotropic and play varied roles in various tissues 
including haematopoietic, nervous and cardiovascular systems (Hilton, 1992); Yang, 1993; 
Kishimoto et al., 1995; Ip and Yancopoulos, 1996). IL-6 is involved in B cell 
differentiation (Miyaura et al., 1988) and is elevated in patients with congestive heart 
failure and myocardial infarction (Miyao et al., 1999) and in the myocardium of the canine 
model of ischaemia/reperfusion (Gwechenberger et al., 1999; Chandrasekar et al., 1999).
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LIF is an inhibitor of Ml cell growth (Hilton and Gough, 1991), and OM has similar 
effects to LIF (Rose and Bruce, 1991). CNTF is involved in survival of ciliary neurons as 
well as motor neurons, and induces differentiation of oligodendrocytes into astrocytes 
(Stokli et al., 1989). IL-11 has similar activites to IL-6, whereas CT-1 is an inducer of 
cardiac hypertrophy (Pennica et al., 1995a).
1.4.3 IL-6 family receptor components
All members of the IL-6 family of cytokines share the common receptor component 
gp 130. Gpl3() expression is ubiquitous and is involved in signal transduction, but does not 
bind to the cytokine itself. The receptor subunit gpl30 is widely expressed in other organs 
including the heart (Saito et al., 1992), Kishimoto et al., 1995) and has been identified to 
be a signal transducing protein The various receptor components of the IL-6 family can be 
seen in figure 1.6. All IL-6 and IL-6 -like cytokines can recruit gpl30 alone (Hibi et al.,
1990) or in combination with the LIF receptor (LIFR), or the OM receptor (OMR) 
(Gearing et al., 1991; Mosley et al., 1996). OM signals via gpl30-LIFR 
heterodimerisation (Gearing et al., 1992).
IL-6, IL-11 and CNTF bind to specific a-receptor subunits: IL-6R, IL-11R, and CNTFR 
(Yamasaki et al., 1988; Hilton et al., 1994; Davis et al., 1991). Ligand binding, 
ligand/receptor-a complexes recruit the corresponding signal transducing receptor 
components. Receptor-a subunit expression, or, the presence of soluble receptors can 
determine the responsiveness of a cell to the cytokine. For example, LIF directly binds to 
the signal-transducing receptor components, as does OM. CT-1, however, requires an a- 
receptor subunit in addition to LIFR and gp!30 (Robledo et al., 1997).
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Figure 1.6 Receptor complex sharing gp!30 as a signal transducer
IL-6 or IL-11 Signalling is triggered by homodimerisaion of gpl30 as does IL-11. LIF, CNTF, OM, and CT-1 signaling 
requires heterodimerisation of gpl30 with LIFR. However, OM can also signal directly through an OM specific receptor 
component with gpl30, whereas CNTF, IL-11, and IL-6 associate with receptor components CNTFR, IL-11R, and IL-6R
with then binds to cause dimerisation of gp!30.
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1.4.4 Identification of CT-1 as a hypertrophic factor
CT-1 was originally identified in a screen based on the finding that conditioned medium 
from differentiated embryoid bodies derived from mouse embryonic stem cells, was able to 
induce a hypertrophic response in neonatal cardiac myocytes. The subsequent screening of 
an expression cDNA library prepared from such embryoid bodies for the ability to induce 
hypertrophy resulted in the identification of two clones encoding CT-1 (Pennica et al, 
1995a). In database sequence analyses, no DNA sequence matching these cDNA clone 
was identified, indicating that a novel factor capable of inducing hypertrophy had been 
isolated, however, CT-1 is related to IL-6. Studies have shown that as well as being a 
hypertrophic factor, CT-1 can protect cells from damaging stimuli in cardiac cells and 
other cell types (Latchman, 1999).
1.4.5 Cloning and Protein Structure of CT-1
The mouse and human CT-1 clones that were originally identified were 80% homologous 
at the amino acid level, and were 200 amino acids in length, thus giving a molecular mass 
of 21.5kDa. Both the human and mouse CT-1 lack a conventional hydrophobic amino 
terminal secretion sequence, however they are found in the medium of transfected cells. 
The coding regions of human and mouse CT-1 are contained in three separate exons of 
genomic DNA. The human CT-1 gene was localized to chromosome 16p 11.1 pi 1.2 
(Pennica et al., 1996).
Expression of both human and mouse CT-1 have been shown to occur during different 
stages of development and different tissues. For example, CT-1 is expressed in the heart at
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(lay 8.5 in the mouse embryo whereas it is not expressed in the other tissues at this stage 
(vSheng et al., 1996). However, in later developmental stages CT-1 is expressed in other 
organs but is still predominant in the heart.
The structure of CT-1 has been established. Its structure contains four amphipathic helices 
that are also observed in structures of other cytokines and growth hormones (Abdel- 
Meguid et al., 1987; Bazan et al., 1991). Although the cytokines share biological activities 
and receptor subunits, the amino acid sequences of human CT-1 and other members of the 
IL-6 family members reveal that they are only distantly related in primary sequences (15- 
25%). The cysteine residues are not conserved between but individual family members are 
more conserved across species (Gearing et al., 1992).
1.4.6 CT-1 signalling in hynertrophv
1.4.6.1 Overview to hypertrophy
Hypertrophy is observed in many pathological conditions and is an important mechanism 
in order to compensate to maintain cardiac function in response to increased work load, 
where increased workload is defined as an increase in wall tension in the heart and can 
occur as a result of hypertension, myocardial infarction or abnormalities in the valves. 
Wall tension is inversely proportional to thickness of the heart wall, therefore thickening of 
the heart as in hypertrophy reduces the wall tension and thereby reduces the oxygen 
demand of the myocardium (Force et al., 1999). Hypertrophy is characterised by an 
increase in cell size without division (Neyes and Pelzer, 1995).
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In vivo, hypertrophy is measured by an increased heart to body ratio. In vitro, hypertrophy 
can be assessed by measurement of cell size, protein synthesis, sarcomeric organisation, 
and altered gene expression (Force et al., 1999). Contractile proteins such as myosin light 
chain 2 (MLC-2) are upregulated in hypertrophy and are involved in the formation of 
additional sarcomeric units in the hypertrophied cell (Lee et al., 1998). Skeletal a- actinin 
and (3 myosin heavy chain ((3-MHC) embryonic contractile protein isoforms are also 
reactivated (Schwartz et al., 1986; Izumo et al., 1987) after 2 days of hypertrophic 
stimulus. Other non contractile foetal genes are also reactivated and include atrial 
natriuretic peptide (ANP- a characteristic marker of hypertrophy) and brain natriuretic 
peptide (BNP) (Knowlton et al., Lee et al., 1988; Harada et al., 1998; Hanford et al., 1994). 
These peptides are vasodilators and diuretics that lower blood pressure and enhance 
excretion of excess fluid, so reducing cardiac wall tension.
Within one hour of hypertrophy, expression of the immediate early genes c-fos, c-myc, c- 
jun and egr-1 is observed (Izumo et al., 1988). Moreover, changes in the expression of 
proteins required to maintain calcium levels are also observed during hypertrophy. 
Elevated intracellular calcium is associated with heart failure and cardiac hypertrophy 
(Richard et al., 1998).
1.4.6.2 Hypertrophic Stimuli
CT-1 and LIF are able to induce cardiac hypertrophy (Pennica et al., 1995a). Other stimuli 
are also able to induce cardiac hypertrophy and include physical stress such as cell stretch 
and mechanical overload (Komura et al., 1990; Kira et al., 1984; Cooper et al., 1985).
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Angiotensin II (Ang II) and endothelin-1 (ET-1) and a-adrenergic agonists noradrenaline, 
adrenaline, and phenylephrine also induce hypertrophy (Dostal and Baker, 1998; Force et 
al., 1999).
1.4.6.3 The p42/p4 MAPK and STAT-3 Pathways in Hypertrophy
As mentioned above, CT-1 is able to induce hypertrophy in the heart and involvement of 
the p42/p44 MAPKinase and STAT-3 pathways have been implicated in CT-1 induced 
hypertrophy. In this section, these two pathways will be addressed.
The activation of the p42/p44 MAPKinase pathway requires the activation of Ras, an 
upstream activator of the p42/p44 MAPKinase pathway. Transgenic mice that express 
constitutively active ras have been shown to develop ventricular hypertrophy (Hunter et al., 
1995). Constitutively active ras is able to stimulate increase in size and a hypertophic 
pattern of gene expression is observed in cardiac myocytes (Fuller et al.,1998). Raf is a 
kinase that is activated by Ras, and activates MEK-1 and the p42/p44 MAPKinase 
pathway. Transfection of constitutively active MEK-1 is able to increase ANP promoter 
activity in cultured cardiomyocytes (Gillespie-Brown et al., 1995). Transfection of a 
dominant negative MEK-1 reduces the induction of the ANP promoter activity by 
phenylephrine but does not effect sarcomeric organisation (Gillespie-Brown et al., 1995; 
Thorbum et al., 1994). Therefore, the p42/p44 MAPK pathway is required for induction of 
ANP by phenylephrine but not for other effects of phenylephrine. Inhibition of MEK-1 
with PD98059 has no effect on ANP promoter activity by phenylephrine, but inhibits 
activation by Angll (Aoki et al., 2000). Therefore, the p42/p44 MAPK pathway is
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involved in some aspects of the hypertrophic response, but it is not known which 
hypertrophic agents utilise this pathway to mediate their hypertrophic effects. In a study 
by Sheng et al. (1997) it is shown that the p42/p44 MAPK pathway is not involved in the 
hypertrophic response mediated by CT-1 since the hypertrophic effect in cardiomyocytes 
was not blocked by either PD98059 or a dominant negative mutant of MEK-1 (Sheng et 
al., 1997), and STAT-3 phosphorylation was not affected by inhibition of the MAPK 
pathway and is therefore likely to mediate the hypertrophic effect by CT-1 (Sheng et al.,
1997).
Evidence to suggest that STAT-3 may be required for CT-1 induced hypertophy has been 
shown in studies in transgenic mice over expressing cardiac specific STAT-3. These mice 
developed hypertrophy with increased expression of ANP, b-MHC and CT-1 genes 
(Kunisada et al., 2000). Mechanical stretch and pressure overload also lead to 
phosphorylation of STAT-3 (Pan et al., 1997) which is mediated via gpl30 (Pan et al.,
1998). CT-1 has also been shown to activate angiotesinogen promoter via STAT-3 in 
cardiac cells and it has been suggested that this is a cellular signal for hypertrophy in 
cardiac muscle (Fukazawa et al., 2000). It is likely that the p42/p44 MAPK pathway is 
required for protective effects of CT-1 and STAT-3 is required for hypertrophic effects of 
CT-1.
1.4.7 CT-1 signalling in cell protection
Other than its ability to cause hypertrophy, it has been shown that CT-1 plays a role in cell 
survival (Sheng et al., 1996). In this study, treatment of rat neonatal cells with CT-1 was 
able to enhance survival in serum free media. Later studies have shown that pretreatment
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of cardiac neonatal myocytes with CT-1 is also able to protect against heat shock or 
simulated ischaemia (Stephanou et al., 1998). Such protection by CT-1 in cardiac cells 
has been shown to be due to the ability of CT-1 to induce elevated levels of the heat shock 
proteins Hsp70 and Hsp90, which are primarily involved in the stress response, and as 
previously described (see section on the stress response) over expression of these proteins 
have shown to protect cardiac cells against ischaemia and heat shock (Heads et al., 1994; 
Cummings et al., 1996).
The protective effect observed in cultured cardiac cells is of great importance and it would 
be valuable to observe whether CT-1 is able to protect against ischaemia in the human 
heart. Sheng et al (1997) have shown that CT-1 is able to promote survival effects by 
minimizing the degree of apoptosis induced by serum removal. This has also been 
observed when cells are exposed to heat shock or ischaemia (Stephanou et al., 1998). 
Severe stresses such as heat shock or ischaemia have shown that more cells are prone to 
die due to apoptosis during the period of reperfusion (Gottlieb et al., 1994). However, 
studies have shown that CT-1 can protect when given after ischaemia at reperfusion in 
cardiac cells (Brar et al., 2001) and as well as before ischaemia. In the isolated rat heart, 
CT-1 is also able to protect whether added before ischaemia or at reperfusion (Brar et al.,
2001). This result is desired since in a clinical setting the therapeutic effects of CT-1 
would be required to operate when given at reperfusion after ischaemia.
Like many other cytokines, CT-1 has multiple effects. However, these effects are probably 
not separate, and there may be a fine- tuning as to when CT-1 should induce hypertrophy,
76
or when it should be protective to the cell. This fine balance can be understood by 
investigating the signaling pathways that CT-1 may activate to exert its effects. It is 
commonly understood that the 1L-6 family of cytokines transmit signals via the gpl30 
subunit. Binding of CT-1 to its receptor results in the activation of the MAPkinase 
enzymes p42 (ERK1) and p44 (ERK2). In turn, threonine phosphorylation of nuclear 
factor IL-6 (NFIL-6) (or C/EBPP) allows it to activate gene transcription (Nakajima et al.,
1993).
In addition to activating the MAPKinases, the JAK/STAT pathway is also activated by 
CT-1 via dimerisation of STAT3 (Akira et al., 1994; Horvath and Darnell, 1997). 
Therefore, these two separate pathways are activated for cell survival or proliferation of the 
signal to cause hypertrophy. Thus Sheng et al (1997) have shown that the protective effect 
of CT-1 can be blocked by using the MAPKinase inhibitor PD98059. In cardiac myocytes, 
similar results have been demonstrated when exposed to ischaemia. The protective effects 
of CT-1 (whether added before or after an ischaemic episode) was abrogated in the 
presence of the PD98059 inhibitor, and similar results were observed in the intact heart 
(Brar et al., 2001). The JAK/STAT pathway is not affected by the inhibitor PD98059 in 
Sheng’s study (1997), therefore, it could be concluded that the MAPKinase pathway is 
involved in the protective effect of CT-1 whereas the JAK/STAT pathway maybe involved 
in the hypertrophic effect of CT-1. Therefore, it may be possible to design CT-1 analogues 
which stimulate only the protective pathway or block the hypertrophic effect of CT-1 
whilst maintaining its protective effect.
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Another possibility would be to examine the inducibility of CT-1 gene expression by using 
various stimuli to enhance CT-1 levels. Recently, mouse CT-1 promoter studies have 
shown that norepinephrine can enhance the activity of the promoter. Various binding sites 
have also been mapped, one of which is a C/EBPp binding site.
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1.5 Urocortin
1.5.1 Introduction
Urocortin is a 40 amino acid peptide that exists endogenously in mammals and belongs to 
the family of corticotropin releasing factors (CRF). This family was originally isolated 
from ovine brain (Vale et al., 1981). CRF is known to coordinate endocrine responses to 
stress through its neurohormonal action as the major physiologic regulator of the 
hypothalamic pituitary adrenal axis (HPAA), and evidence supports the idea that CRF can 
function as a neurotransmitter within the central nervous system (CNS), along with 
coordinating autonomic, behavioural and immunological responses to stress (Owens and 
Nemeroff, 1991). Homologues to CRF have been isolated from fish as well as some 
amphibians (Okawara et al., 1988; Montecucchi and Henschen, 1981; Anastasi et al., 
1980) and eventually from vertebrates (Stenzel et al., 1992).
It was thought that many other members of the CRF family would exist in mammals, 
which may be closely related to urotensin I, which was also isolated as a relative of CRF 
from fish. UCN was isolated by using urotensin I cDNA probes as well as antisera, and 
was found to be a peptide of 40 kDa, similar to CRF. This novel peptide was isolated from 
the rat brain, and showed at least 45% homology to rat CRF and 63% homology to carp 
urotensin I (Vaughan et al., 1995). Mouse and human UCN were isolated and 
characterized (Zhao et al., 1998). The human homologue for UCN was identified from 
partial genomic sequences (Donaldson et al., 1996). Nucleotide cDNA homology between 
human and mouse amounts to 88% and 97% respectively and 95% and 100% homology at 
the mature peptide level. UcnII and UcnIIl have also been isolated.
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At the genetic level, the UCN gene is very similar to the CRF gene, with 2 exons and the 
coding region being contained within the second exon (Zhao et al., 1998). In transient 
transfections, promoter activity of urocortin was significantly reduced in response to 
forskolin stimulation when mutations were introduced in the CRE sequence, suggesting 
that CRE is involved, but other factors may be involved in regulation of the urocortin 
promoter. The CRE has also been shown previously to mediate activation of the CRF 
promoter by cAMP (Dorin et al., 1993; Seasholtz et al., 1998).
Messenger RNA for Ucn is predominantly located in the Edinger-Westphal nucleus 
(EWN) and the lateral superior olive in the central nervous system (Bittencourt et al., 1999; 
Kozicz et al., 1998). Reasonable levels of mRNA of Ucn are found in other regions of the 
brain including cerebellum, hippocampus, neocortex, olfactory system, basal ganglia, 
supra optic nuclei (Bittencourt et al., 1999).
1.5.2 CRF receptors
High affinity binding sites for CRF were identified by autoradiographic techniques (De 
Souza et al., 1985) and the first receptor was cloned in 1993 (Chen et al., 1993; Perrin et 
al., 1993). This receptor, CRF1R, is 415 amino acids in length, and is a member of the 
seven transmembrane spanning G-coupled protein receptor family. CRF receptors are 
coupled to adenylate cyclase (Vaughan et al., 1995). Binding of the ligand to the receptor 
causes phosphorylation of PKA by cyclic AMP release. In turn, phosphorylated PKA 
phosphorylates calcium channels to allow calcium ions to enter the cell (Ikeda et al., 1998).
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There is a splice variant of Ucn receptor which is found in humans, and has 29 amino acids 
extra in the extracellular domain (Xiong et al., 1995).
The second receptor, CRF2R, was later cloned from mouse, rat, and human in 1995 in 
three separate studies (Kishimoto et al., 1995; Lovenberg et al., 1995; Liaw et al., 1996). 
The CRF2R shows 70% homology to CRF1R. CRF2R exists as two splice variant forms a  
and p, and the distribution of these variants is different. The CRF2Ra is 411 amino acids 
in length and is the primary isoform found in the brain, whereas CRF2Rp is only expressed 
in the heart. In addition, a third splice variant has been identified as CRF2Rc (Kostick et 
al., 1998). Ucn appears to be the preferred endogenous ligand for the CRF2R as it has 
high affinity for CRF2R. CRFR1 receptors show little specificity between CRF family 
members (Gottowik et al., 1997). Synthetic UCN has much higher affinity binding to the 
CRFR2 than CRF itself (Zhao et al., 1998).
Ucn has been implicated in various biological effects. For example, as mentioned earlier, 
it is responsible for many behavioural and physiological effects that are in fact, similar to 
the effects of CRF. Action of synthetic UCN on the CRFR1 leads to stimulation of 
pituitary ACTH release, increase in anxiety, and action on the CRFR2 leads to 
vasodilation, cardiac ionotropism, reduction of vascular permeability and suppression of 
appetite (Vaughan et al., 1995; Parkes et al., 1997; Turnbull et al., 1996; Spina et al., 
1996).
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CRF1R antisense, agonists, and knock out mice have shown that CRF1R is predominantly 
required for stress responses (Skelton et al., 2000). Interestingly, mice that lack a CRF2R 
exhibit effects on the co-ordination of food and appetite intake (Coste et al., 2000), and 
lack of cardiovascular effects of Ucn.
The CRF2Ra message is found in arteries and arterioles (Chalmers et al., 1995)and is the 
predominant isoform in the human heart (Chen et al., 1993). CRF2Rp is highly expressed 
in the rat heart (Stenzel et al., 1995). CRF/Ucn affect cardiovascular and respiratory 
functions indicated by hyperventilation and hypotension (Kubler et al., 1994). Ucn can 
also induce relaxation of blood vessels in vitro (Lei et al., 1993), and has recently been 
shown to have relaxant actions in the isolated rat basilar artery (Schilling et al., 1998). 
Evidence is also increasing showing that Ucn can affect mechanisms in the heart 
predominantly via the CRF2P receptor. The first report to find that Ucn mRNA was 
present in rat cardiac myocytes suggested that Ucn may play roles in protecting these cells 
from hypoxia induced apoptosis (Okasi et al., 1998) and it also stimulates the secretion of 
atrial natriuretic peptide (ANP) (Ikeda et al., 1998).
1.5.3 Urocortin in the Heart
Many studies have shown that Ucn has an important role in the heart. By injecting Ucn 
intravenously, cardiac contractility increases in a dose-dependent manner, as does heart 
rate, cardiac output and coronary blood flow (Parkes et al., 1997).
Ucn levels are increased in cardiac myocytes in response to simulated ischaemia.
Ucn can protect cardiac myocytes from lethal ischaemic injury and subsequent apoptosis. 
Cardiac myocytes that are given preconditioned media exposed to 2 hour simulated
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ischaemia were protected from cell death induced by 6 hours ischaemia. This protective 
effect is blocked by a  helical CRF, which is a competitive inhibitor of CRF family 
peptides. Ischaemia increases Ucn mRNA through the CCAAT enhancer binding protein 
(C/FBPP) and that mature peptide protected via the CRF2R (Brar et al., 1999a). Ucn 
causes rapid phosphorylation of the ERK l/2-p42/p44 MAPkinase pathway, and the effect 
is abrogated by blocking MEK1-ERK1/2 p42/p44 cascade using a specific inhibitor 
PD98059 in the intact heart (Brar et al., 2000). Ucn/hypoxia reoxygenation leads to 
cardioprotection by MEK1 and MEK2, which is an upstream component of the p42/p44 
MAPK pathway (Brar et al., 2002).
Ucn is also able to protect cardiac cells by activating Akt (Brar et al., 2001). Akt is known 
to be activated by growth factors and also PI-3 Kinase (PI-3K is crucial for cell survival of 
non cardiac and cardiac cells (Yao et al., 1995; Kaufmann et al., 1997; Kuwahara et al., 
2000)). Akt phosphorylation inhibits caspase 9 activity (Cardone et al.,1998). Inhibitors 
of PI-3K, Akt block the cardioprotective effect of Ucn. CT-1 is also known to activate Akt 
and PI-3K to mediate cell protection (Brar et al., 2001), therefore, signaling pathways of 
CT-1 and Ucn are identical. In addition, the protective effect of Ucn requires de novo 
protein synthesis whereas that of CT-1 does not (Brar et al., 2002). Ucn has also been 
shown to increase expression of hsp90 in cardiac myocytes in a MEK1/2-dependent 
manner (Brar et al., 2002).
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CHAPTER 2. 
MATERIALS AND METHODS
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2.0 Consumables and Conditions
Bacterial culture manipulations were carried out under sterile conditions using media and 
glassware that were autoclaved prior to use at 120°C, lOlb/square inch for 20 minutes. All 
plastics also used were sterile. Aseptic conditions were used to prevent contamination.
2.1 Propagation and purification of plasmid DNA
2.1.1 Preparation of competent cells
XLlBlue Escherichia coli (E. coli) were used to propagate plasmid DNA. XLlBlue cells 
were streaked on a Luria Bertani (LB) agar plate (1% (w/v) NaCl, 1% (w/v) Bacto®- 
tryptone, 0.5% Bacto®-yeast extract, and 2% Bacto®-agar) and incubated at 37°C for 18 
hours. A colony was picked from the plate to inoculate 5ml LB broth (1% (w/v) NaCl, 
1% (w/v) Bacto®-tryptone, 0.5% Bacto®-yeast extract). The culture was grown at 37°C at 
220 rpm in an orbital shaker for 18 hours.
200p.l of the culture was used to inoculate 200ml LB in a sterile conical flask and 
incubated at 37°C 220rpm for 4-6 hours until opaque. The culture was centrifuged at 
3000g in 50ml Falcon tubes for 10 minutes in a Sorvall centrifuge at 4°C to obtain a pellet. 
The pellet was washed in 500pl of ice- cold lOOmM CaCl2 by re-suspending the cells 
carefully and centrifuged for 2 minutes at 13000rpm at 4°C. After discarding the 
supernatant, the pellet was re-suspended in 2ml of ice cold CaCl2 (lOOmM) and stored on 
ice for 30 minutes. lOOpl aliquots were made in sterile 1.5ml eppendorfs for immediate 
use.
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2.1.2 Transformation of plasmid DNA
For transformation, 1 fig of plasmid DNA was added to 50p.l of competent cells and 
incubated on ice for 15 minutes. Cells were heat shocked for 1 minute at 42°C and placed 
on ice immediately after for a further 15 minutes. 900p.l of LB was added to the cells and 
incubated at 37°C for 1 hour in an orbital shaker at 220rpm. The cells were centrifuged for 
30 seconds at 145g at 20°C. The supernatant was discarded and the cell pellet was re­
suspended in lOOp.1 LB and spread on a LB agar plate containing lOOpg/ml Ampicillin. 
The plate was kept in a 37°C incubator for 18 hours and then stored at 4°C for at least a 
month.
2.1.3 Extraction of plasmid DNA from E. coli XLlBlue bacterial cells (Large Scaled
For a large- scale DNA preparation, a single colony of the transformed E. coli cells 
containing the DNA plasmid of interest was picked to inoculate 250ml of LB medium 
containing lOOfig/ml of Ampicillin and grown for 18-24 hours at 37°C in an orbital shaker 
at 220rpm. Plasmid DNA was isolated by alkaline lysis of cells, purification of DNA 
using a QiatiplOO (Qiagen Ltd, UK), followed by elution and precipitation in cold 
isopropanol. Precipitated DNA was centrifuged at 12000g for 30 minutes at 20°C, and 
then washed in 70% ethanol. Purified DNA was dried and re-suspended in lOOpJ of sterile 
water.
Concentration of DNA was determined by spectrophotometry by reading the absorbance 
wavelengths at A26o and A280. The average yield of DNA obtained from a Qiatip 100 
preparation was lOOpg per preparation. DNA concentration was calculated by the 
following equation:
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Purity of DNA = OD260/OD28o = 1.7 in a pure sample of DNA.
1 OD at A260 =50p.g/ml of double stranded DNA 
Concentration of DNA = OD^n x 50 x 100
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2.1.4 Extraction of plasmid DNA (small scale)
Small- scale DNA preparations were carried out to screen several colonies for the correct 
plasmid. A single colony of transformed XLlBlue cells was picked from a plate to 
inoculate 5ml of LB containing Ampicillin at lOOpg/ml and grown for 18 hours at 37°C in 
an orbital shaker set at 220rpm. 1.5ml of the resulting culture was transferred to a sterile 
1.5ml eppendorf tube and centrifuged for 1 minute at 12000g. The supernatant was 
discarded and the pellet was re-suspended in lOOpl of re-suspension buffer (lOOmg/ml 
RNAse-A, 50mM Tris-HCl pH 7.5, lOmM EDTA pH 8.8). Cells were lysed in 200pl of 
lysis buffer (200mM NaOH, 1% Triton X-100) and neutralized in 150pJ 3M NaOAc, pH 
5.5. Tubes were vortexed and centrifuged at 12000g for 2 minutes. The pellet (cell debris) 
was removed with a bent hypodermic needle. To precipitate DNA, 500p.l of isopropanol 
was added and mixed. The supernatant/isopropanol was centrifuged at 12000g for 5 
minutes. The supernatant was discarded and the pellet washed with 500pl of 70% ethanol. 
The ethanol was removed carefully and air-dried. The DNA pellet was re-suspended in 
25pil distilled H2Q.
2.1.5 Identification of plasmid DNA bv Restriction digestion
Plasmid DNA was digested with the appropriate restriction enzymes (Promega) to identify 
plasmid and insert DNA. lpg of DNA was incubated with 10 units of restriction enzyme. 
lp.1 of restriction buffer was added and the final volume was made up to lOpl with ddfhO. 
DNA digestion was carried out at 37°C for 2 hours, or as recommended by Promega, 
depending upon the enzyme being used.
Digested DNA products were examined on a 1% agarose gel (1% agarose (w/v) dissolved 
in lxTAE (0.4 M Tris, 0.2M NaAc, pH8.3 adjusted with HC1). Ethidium bromide 
(0.5mg/ml) was added upon cooling. The gel was cast in a tray containing a suitable 
comb. Once set, the comb was removed and the gel was placed in an electrophoresis tank 
containing lxTAE. DNA was mixed with lxDNA loading buffer (0.025% (w/v) 
bromophenol blue, 50% glycerol (w/v), lxTAE). A Ikb ladder (Gibco) was loaded along 
side the samples and run at 70-100 volts depending on the size of the gel. DNA bands 
were observed on a trans-illuminator and a photograph was taken on the Syngene gel 
analyzer).
2.2 Mammalian Cell Culture
All media, balanced salt, trypsin, versene, penicillin/streptomycin, and foetal calf serum 
were purchased from Life Technologies, UK. All plastics used were supplied by Nunc 
and Falcon.
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All cell culture work was carried out under sterile conditions in a class II microbiological 
safety cabinet. Media and reagents were either filter sterilized (0.2p.m filter) or autoclaved 
before use.
2.2.1 Cell Lines
2fTGH and U3A human fibrosarcoma cell lines were obtained from the Imperial Cancer 
Research Fund (ICRF, London, U.K.). They were maintained in Dulbecco’s modified 
Eagle Medium (DMEM) supplemented with 10% FCS (w/v), 100 units/ml penicillin and 
streptomycin (all Life Technologies, U.K.) and 250pg/ml Hygromycin B (Sigma).
For 2fTGH and U3A cells, 2ml of 10% trypsin (w/v) in versene was used to wash cells. A 
further 2ml was added, making sure that all cells were covered and incubated at room 
temperature for 60 seconds. The side of the flask was tapped to detach cells from the flask.
Cells were transferred to a 15 ml Falcon tube and centrifuged at 145g for 5 minutes. PBS 
was removed carefully and the cell pellet re-suspended in fresh growth medium. Cells 
were plated at a density of lx l0 3 cells/ml for transfections, and lxlO6 cells/ml for Western 
blotting. Freezing Cells for maintenance of stock cells
Stocks of cells were maintained by freezing and storing them at -80°C. Cells were 
trypsinised and centrifuged as previously described. The cell pellet was re-suspended in 
media I (60%DMEM and 40% FCS in a total of 2.1ml). 0.9ml of cells was aliquoted into
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cryo tubes and made up to 1.8ml with media II (5.4ml DMEM, 3.0ml FCS, 1.6ml DMSO). 
Tubes were placed on ice for 30 minutes before transferring to -80°C for 24 hours. Cells 
were placed in liquid nitrogen until required.
To recover cells, the vial was placed in 37°C incubator. Cells were transferred to 25cm3 
flask containing media with 20% FCS. After 24 hours of incubation, any dead cells were 
removed and replenished with fresh media (20% FCS).
2.2.2 Preparation of primary neonatal cultured cells
Primary rat neonatal cardiac cells were prepared according to the method described by 
Simpson and Savion (1982b). Hearts were tri-sected from 2-3 litters of neonatal rats into 
ADS buffer (6.8g NaCl, 4.76g HEPES, 0.12g NaH2P 04, l.Og, 0.4g KC1, O.lg MgS04). 
The heart tissue was then incubated in an enzyme solution to digest the tissue (30mg 
collagenase and 500pl pancreatin in 100ml ADS buffer). 5mls of the enzyme containing 
ADS buffer was added to wash the tissue. Subsequent digestions of the tissue were carried 
out by digesting for 15 minutes in an incubator at 37°C with 5%C02, 95%02. Cells were 
then centrifuged for 5 minutes at 500g. The supernatant was discarded, and the pelleted 
cells re-suspended in 2ml of FCS. The cell suspension was kept in the incubator at 37°C. 
Digestions were repeated 5 more times, and the cell suspension was pooled, and 
centrifuged. The pellet was re-suspended in DMEM containing 15% (v/v) FCS, 1% 
Penicillin and Streptomycin. Cells were pre-plated in a 175cm3 flask so that fibroblasts 
adhere to the plate, leaving cardiac myocytes in suspension. Medium containing mostly 
cardiac cells were then plated on gelatin- coated dishes (1% gelatin in PBS) at 106 cells per
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ml. The cells were allowed to adhere to the plates by incubating for 24 hours, after which 
they were ready to either transfect or treat otherwise. When stimulating cells, media was 
replenished with DMEM containing 1% FCS and l%Penicillin-Streptomycin).
2.2.3 Cell stimulation treatments
Recombinant Murine Interferon y (Sigma) and recombinant human Interferon y (Sigma) 
were dissolved in sterile lx PBS to a final concentration of 25ng/pl. For experiments, a 
final concentration of 50ng/pl was used.
Synthetic Rat Urocortin (Sigma) was dissolved in ethanol and used at a dose of 1x10'7M.
Heat stress was applied to cells by wrapping the plate containing cells with parafilm and 
floating in a water bath for 30 minutes at 43°C. Since pre-warming the medium did not 
have any affect when small amounts of media were used, medium on cells was not 
changed prior to or after heat shock. After heat shock, parafilm was removed and the plate 
dried of excess water and placed back in the incubator at 37°C.
Simulated hypoxic stress was administered by using a hypoxic chamber with a constant 
flow of 5%C02, 95%Argon (BOC gases) at 37°C. Prior to hypoxic stress, cells were 
replenished with media (either 500pi of media for a 6 well plate, or 200pl for a 24 well 
plate. With low or nil oxygen conditions, hypoxic conditions are achieved, and any small 
amount of molecular oxidative phosphorylation will dissipate within minutes and the cells 
will no longer have any molecular 0 2 to respire). The plate was placed in the chamber in a 
sealed environment to prevent escape of any gas and stress was given for 4 hours, after
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which 1.5ml of fresh media was added to each of the wells and the plate returned to the 
incubator at 37°C, 95%C>2, 5%CC>2.
Simulated ischaemia/re-oxygenation was applied by using the hypoxic chamber as 
previously described. However, cells were replenished with ischaemic buffer (137mM 
NaCl, 12mM KC1, 0.49mM MgCl2, 0.9mM CaCl2.2H20, 4mM Hepes, lOmM 
deoxyglucose, and 20mM sodium lactate pH 6.7) (Esumi et al., 1991) and placed in the 
chamber for 4 hours.
2.2.4 Transient transfections
All transfections were carried out by the calcium phosphate method. Cell lines and 
primary neonatal rat cardiac myocyte cells were transfected 24 hours after plating. In 
order to determine transfection efficiency, 5pg of p-gal expression vector was transfected 
overnight into cardiac myocytes. The cells were allowed to express the gene for 24 hours. 
The cells were then fixed with 1% (w/v) paraformaldehyde solution in PBS and stained 
with X-gal (Stephanou et al. 2000). The number of blue stained P-gal expressing cells is 
expressed over the total number of cells. The transfection efficiency for myocytes was 5% 
and for cell lines 10%. Plasmid DNA used for transfections are shown in table 2.1.
The DNA precipitate was prepared by aliquoting DNA and making up the remainder up to 
250pl with sterile distilled water. 31 pi of 2M CaCl2 was added to the DNA and mixed. 
The DNA/CaCh mix was added dropwise to 220pl of 2xHepes buffered saline (HBS) 
(50mM HEPES, 280mM NaCl, 1.5mM Na2HP04 made up in water to pH 7.1). This 
mixture was left at room temperature for 20-30 minutes so that a fine white precipitate had
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formed. 501 pi of the precipitate was added to either a 6 well plate or 24 well plates and 
incubated at 37°C for 18 hours. Cells were washed with fresh DMEM containing 1% FCS, 
followed by a final 1ml of the same media per well. Cells were then treated as required.
Table 2.1. A list of DNA plasmids used in transient transfections
Plasmid Details Reference
Hsp90(3-A -1044 to +36 region of the hsp90(3 
promoter upstream of the CAT reporter 
gene
Rebbe et al., 1989
Rccmv Empty vector containing the cmv 
promoter only
Invitrogen, 9351 NV 
Netherlands
cmv-p-gal Lac-z cDNA driven by the cmv 
promoter
Liu et al. (1998)
pR 19-27 Chinese hamster hsp27 cDNA driven 
by cmv promoter
Wagstaff et al (1997)
CT-ld -99 to +19 region of the ct-1 promoter 
upstream of the luciferase reporter gene
Funamoto et al., 1998
TK- Renilla 
luciferase
Viral thymidine kinase (TK) promoter 
driving expression of the Renilla 
luciferase gene
Promega
STAT-1
STAT-1
390-750
Full length cDNA of STAT-1 
Amino acids 390-750 of STAT-1
Curt Horvath,
Mount Sinai Hospital, 
USA
STAT-1 
691- 750
Amino acids 691-750 of STAT-1
STAT-3 Full length cDNA of STAT-3 Akira et al. (1994)
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cloned in expression vector
1,3297-514i Aa 1-297 of STAT-1 fused with aa 
293-514 of STAT-3, and 509-750 of 
STAT-1 at the C-terminus
Darnell et al. (1995)
3,293-5083 Aa 1-296 of STAT-3 fused with 
aa293-508 of STAT1, and 515-781 
of STAT-3
Darnell et al. (1995)
3296' Aa 1-296 of STAT-3 fused with 
293-750 of STAT-1
Darnell et al (1995)
pEF STAT-1 a  
D694/E
Mutation at position 694 of 
asapartic acid residue to glutamic 
acid in STAT1
King and Goodbourn 
(1998)
pEF STAT-1 a  
D694/A
Mutation at position 694 of aspartic 
acid to alanine
King and Goodbourn 
(1998)
pEFSTAT- 
1 a  G695/STOP
C-terminal amino acids at glycine 695 
replaced with STOP codon King and Goodbourn, 
(1998)
2.3 Assessment of promoter activity
Treated cells were washed in lxPBS to remove excess media with an aspirator. 1 x 
reporter lysis buffer was added to the cells (lOOpl to 6 well dish) and incubated at room 
temperature for 10 minutes to allow lysis of cells. Cells were scraped using a cell scraper 
and transferred to a sterilel .5ml eppendorf. The cell suspension was centrifuged at 13000g 
for 5 minutes at 4°C to pellet the cell debris. The supernatant containing total cell contents 
was transferred to a sterile eppendorf and stored at -20°C until required.
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2.3.1 Luciferase assay
In order to measure the amount of luciferase produced by the reporter constructs, the dual 
luciferase system™ (Promega) was used. This system allows quantification of the firefly 
luciferase and sea pansy (Renilla reniformis) luciferase in the same assay, because their 
enzyme structures are dissimilar, therefore the bioluminescent reactions of both can be 
distinguished. The Renilla luciferase is driven by the constitutively active thymidine 
kinase promoter and is co-transfected with the firefly luciferase construct and is an internal 
control for the assay.
The general method that has been adopted is according to the manufacturers instructions. 
Briefly, 10p.l of the lysate is mixed with lOOpl of the Luciferase assay Reagent (LARII). 
The amount of luciferase was measured by using a delay time of 5 seconds, and an 
integration time of 20 seconds (actual reading) on the luminometer (Turner). In order to 
read the Renilla, lOOjal of Stop and Glow® was added to the tube and mixed and the 
Renilla reading was taken from the luminometer. For standardized transfection efficiency, 
the firefly luciferase reading was divided by the Renilla luciferase reading.
2.3.2 Chloramphenicol acetyl transferase (CAT) assay
As previously described, protein was extracted from cells that were transfected with CAT 
reporter constructs. In addition, 3 cycles of freeze-thaw were also carried out to increase 
the amount of protein for the assay. CAT catalyses the transfer of the acetyl group from 
acetyl-CoA to the substrate, chloramphenicol. The enzyme reaction can be quantified by 
incubating the lysates with [14C]chloramphenicol and following product formation by
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physical separation with thin layer chromatography (TLC). The components for the assay 
were as below per tube:
50 j l l 1 cell extract
20pl 40mM acetyl CoA
2pl 200uCi/ml [,4C] chloramphenicol
32.5pl 1M Tris-Cl, pH 7.5
45.5pl ddH20
The reaction was incubated at 37°C for 2 hours. To stop the reaction, 1ml of ethyl acetate 
was added to the tube and vortexed for 1 minute. The top layer (organic phase) was 
transferred to a sterile 1.5ml eppendorf tube and dessicated in a Speedvac for 45 minutes, 
after which the sample was re-suspended in 15-20pl of ethyl acetate. The sample was 
spotted 5ul at a time onto a dot (marked by pencil) on a thin layer chromatography plate 2 
cm from the bottom. The plate was run for 55 minutes in a tank containing 100ml of 19:1 
chloroform:methanol. The tank was covered with a glass lid, and sealed with Vaseline to 
prevent evaporation of the solvent. The TLC plate was allowed to dry, and then exposed 
to autoradiographic film for 2-3 days. For quantification, spots on the film were measured 
by using a GS-800 denistometer (BioRad), and CAT activity was calculated as:
% Acetylated = Acetvlated product
Acetylated product + Non-Acetylated product
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2.3.3 (3-galactosidase assay
The (3-galactosidase reporter vector was used in co-transfections with the CAT constructs 
as a control vectors for normalizing transfection efficiency. The lac-z reporter gene is 
driven by the RSV promoter, and the amount of (3-galactosidase enzyme produced was 
measured with the Galacto-Light™ kit (Tropix Inc. Massachusetts, USA) according to the 
manufacturer’s instructions.
The Galacton substrate was diluted with Galacto-Light reaction buffer diluent (1/100 
dilution). 20pJ of cell lysate was mixed with 50pl of reaction buffer in an eppendorf tube 
and incubated at room temperature for 30 minutes. 30pl of accelerator was added to the 
tube, mixed and read on a luminometer with a 5 second delay and 45 seconds reading time. 
A negative control was used where cells were not transfected with the lac-z reporter 
construct. The amount of enzyme in the lysate was proportional to the luminometer 
reading, which represented the amount of light produced by the (3-gal reaction.
2.4 Preparation of complementary PNA (cDNA) probes
Complementary DNA probes were designed and supplied by (company). The probes were 
labeled by random priming (Feinberg and Vogelstein, 1983). All solutions and water were 
treated with diethyl pyrocarbonate (DEPC) to prevent any RNAse contamination.
In order to label DNA probes, 2 pil of the DNA fragment was denatured at 97°C for 10 
minutes in 20pl of ddH20 and snap cooled on ice. 1 OjliI of oligolabelling buffer, 2pl of 
bovine serum albumen, 50pCi a-32P-dATP and 5 units of DNA polymerase large fragment
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1 (Klenow) were added to the single strand DNA and incubated at 37°C for 1 hour. The 
labeled probe was then filtered through a G50 sephadex column by centrifugation for 5 
minutes at 400g.
2.4.1 Analysis of RNA levels
Gloves were worn at all times to prevent contamination from RNAses and all solutions 
were DEPC treated and autoclaved. All plastics were sterile, and all equipment was treated 
with RNAse Zap (Invitrogen) and washed with DEPC treated water.
2.4.2 RNA extraction
Cells were washed twice in sterile lxPBS, and all traces of PBS were removed. To cells 
plated on a 6 well plate, 500fil of RNAsol (Genyosys) was added per well. Cells were 
scraped using a cell scraper, and transferred to a sterile 1.5ml eppendorf tube. Cells were 
incubated at room temperature for 15-20 minutes and then centrifuged at 13000g for 1 
minute at 4°C. The aqueous layer (upper) was transferred to a sterile 1.5ml eppendorf 
tube. 500p.l of chloroform was added and vortexed. This mixture was incubated for 2 
minutes on ice before centrifuging at 13000g for 1 minute at 4°C. The aqueous layer was 
transferred to a sterile 1.5ml eppendorf tube. 500pl of isopropanol was added and mixed. 
RNA precipitation was achieved by storing at -80°C for 24 hours. The RNA was pelleted 
by centrifugation at 13000g for 20 minutes at 4°C. The supernatant was carefully removed 
and the pellet re-suspended in 20p.l of DEPC treated water, and stored at -80°C until 
required. 1 \A of the RNA was used to run on an agarose gel to determine the quality of the 
RNA preparation.
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2.4.3 RNA slot blot
lOmg of RNA was incubated in 3 volumes of denaturing solution (500ml formamide, 
163ml formaldehyde (37% solution), 100ml lOxMOPS buffer) at 65°C for 5 minutes. The 
denatured RNA was then chilled on ice and one volume of ice -cold 20x SSC (150mM 
NaCl, 15mM sodium citrate, pH 8) was added. RNA was spotted on to Hybond N+ 
membrane using a slot blotting apparatus, and fixed to the membrane by UV cross linking.
The membrane to be probed was pre-hybridised in hybridization solution (5x SSC, 5x 
Denhardts reagent, 0.5% (w/v) SDS, lOOpg/ml denatured herring sperm DNA, made up to 
volume with ddH20) for 1 hour at 65°C. The hybridization solution was replaced with 
fresh pre-warmed hybridization solution. The radiolabeled probe was denatured at 97°C 
for 5 minutes and snap- cooled on ice. The denatured radiolabeled probe was added to the 
hybridization solution with the membrane and incubated overnight at 65°C in a rotating 
hybridization oven for 20 hours. The membrane was washed in 2 x SSC, 0.1% SDS in 
ddH20  at 65°C for 15 minutes and wrapped in cling film to be exposed to film for 20 
hours. If the membrane was not clean, additional washes were performed and 
subsequently exposed to film.
2.4.4 Non competitive Immunoluminometric Assay for CT-1
Medium supernatants from cardiac myocytes subjected to hypoxia, urocortin or both were 
recovered and EDTA and aprotinin added to a final concentration of 4 mmol/L and lmg/L, 
respectively, before freezing at -70°C until assayed.
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The assay was devised and performed by Professor Leong L. Ng (Leicester Royal 
Infirmary, University of Leicester). Enzyme-linked immunosorbent (ELISA) plates were 
coated with lOOng per well of CT-1 antibody directed toward the mid-section (amino acids 
105-120) of human CT-1 followed by blocking in 10% foetal calf serum. The affinity 
purified antibody directed towards that C-terminal (amino acids 186-199) of CT-1 was 
biotinylated and added to the wells with 100 pL of standards (ranging from 0-20 fmol per 
well) or media supernatants. After incubation for 24 hours and washes, detection was with 
streptavidin labelled with 4-(2-succinimidyl oxycarbonylethyl) phenyl-10- 
methylacridinium 9-carboxylate fluorosulfonate, with sequential injections of H20 2 in 
HN03 followed by NaOH and acetyl ammonium bromide. Chemiluminescence was 
measured as relative light units on a Dynex MLX microplate luminometer. The lower 
limit of detection in this assay was 2.9fmol/mL and can be seen in figure 2.1.
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Figure 2.1 Standard curve to show CT-1 levels
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2.5 Analysis of protein levels
After treatments, cells were washed in 1ml lxPBS. Cells were then harvested by scraping 
in 80p.l of 2xSDS sample loading buffer (10% glycerol, 0.1% bromophenol blue, 2%SDS, 
50mM Tris, lOOmM dithiotheitol). Samples were then heated at 80°C for 4 -5 minutes.
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Samples were loaded and run on a 10% polyacrylamide SDS gel ((made from 30% 
acrylamide (w/v), 0.8% bisacrylamide) (Amersham, UK), 375mM Tris-HCl pH8.8, 0.1% 
SDS (w/v), 0.05% ammonium persulfate, 0.05% NNNN-tetraethylethalinediamine 
(TEMED)) with a 5% stacking gel (5% acrylamide, 125mM Tris-HCl pH 6.8, 0.1%SDS 
(w/v), 0.1% ammonium persulfate, 0.1% TEMED). Rainbow molecular weight marker 
(Amersham, UK) was also run to identify protein size in samples. The gel was run in tris- 
glycine running buffer (25mM Tris, 250mM glycine (pH8.3), 0.1% SDS) at 30 milliamps 
for 4 -6  hours, or until the dye was 2 cm from the bottom of the gel. Proteins were 
transferred onto Hybond C membrane (Amersham, UK) for 18 hours (Medium size gel) or 
for 2 hours at 4°C (Biorad Protean III) in a transblotter (Biorad) in transfer buffer (192mM 
glycine, 20% (v/v) methanol, 25mM Tris-HCl pH 8).
The membrane was placed in block buffer (5% Marvel (skimmed milk powder), 0.1% 
Tween-20 in PBS) for 1 hour to block non-specific sites. The primary antibody was the 
added (antibody was diluted in 0.1% Tween 20 in PBS, 4% Marvel) and incubated for 1 
hour at room temperature. The membrane was then washed with wash buffer (1% Marvel, 
1% Tween 20 in PBS) for 5 minutes twice. The secondary antibody was then incubated 
for 1 hour (HrP conjugate in 4%marvel, 0.1% Tween 20 in PBS). The membrane was then 
washed 3 times for 5 minutes with wash buffer and the final wash in wash buffer without 
marvel.
In order to visualize bands, enhanced chemiluminescence (ECL, Amersham, UK) was 
applied and used according to manufacturer’s instructions followed by exposure to
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photographic film. The membrane was also probed with an actin antibody to check for 
equal loading of protein. Bands were quantified by using a GS-800 densitometer.
The membrane was stripped in 1M glycine pH 2.8 for 15 minutes so that it could be re­
probed with other antibodies. The antibodies used are shown in table 2.2.
Table 2.2 List of Antibodies Used in Western Blotting
Antibody Species raised 
against
Species raised in Species
recognised
Dilution Secondary
Antibody
Company
Actin 
(46 kDa)
Human Goat polyclonal Most
Mammalian
species
1:1000 Anti-goat 
HrP (DAKO)
Santa Cruz
Biotechnology
USA
Hsp90
(90kDa)
Achlyia
ambisexualis
Mouse polyclonal Most
mammalian
species
1:500
Anti-mouse 
HrP (DAKO)
Kind gift from 
D.O. l  oft, 
Rochester, USA
Hsp70
(inducible
70kDa)
Human Mouse monoclonal Most
species
1:1000 Anti-mouse 
HrP (DAKO)
StressGen 
Biotechnologies 
York, UK
ST A T -1 
(91 kDa)
Human Rabbit polyclonal Most
mammalian
species
1:1000 Anti-rabbit 
HrP (DAKO)
StressGen 
Biotechnologies 
York, UK
2.6 Identification of p-galactosidase positive cells bv X-gal staining
This technique would identify those cells that were successfully co- transfected with the (3- 
galactosidase expression vector along with the expression vector being studied. After 
stress treatments, cells were washed with PBS and fixed with 1 ml 0.5% gluteraldehyde in 
PBS for 10 minutes. The fixative was removed and cells were washed twice with PBS. X-
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gal stain (12mM MgCl2, 200mM potassium ferrocyanide, 200mM potassium ferricyanide, 
and 0.4mg/ml 5-Bromo-4-Chloro-3-tridoyl-(3-D-galactopyranoside in dimethyl sulfoxide 
(DMSO, Sigma)) was added to each well (1ml) and incubated for 16 hours at 37°C. Cells 
were washed twice in lxPBS.
2.7 Assessment of cell death
Cell death was measured by Annexin V staining, TUNEL and trypan blue exclusion
2.7.1 Trypan blue exclusion
Cells were washed in phosphate buffered saline (PBS) and trypsinised for 1 minute in 
0.25p./ml trypsin in versene (Gibco, Life Technologies, UK). The cell suspension was 
centrifuged for 5 minutes at 1000 rpm, and the supernatant aspirated. The cell pellet was 
resuspended in 100p.l PBS and stored on ice. Cell counts were made, using a 
haemocytometer, by addition of 0.4% trypan blue (Sigma) to equal volume of cell 
suspension. The percentage of blue cells/total cells was counted by scoring 100 cells per 
well 3 times.
2.7.2 Assessment of apoptosis by TUNEL labelling
Cells were stained with Terminal deoxynucleotidyl transferase (3’-OH labelling of DNA) 
and 2mM Fluorescein-12-2’-deoxy-uridine-5’-triphosphate (Roche, Germany) and 
incubated for 1 hour 30 minutes in a humidified incubator at 37°C in the dark. Cells were 
washed with PBS and subsequently viewed under a phase contrast microscope (Zeiss) for 
the total number (3-galactosidase ((3-gal) positive cells and fluorescent microscopy for (3-
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gal and TUNEL positive cells. The percentage of apoptotic cells was expressed as the 
percentage of total P-gal positive cells, which were TUNEL positive.
2.7.3 Assessment of appptosis bv Annexin V staining
To assess early apoptosis and the changes that occur on the cell surface, Annexin-V-Fluos 
(Roche, Germany) staining was applied after heat shock or ischaemic stress. Incubation 
buffer (lOmM Hepes/NaOH, pH 7.4, 140mM NaCl, 5mM CaCh) was prepared. Annexin- 
V-Fluos-labelling solution was prepared by pre-diluting 20pl of Annexin-V-Fluos labelling 
reagent in lOOOpl of incubation buffer and 20pl of propidium iodide (PI) (50p.g/ml stock). 
PI was included to differentiate necrotic cells from apoptotic cells. 200pl of labelling 
solution was added per well and incubated for 15 minutes in dark at room temperature. 
Annexin-V binding cells were observed under fluorescent light (Zeiss). Cells from 3 
separate fields of view (200 cells per view) from the same well were counted and apoptotic 
cells were expressed as a percentage of total cells.
2.8 Site directed mutagenesis of murine CT-1 -99 to +19 plasmid
Mutagenesis of plasmids was carried out using the QuickChange™ Site-Directed 
Mutagenesis Kit (Stragagene) and was followed according to manufacturer instructions. 
Prior to using the kit, primers were designed to the C/EBPp sequence from the CT-1 -99 to 
+ 19 promoter (Figure 2.2).
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-99 ctgaactatg attggccgag cccgagccac gcccctagcc c t t t c c c c c t  t t t t c c c c c t  
gacttgatac taaccggctc gggctcggtg cggggatcgg gaaaggggga aaaaggggga
gg cc
t t t t c c c c c t  c c c c tc c tc c  tc c c c c g g a g  g gg t g t g t t g  aggaa_cctgg 
aaaaggggga ggggaggagg agggggcc tc c c c acacaac  t c c t t  g gacc
a t a a g c c t g g  g g c c a g c a tg  ag +19 
t a t t c g g a c c  c c g g t c g ta c  tc
Figure 2.2 DNA sequence of the CT-1 minimal promoter (-99 to 
+ 19) region showing the C/EBPp transcription factor binding site 
(italics) and mutations (underlined)
This region also contained a C/EBPp binding site and was of interest since previous studies 
have demonstrated that the ucn promoter also contains a C/EBP binding site and that the 
expression of C/EBP transcription factors is increased in response to simulated ischaemia 
(Brar et al., 1999). Four base mutations were included in the forward and reverse primers:
5 GGAGGGGTGTGTTGAGGAACCTGGA TAAGCCTG-3 ’ and
5'-CCAGGCTTATCCAGGTTCCTCAACACACCCCTCC-3\ In addition, the DNA that 
was to be mutated was prepared from a Qiagen plasmid DNA purification kit, and the 
concentration was determined by spectophotometry. A control reaction was set up with 
pWhitescript (comes with kit), and a sample reaction was set up as follows:
5pl of lOx reaction buffer 
X (5-50ng) of dsDNA template 
Xpl (125ng) of oligonucleotide primer #1 
Xpl (125ng) of oligonucleotide primer #2 
1 pi of dNTP mix
ddH2Q to a final concentration of 50pl
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-Then 1 j l x I  of Pfu Turbo DNA polymerase was added (2.5U/pl)
Cycling parameters for mutagenesis by the polymerase chain reaction (PCR) were 
modified depending upon the size of the template DNA and also the number of mutations 
to be introduced into the generated template.
The reaction was placed on ion reaction was then digested with Dpnl restriction enzyme 
(lOU/pl) and mixed before centrifuging and incubating the digestion for 1 hour at 37°C. 
This digestion allowed the parental (non-mutated) DNA to be digested, leaving only the 
mutated DNA.
Mutated DNA was then transformed into XLl-Blue super-competent cells and plated on 
agar-Ampicillin plates for 16 hours at 37°C. The resulting mutant plasmid was sent for 
sequencing to confirm that the mutation was successful.
2.9 In vitro protein-protein interaction
HSF1 expression vector were kindly given by I Benjamin, USA
Brn3b and p53 vectors were kindly provided by A Nissam, MRC Centre for protein 
engineering, Cambridge, UK
2.9.1 Transformation of plasmid DNA containing protein of interest
Expression vectors were transformed into Epicurian coli competent cells (BL-21 PlysS) 
provided by Stratagene. Cells were kept on ice for 30 minutes before heat shocking for 20 
seconds at 42°C. Transformants were returned to ice for 30 minutes, after which they were 
incubated in 800 pi LB at 37°C in an orbital shaker for 1 hour. Cells were centrifuged for
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20 seconds at 13000rpm. The supernatant was discarded, but leaving lOOul in the 
eppendorf to resuspend the bacterial pellet. The cell suspension was spread on agar plates 
containing chloramphenicol and ampicillin antibiotics. Plates were incubated for 16 hours 
in a 37°C incubator.
2,9,2 Sub-culturing transformed colonies (large scale)
A colony was picked from the plate and inoculated in 5ml LB containing the appropriate 
antibiotics and incubated at 37°C in an orbital shaker for 16 hours. 250ml of sterilized 
LB/Ampicillin was inoculated with 5ml sub-culture. The LB culture was incubated at 
37°C in an orbital shaker until the OD600nm reached 0.5 (an aliquot of 1ml was taken to 
run on SDS gel). Depending on the type of vector (pET or GST), proteins were over­
expressed by inducing with the appropriate concentrations of 1PTG (1M stock) for 2-4 
hours at 37°C in an orbital shaker until the OD at 600nm reached 1.0 (an aliquot of 1ml 
was taken to run on SDS gel).
The bacterial culture was centrifuged at 13000rpm. The supernatant was discarded and the 
pellet re-suspended in SDS gel loading buffer with p mercaptoethanol. Samples were 
boiled for 2-3 minutes and proteins were separated on 10% polyacrylamide gel in the 
presence of Rainbow marker (Amersham, UK). Electrophoresis was carried out at 60 volts 
on a mini-gel. Un-induced and induced proteins were detected by staining the gel with 
Coomassie blue stain for 1 hour at room temperature and de-stained until bands were 
observed. The gel was dried in a gel dryer for 20 minutes and kept as a reference to 
identify over-expressed proteins.
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2.9.3 Purification of Histidine tagged fusion proteins
The cell pellets (see section 2.9.2) were lysed by 3 cycles of freeze thaw from -20°C to 
room temperature in lxextraction/wash buffer (Clontech,USA). To remove cell debris the 
suspension was centrifuged at 13000rpm for 5 minutes. The supernatant was carefully 
transferred to a clean sterile eppendorf.
Talon Resin (Clontech, USA) was completely resuspended and 200pl of resin transferred 
to a 15ml falcon tube so that it would accommodate 10-20x the resin bed volume. The 
resin was equilibriated by centrifugation at 700xg for 2 minutes. The pellet was re­
suspended in 1ml of lx extraction/wash buffer (triton X-100 in PBS). This step was 
repeated 3 times before the clarified protein sample was added. The protein/resin complex 
reaction was carried out at room temperature for 20 minutes with gentle agitation (rotating 
wheel). A final centrifugation at 700g for 5 minutes was carried out and the supernatant 
removed carefully not disturbing the pelleted resin. To wash the pelleted resin, two 
washes of 1.5ml of lx extraction wash buffer was added and mixed gently on a rotating 
wheel for lOminutes at room temperature. Resin was centrifuged at 700g for 5 minutes, 
and the supernatant removed.
The resin was re-suspended in 1ml of 1 x extraction wash buffer by vortexing, and stored 
at -20°C until required for interaction studies.
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2.9.4 Purification of GST tagged fusion proteins
Cells were lysed in 1 x PBS/Triton 1% (37ml) by three cycles of freeze thaw from -20°C 
to room temperature. For 1 litre cultures, 500pl of Glutathione Sepharose 4B beads 
(Amersham, UK) was used.
2.9.4.1 Preparation of Glutathione Sepharose 4B medium
Glutathione Sepharose 4B (supplied as 75% slurry) medium was transferred to a new tube. 
The transferred medium was sedimented by centrifuging at 500x g for 5 minutes. The 
supernatant was discarded and the Glutathione Sepharose 4B washed by adding 3.76ml of 
cold (4°C) lxPBS (Manufacturer protocol suggests 10ml of lxPBS per 1.33ml of 75% 
slurry of Glutathione Sepharose 4B). The tube was inverted to mix. The medium was 
sedimented again by centrifuging at 500 xg for 5 minutes. For 500pl of original slurry 
used, 0.376ml of lx PBS was added (Manufacturer protocol suggests 1ml of lxPBS per 
1.33ml of 75% slurry of Glutathione Sepharose 4B), resulting in 50% slurry. The medium 
was mixed well before subsequent steps.
2.9.4.2 Purification of Protein of interest
The bed volume is equal to 0.5 x the volume of the 50% slurry used.
0.7446 ml of the prepared glutathione sepharose 4B (50% slurry) was equilibriated with 1 
xPBS to 37ml of bacterial lysate. This mixture was incubated at room temperature for 30 
minutes, by gentle agitation. The medium was sedimented by centrifuging at 500 x g for 5 
minutes. The supernatant was carefully decanted. The medium was washed with 10 bed 
volumes of lxPBS and inverted to mix. The medium was then sedimented by centrifuging
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at 500g for 5 minutes. The supernatant was carefully removed. This washing step was 
repeated twice. The Glutathione Sepharose 4B-bound protein was eluted from the 
sedimented medium by adding 1ml of elution buffer (50mM Tris-HCl, lOmM reduced 
glutathione, pH 8.0) per 1 ml bed volume of the original slurry. The medium was mixed 
gently to resuspend and incubated at room temperature for 10 minutes to elute the fusion 
protein from the medium by gentle agitation of the tube. The medium was sedimented by 
centrifuging at 500 x g for 5 minutes. The supernatant containing eluted protein was 
carefully transferred to a new tube and used for in vitro protein-protein interaction studies.
2.9.5 In vitro translation of proteins
The appropriate expression vector containing cDNA of the transcription factor was in vitro 
translated to radiolabel methionine residues with 35S. This was carried out using the in 
vitro transcription/translation kit from Promega, using T4 polymerase enzyme. 2pl of 
radiolabelled products were separated on an acrylamide gel containing SDS (10% w/v) and 
the gel dried on a gel dryer for 30 minutes at 80°C. Photographic film was then exposed 
for 24 hours so that the radiolabelled protein size would be visible.
2.9.6 Pull down method for protein-protein interaction
Fusion beads were washed in NENT buffer (lOOmM NaCl, ImM EDTA, 20mM Tris pH8, 
1% (v/v) NP-40 or Igepal) containing 0.5% milk powder to a final volume of 1ml. Beads 
were incubated at room temperature for 20-30 minutes in the wash buffer. The supernatant 
was carefully removed and NENT buffer containing 20% milk powder was added to the 
beads to a final volume of 0.5ml. Beads were incubated at room temperature on a rotating
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wheel for 15 minutes. A further 1ml of NENT buffer (without milk) was added to the 
beads in order to make it easier to see the pellet. After mixing the suspension, beads were 
centrifuged for 1 minute at 13000rpm. The supernatant was removed and beads were 
washed twice with 1ml of NENT alone, followed by one wash with transcription buffer 
(20mM Hepes pH7.9, 60mM NaCl, ImM DTT, 6mM MgCh, 8.2% Glycine, 0.1 mM of 0.5 
M EDTA). Beads were stored in this buffer.
For protein-protein interaction, 30pl of beads were equalized to lOOp.1 with transcription 
buffer. 5pi of the in vitro translated radio-labelled product was mixed with the fusion 
beads and incubated at room temperature on a rotating wheel for 1 hour. The beads were 
then washed five times with 1ml of NENT buffer. Beads were centrifuged for 5 minutes 
on a microcentrifuge. The supernatant was removed, and SDS loading buffer (with p- 
mercaptoethanol) was added to beads to separate on a SDS polyacrylamide gel. 10% of 
the in vitro translated product was also loaded on the same gel in order to identify 
interacting protein. The gel was dried for 30 minutes to 1 hour at 80°C and a film was 
exposed for 24 hours.
2.10 Statistical analysis
In results where two comparisons were made in a data set, the Students t-test was 
performed to test for significance between the means. A p value of less than 0.05 was 
considered significant. T-tests were performed using Microsoft Excel Analyse It.
For data sets where multiple comparisons were made between treatment groups, one -way 
analysis of variance (ANOVA) was performed. This test determines whether there are any
differences between the treatments and a p value of less than 0.05 was considered 
significant.
When an ANOVA test showed significant differences between treatment groups, the post 
hoc Bonferroni’s test was performed to test for significant differences between specific 
treatments, and a p value of less than 0.05 was considered significant.
For comparisons being made from scanned Western blots, the Wilcoxon signed ranked test 
was used as this test determines whether there is an increase or decrease in pairs of data, 
and is appropriate when n numbers are low. Microsoft Excel Analyse It was used.
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CHAPTER 3.
The C-terminal Domain of STAT-1 
is Necessary and Sufficient for 
Stress-Induced Apoptosis
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3.0 INRODUCTION
The STATs are known to play key roles in mediating transcriptional responses to specific 
interferons and cytokines. It is known, for example, that treatment with IFNy results in 
phosphorylation of STAT-1 at tyrosine 701 and serine 727 residues within the C-terminal 
domain, leading to the formation of STAT-1 dimers which translocate to the nucleus to 
bind DNA and activate transcription of STAT-1 responsive genes (Horvath and Darnell, 
1997; Darnell, 1997; Chatterjee-Kishore, van der Akker, and Stark, 2000; Horvath, 2000).
Other STATs are activated by specific cytokines (see Introduction section). For example, 
STAT-3 is activated by cytokines belonging to the IL-6 family via a common receptor 
subunit known as gpl30. STAT-3 activation has been linked to enhanced cell 
proliferation. In addition, when over-expressed, a constitutively active form of STAT-3 
can behave as an oncogene that is able to transform cells either alone or in co-operation 
with other oncogenes (Bromberg et al., 1999; Ram, Horvath and Iyengar, 2000).
In contrast to this role for STAT-3 in cell proliferation (Bromberg et al, 2000; Ram et al., 
2000), STAT-1 has been shown to play a role in the induction of programmed cell death or 
apoptosis. Treatment of various cell lines with IFNy induces apoptotic cell death and 
activation of a proteolytic enzyme called caspase 1 (Chin et al., 1997). Moreover, cells 
that lack either functional STAT-1 protein or Jakl kinase are not sensitive to apoptotic cell 
death, and caspase 1 is not activated in response to IFNy in these cells (Chin et al., 1997). 
Similarly, cells that lack functional STAT-1 protein show reduced caspase expression and
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arc- also less sensitive to TN F-a induced apoptosis compared to parental cells that do 
express STAT-1 (Kumar et al., 1997).
These studies demonstrate that STAT-1 plays a key role in inducing apoptotic cell death in 
response to regulatory factors such as IFNy or TNF-a. Interestingly, recent studies have 
also shown that STAT-1 plays a role in apoptosis induced by simulated ischaemia/re- 
oxygenation in cardiac cells. Moreover, STAT-1 is shown to be expressed at enhanced 
levels following simulated ischaemia/re-oxygenation and phosphorylation of STAT-1 
occurs on both tyrosine 701 and serine 727 residues respectively (Stephanou et al., 2000; 
Stephanou et al., 2001). In addition, introduction of an antisense STAT-1 construct into 
cardiac cells protects them from apoptosis induced by simulated ischaemia/re-oxygenation 
(Stephanou et al., 2000).
Therefore, this study aims to investigate further the features of STAT-1 required for stress- 
induced apoptosis. The U3A cell line which lacks a functional STAT-1 protein is a 
fibrosarcoma cell line (Darnell, Kerr and Stark, 1994) will be used and will be compared to 
the parental 2fTGH cell line, which does contain a functional STAT-1 protein (Darnell, 
Kerr and Stark, 1994). The U3A cells will be transfected with expression vectors encoding 
different forms of STAT-1 to determine which region(s) of the transcription factor are 
required for stress-induced apoptosis observed in previous studies.
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3.1 Differences in S tress-Induced  Cell Death In Parental 2fTGH Cells
Expressing STAT-1 and M utant U3A cells Lacking Functional STAT-1
In order to study the role of STAT-1 in stress-induced apoptosis, the 2fTGH and U3A cell 
lines were used. 2fTGH is a human cell line containing the selectable marker guanine - 
phosporibosyltransferase regulated by IFNa. 2fTGH cells contain a functional STAT-1 
protein, whereas U3A cell line does not contain functional STAT-1 (Figure 3.1). In 
addition, U3A cells are unresponsive to IFNa and also responsive to IFNy (McKendry et 
al., 1991). For this reason, the introduction of various expression vectors was possible into 
the mutant cell line to compare with the parental cell line.
STAT-1
Actin
Figure 3.1 Western blot analysis of 2fTGH and U3A cell 
lines. 2fTGH cells show band for STAT-1 (Lane 1), and 
U3A with no band for STAT-1 (Lane 2).
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Previous studies have demonstrated that STAT-1 is involved in, for example, apoptosis 
induced by simulated ischaemia (Stephanou et al., 2000; Stephanou et al., 2001). Thus, in 
primary experiments, the effect of stress such as simulated ischaemia and elevated 
temperature was investigated in 2fTGH and U3A cell lines. The effect of simulated 
ischaemia was investigated to determine whether any differences in cell death could be 
observed between 2fTGH and U3A cell lines. Cells to be subjected to stress were placed 
them in a simulated ischaemic chamber for 2 hours, 4 hours or 8 hours. Control cells were 
kept under normoxic conditions. The percentage of cell death was measured by trypan 
blue exclusion, which would identify live cells (white) and dead cells (blue). The mean 
percentage cell death was calculated as the number of live cells divided by the total 
number of cells counted. 200 cells per sample were scored (Figure 3.2a).
119
2fTGH
Controls 2 hours 4 hours 8 hours
Simulated Simulated Simulated
Ischaemia Ischaemia Ischaemia
Figure 3.2 a. Cell Death in Parental 2fTGH cells (expressing STAT-1) or 
in U3A derivative (lacking STAT-1) following exposure to either simulated 
ischaemia for the period indicated. Values indicate percentage dead cells 
unable to exclude trypan blue and are the means of three determinations each 
performed in duplicate whose standard error is shown by the bars. *p<0.05 
U3A versus 2fTGH determined by Student t test
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The experiment showed differences in cell death between 2fTGH cells and U3A cells 
(Figure 3.1a). 2fTGH cells showed a greater percentage of cell death at each time point of 
simulated ischaemic treatment compared to the U3A cells. The percentage of cell death in 
2fTGH cells increased significantly with increasing time of exposure to simulated 
ischaemia, with the level of cell death being greater at 4 hours (p<0.05) and 8 hours 
(p<0.05). These results show that the levels of cell death observed is regulated by STAT- 
1, and that the effect may be specific to stress since no difference in death was observed in 
unstressed cells.
In order to determine that the differences in cell death observed in the previous experiment 
were not specific to the use of simulated ischaemia as a stress. 2fTGH and U3A cells were 
subjected to lethal heat stress at either 43°C or 44°C for 2 hours as sensitivity to such stress 
had not been determined. Total cell death was determined by trypan blue exclusion, and 
cell death was expressed as a mean of total cells (Figure 3.2b).
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2fTGH
Controls 43°C i  hours 44’C 2 hours
Heat shock Heat shock
Figure 3.2b. Cell death in parental 2fTGH cells (expressing STAT-1) 
or their U3A derivative (lacking STAT-1) following exposure to heat 
shock for 2 hours at 43°C or 44°C. Values indicate the percentage of 
dead cells unable to exclude trypan blue and are the mean of three 
determinations each performed in duplicate whose standard error is 
shown by the bars. p^0.05 versus 2fTGH determined by Student t test
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In this experiment, the 2fTGH cells again displayed a greater level of cell death compared 
to U3A cells. The difference in cell death between both cell types was apparent at 43 C 
(p<0.05) and was more severe at 44°C (p<P-05) as there was a 2 -fold increase in death 
compared to U3A cells.
It is apparent from these experiments that greater sensitivity to either stress is observed in 
21TGH cells compared to mutant U3A cells, and that the effects observed are not specific 
to the nature of the stress.
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3.2 Confirmation of Apoptosis bv Annexin V and 
TIJNEL Assays
The previous experiments showed that STAT-1 enhances cell death in response to two 
dillerent stimuli. Although trypan blue can distinguish between those cells that are dead 
and those cells that are alive, this method cannot determine whether dead cells result from 
necrosis or apoptosis.
Since STAT-1 has been implicated in apoptotic cell death induced by simulated 
ischaemia/repersfusion, in other studies, it was important to determine whether the 
differences in sensitivity to stress observed in this study was due to enhanced apoptosis. 
Again, 2fTGH and U3A cells were subjected to heat stress at 43°C or simulated ischaemia 
for 4 hours. In order to measure cell death by apoptosis, two methods of detection were 
used. Annexin V surface staining is used to identify early stages of apoptosis by detecting 
phosphatidyl serine, which translocates to the surface of the cell. In normal cells, 
phosphatidyl serine is located on the inside of the membrane. TUNEL label detects cells 
that are at later stages of apoptosis, as it labels 3’ OH ends of fragmented DNA.
In this experiment, those cells that were TUNEL positive or annexin V positive were 
scored and represented as a mean percentage of cells that were apoptotic (Figure 3.3).
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Figure 3.3. Apoptotic cell death in 2fTGH cells or their U3A derivative 
following exposure to heat shock or simulated ischaemia as assayed by TUNEL 
or Annexin V staining. Values are the mean of three determinations 
each performed in duplicate whose standard error is shown by the bars.
*p<0.05 U3A versus 2fTGH determined by Student t test
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2IICJH cells were more sensitive to both simulated ischaemic stress (p<0.05) and heat 
stress (p<0.05). The pattern of apoptotic cell death was similar in both TUNEL and in 
annexin V assays, with apoptotic cell death being more marked in 2fTGH cells. U3A cells 
were less sensitive to the treatments.
These results demonstrate that simulated ischaemia and heat stresses cause these cells to 
die as a result ol apoptosis, and STAT-1 enhances the extent of apoptosis observed.
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3.3 Enhanced Sensitivity of U3A cells to stress bv introduction 
of ST AT- t
In the following experiments, an expression vector encoding full length STAT-1 a  was 
introduced into the U3A cell line to determine whether enhanced apoptosis in response to 
stress could be restored by expression of STAT-1. U3A cells were transfected with the 
STAT-1 a  full length expression vector and also a cmv p-galactosidase expression vector 
(Figure 3.4).
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U3A+STAT-lawt
Figure 3.4. Apoptotic cell death in U3A cells transfected with expression vector 
lacking any insert or with STAT-1 expression vector and then either left untreated or 
exposed to simulated ischaemia for 4 hours or heat shock for 2 hours at 43°C. 
Values indicate percentage of successfully transfected (p-galactosidase positive, 
10%) cells which are positive in TUNEL assay of apoptosis and are the mean of 
three determinations each performed in duplicate whose standard error is shown by 
the bars. *p^0.05 U3A+STAT-1 cells versus control U3A cells determined by 
Student t test
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The cmv p-galactosidase vector was included to identify successfully transfected cells. 
Transfected cells were subjected to either simulated ischaemia or heat shock, and then 
stained with X-gal to identify P-gal positive cells (Figure 3.5a). Apoptotic cells were 
identified by assaying with TUNEL (3.5b). Annexin V stain was not used as this stain can 
only be used on live cells and not cells that are fixed.
Figure 3.5 2fTGH cells transfected with p- 
galactosidase and stained with X-gal (X) 
(Magnification x 10, light microscope) (a); 2fTGH 
cells assayed for TUNEL (Magnification x 40, 
fluorescence microscope) (b). Brightly fluorescent 
cells were p-galactosidase and TUNEL positive (T)
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In cells transfected with STAT-1 only a minimal effect of apoptotic cell death was 
observed in the absence of stress (Figure 3.4). When STAT-1 transfected cells were 
exposed to stress, the percentage of apoptotic cells was increased compared to the U3A 
cells transfected only with control vector. A four-fold increase was observed in U3A plus 
STAT-1 cells exposed to heat stress (p<0.05) compared to control U3A cells. An 
approximately 3 -fold increase in apoptotic cell death was observed in U3A plus STAT-1 
cells exposed to simulated ischaemia (p<0.05) compared to control U3A cells.
Therefore, this experiment demonstrates that STAT-1 mediates pro-apoptotic effects in 
cells that are exposed to heat or simulated ischaemic stress.
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3,4 Opposing Effect on Apoptosis by STAT-3 in U3A 
Cells
The previous experiment demonstrated that by transfecting a functional STAT-1 protein 
into the mutant U3A cells, levels of apoptotic cell death were enhanced to levels observed 
in the parental 2fTGH stresses cells after heat or simulated ischaemic stress.
The next set of experiments involved testing whether this effect of STAT-1 could be 
reproduced with the related protein STAT-3 or with mutant or truncated derivatives of 
STAT-1. In other experiments, these factors have been shown to be expressed at similar 
levels in the transfected cells (Stephanou et al., 2000; Stephanou et al., 2001) and this was 
also confirmed in these experiments in a Western blot (Figure 3.6).
2 3
STAT-1 “► 1 91kDa
STAT-1 390-750 -► 40kDa
Figure 3.6 Western blot with an antibody to STAT-1 using 
extracts of U3A cells transfected with wild type STAT-1 (lane 1), 
tyrosine 701 to phenylalanine mutant (lane 2), and 390-750 
STAT-1 C-terminal construct (lane 3)
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A STAT-3 expression vector was transfected into the mutant U3A cells to compare levels 
of enhanced apoptosis with those cells transfected with STAT-1 (Figure 3.7). In other 
studies STAT-3 has been shown to have an anti-apoptotic role in enhanced cell 
proliferation and transformation (Bromberg et al., 1999; Ram et al., 2000).
In addition, both STAT-1 and STAT-3 expression vectors were also transfected together 
into U3A cells (figure 3.7). All transfected cells were subjected to either heat stress or 
simulated ischaemic stress, after which they were assayed for apoptosis by TUNEL 
labelling. Those cells that were p-gal positive and also TUNEL positive were scored as a 
mean percentage of apoptotic cells.
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I Treatment Heat shock
Simulated
Ischaemia
Figure 3.7. Apoptotic cell death in U3A cells transfected with empty expression 
or expression vectors encoding STAT-1 or STAT-3 singly or in combination and 
then either left untreated or exposed to heat shock at 43°C for 2 hours or 
simulated ischaemia for 4 hours. Values indicate the percentage of successfully 
transfected cells which are TUNEL positive and are the mean of three determinations 
each performed in duplicate whose standard error is shown by the bars.
*p<0.05 versus empty expression vector transfected cells determined by Student t test.
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Transfection of STAT-1 alone significantly induced enhanced apoptosis after heat and 
simulated ischaemic stress compared to controls (heat stress p<0.05; ischaemic stress 
p<0.05). However, transfection of STAT-3 produced a small enhancement of apoptosis 
following exposure to either heat or simulated ischaemia, and this effect was much smaller 
than observed with STAT-1 alone. Co-transfection of STAT-1 and STAT-3 did not 
enhance apoptosis significantly indicating that STAT-3 can block the apoptotic effect of 
STAT-1 (figure 3.7).
These results demonstrate that the stress induced enhanced apoptotic effect is due to the 
presence of STAT-1, and that STAT-3 reduces the apoptotic effect, although this was not 
statistically significant. The pro-apoptotic effect of STAT-1 is abolished when both 
STAT-1 and STAT-3 are co-transfected suggesting that STAT-3 may behave as a negative 
control for STAT-1 activity. This could occur by competing for the same proteins as 
STAT-1 by forming heterodimers with it or by blocking its DNA binding site.
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3.5 Identification of Region of STAT-1 Required for 
Apoptosis
Differences observed by introducing STAT-1 or STAT-3 into the mutant U3A cells 
showed that these two proteins had opposing effects on apoptotic cell death induced by 
simulated ischaemia or heat stress. In order to probe further the regions of STAT-1 
required for apoptosis, chimaeric expression vectors encoding different regions of STAT-1 
or STAT-3 were used (Figure 3.8):
STAT-1 a  wt 
STAT-3 wt
u  297-5141 
3J 293-5083
3 296'
domain
297 293 514 509
296 293
390 750
691 750
Figure 3.8 Structure of the STAT-l/STAT-3 chimaeric constructs, 
and truncated STAT-1 constructs
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In these experiments, U3A cells were transfected with various chimaeric constructs. Cells 
were subjected to either simulated ischaemia or heat stress. Only those cells that were p 
gal positive and also TUNEL positive were scored and represented as a mean percentage of 
apoptotic cell death (Figure 3.9)
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Figure 3.9 Apoptotic cell death in U3A cells transfected with expression 
vectors encoding STAT-1, STAT-3, STAT-l/STAT-3 chimaeras or 
constructs encoding amino acids 390-750 or 691-750 of STAT-1 followed by 
exposure to heat shock at 43°C for 2 hours or to simulated ischaemia for 
4 hours. Values indicate the percentage of successfully transfected cells, which 
are TUNEL positive and are the mean of three determinations whose standard 
error is shown by the bars. *p<0.05 versus empty expression vector 
transfected cells determined by Student t test
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I he first chimaeric construct to be tested contained the C-terminal domain and N terminal 
domain of STAT-1 and the DNA binding domain of STAT-3 (construct 1,3 297-5143). An 
enhancement of apoptotic cell death was observed with this construct. The reciprocal 
construct was transfected in U3A cells (construct 3,l293-5083) and subjected to simulated 
ischaemia or heat stress. This chimaera did not have an enhanced apoptotic effect in 
response to either stress (figure 3.9). Interestingly, an enhancement of apoptotic cell death 
was observed in simulated ischaemia or heat treated U3A cells transfected with chimaera 
3296' (N domain of STAT-3 fused with DNA binding domain and C-terminal domain of 
STAT-1) that was statistically significant (simulated ischaemia p^0.05; heat p<:0.05).
Therefore, these experiments demonstrate that the N-terminal domain of STAT-1 is not 
required for the effects observed. Furthermore, the DNA binding domain of STAT-1 alone 
cannot induce enhanced apoptosis, with the major effect requiring the C-terminal domain 
of STAT-1 as observed with chimaera 3296'.
Further expression vectors of STAT-1 were made to probe the C-terminal domain of 
STAT-1 and its involvement in stress induced apoptosis. A construct was made contained 
the DNA binding domain and the C-terminal domain (amino acids 390-750) of STAT-1. 
U3A cells transfected with the STAT-1 390-750 C-terminal construct displayed 
enhancement of apoptosis when exposed to heat stress (p<0.05) and also simulated 
ischaemia (p<0.05) although to a lesser extent than wild type STAT-1 (Figure 3.9). 
Therefore, this result demonstrates further that the effect observed with the chimaeric
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construct is not due to the N-terminal domain of STAT-3 substituting for that of STAT-1. 
Rather, enhanced apoptosis can still be observed in the absence of the N-terminal domain.
To determine whether the isolated C-terminal domain without the DNA binding domain is 
not only necessary but also sufficient for enhanced stress-induced apoptosis, a construct 
expressing only amino acids 691-750 of STAT-1 was also prepared. In transfected U3A 
cells, this construct was able to induce enhanced apoptosis exposed to heat stress (p<0.05), 
and similar levels of enhancement to STAT-1 wild type when exposed to simulated 
ischaemia (p<0.05) (Figure 3.7). In addition, a truncated STAT-1 construct in which the 
694-750 region had been replaced with a STOP codon was not able to induce enhanced 
apoptosis, suggesting that the C-terminal domain of STAT-1 is essential for stress-induced 
apoptosis (Figure 3.9). Hence, the C-terminal domain of STAT-1 is not only necessary for 
enhanced stress-induced apoptosis but is also sufficient for this effect, producing it in the 
absence of the adjacent DNA binding domain or other regions of STAT-1.
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3.6 Requirement of Caspase Cleavage of STAT-1 in 
Stress Induced Apoptosis
The previous results demonstrated that the isolated 691-750 domain of STAT-1 was able to 
induce enhanced apoptosis significantly. STAT-1 in other studies has been shown to be 
cleaved by caspase 3 at amino acid position 694 to release a C-terminal fragment (King 
and Goodboum, 1998).
Therefore, in order to determine whether this cleaved C-terminal fragment was essential 
for stress induced apoptosis, two mutant constructs in which an aspartic acid at position 
694 had been replaced by either an alanine or glutamic acid residue were used . In another 
study, a cleavage site for caspases at aspartic acid residue 694 in the STAT-1 protein was 
identified (King and Goodboum, 1998). To test whether this residue was a target for 
cleavage, the aspartic acid residue was changed to alanine or glutamic acid. Upon 
treatment with double stranded RNA and cyclohexamide, these mutant STAT-1 proteins 
were not cleaved, but endogenous STAT-1 a  and STAT-1 (3 was cleaved (King and 
Goodboum, 1998).
Therefore, in this study, using these two mutants would determine whether cleavage of 
STAT-1 to release a C-terminal fragment is necessary for stress- induced apoptosis (Figure 
3.10).
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IschaemiaHeat shock
Figure 3.10. Apoptotic cell death in U3A cells transfected with expression 
vectors encoding full length STAT-1, a construct encoding amino acids 
1-694 of STAT-1 with a STOP codon at position 695, and two constructs 
(D694A and D694E) in which amino acid 694 has been replaced with a 
residue to prevent caspase cleavage. Transfected cells were either left 
untreated or exposed to heat stress at 43 °C for 2 hours or simulated 
ischaemia for 4 hours. Values indicate the percentage of successfully 
transfected cells, which are TUNEL positive and are the mean of three 
determinations each performed in duplicate whose standard error is shown 
by the bars. *p<0.05versus empty expression vector transfected cells 
determined by Student t test.
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When cells were transfected with these two vectors separately both constructs were able to 
induce enhanced apoptosis significantly (D694A, p<0.05; D694E, p<0.05).
Therefore, these results demonstrate that a cleaved C-terminal fragment is not essential for 
stress-induced apoptosis, and that the apoptotic effect can be induced by STAT-1 as an 
intact molecule as well as an isolated C-terminal fragment.
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3.7 Determination of phosphorylation sites of STAT-1 
required for stress-induced apoptosis
The previous results show that an enhanced apoptotic effect can be produced when STAT- 
1 is an intact molecule as well as by a truncated fragment containing only the C-terminal 
domain (residues 691 -750).
The C-terminal domain of STAT-1 contains two phosphorylation sites; a tyrosine residue 
at position 701 and a serine residue at position 727 (Horvath and Darnell, 1997; Darnell, 
1997; Chatterjee-Kishore et al., 2000; Horvath, 2000). Previous studies have shown that 
phosphorylation on serine 727 residue is required for STAT-1 activation (Zhang et al., 
1995). Moreover, it has been shown that phosphorylation of serine 727 is not coupled to 
prior tyrosine 701 phosphorylation following stress (Kovarik et al., 2001). Therefore, in 
order to determine whether tyrosine 701 and/or serine 727 phosphorylation was important 
in apoptosis induced by stress, U3A cells were transfected with either a tyrosine 701 
mutant (tyrosine changed to phenylalanine) or a serine 727 mutant (serine changed to 
alanine). These cells were exposed to heat and simulated ischaemic stress (figure 3.11).
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Figure 3.11 Apoptotic cell death in U3A cells transfected with expression 
vectors encoding wild type STAT-1 or mutants and then exposed to 
heat stress at 43°C for 2 hours or simulated ischaemia for 4 hours.
Values indicate the percentage of successfully transfected cells, 
which are TUNEL positive and are the mean of three determinations 
performed in duplicate whose standard error is shown by the bars.
Single factor ANOVA was carried out and showed significant differences 
between treatment groups (p<0.0001). Post- hoc Bonferroni test 
was carried out and significant levels compared to STAT-1 wt are depicted 
as follows: *<0.05 **<0.01 ***<0.0001
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Both STAT-1 mutants significantly reduced the effect on apoptotic cell death compared to 
STAT-1 wild type (701 mutant, p<0.05; 727 mutant p<0.05). Therefore, in these cells, 
both tyrosine and serine residues are essential for STAT-1 phosphorylation in stress- 
induced conditions.
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3.8 Discussion
The aim of this study was to investigate the role of STAT-1 transcription factor in stress- 
induced apoptosis. By using the U3A mutant cell line, which lacked a functional STAT-1 
protein, the region of STAT-1 required for stress-induced apoptosis was also identified.
This study demonstrates that differences in sensitivity to stress occur in the presence and 
absence of STAT-1 in 2fTGH and U3A cells respectively. U3A cells are resistant to 
simulated ischaemia or heat stress. This could be due to the loss of STAT-1 or the other 
factors such as increased number of passages of cells in culture (Darnell et al., 1994).
However, confirmation that the sensitivity of 2fTGH cells to stress is due to STAT-1 has 
been obtained when STAT-1 is re-introduced into the U3A cell line. The level of 
apoptosis is enhanced to levels observed in the parental 2fTGH cell line, which 
demonstrates that STAT-1 is behaving as a pro-apoptotic factor. It is also apparent that the 
pattern of cell death induced by both simulated ischaemia and heat stress is similar, which 
suggests that death occurs via a common pathway, and that STAT-1 is required for this 
process.
Transfecting STAT-3 into U3A cells did not induce enhanced apoptosis but had similar 
characteristics to the wild type U3A cells. Co-transfection of STAT-1 and STAT-3 
resulted in abolition of the enhanced apoptotic effect observed with STAT-1 alone. In this 
case, the apoptotic characteristic of STAT-1 may be hindered by STAT-3 interference by 
forming a STAT-l/STAT-3 heterodimer, which is unable to induce enhanced cell death, or
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by competing with STAT-1 for binding to a cellular protein or DNA binding site required 
for death induction.
By transiently transfecting various expression vectors encoding chimaeras and mutants of 
STAT-1, the region responsible for stress-induced apoptosis was identified. Chimaeric 
STAT-1 and STAT-3 expression vectors used to probe regions of STAT-1 that may be 
required for the apoptotic nature of STAT-1 revealed that the N- terminal domain was 
dispensable for the apoptotic effect observed since the 3296* construct was still able to 
induce enhanced apoptosis. This was confirmed by transfecting the C-terminal STAT-1 
construct containing part of the DNA binding domain (390-750) as it also induced 
enhanced apoptosis. Therefore the effect observed with the chimaeric construct was not 
due to the N-terminal domain of STAT-3 substituting for that of STAT-1 but rather 
enhanced apoptosis could still be observed in the absence of the N-terminal domain.
Further experiments confirmed that indeed the N terminal domain was not required for the 
enhanced apoptotic effect. A STAT-1 construct containing a STOP codon at position 695 
showed that the C-terminal domain of STAT-1 downstream of amino acid 695 was 
essential for the apoptotic effects observed. In addition, the C-terminal domain alone 
induces apoptosis without the DNA binding domain (STAT-1 691-750 construct).
Other studies have shown that the C-terminal fragment of STAT-1 is released as a result of 
cleavage by caspase 3 at position 694 (King and Goodboum, 1998). However, in this 
study, mutation of the 694 amino acid residue to either alanine or glutamic acid, which
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blocks cleavage, still significantly induced apoptosis. Therefore, cleavage of STAT-1 to 
release a free C-terminal fragment is not essential for stress-induced apoptosis and hence 
the C-terminal domain can produce apoptotic effects either within an intact molecule or as 
an isolated domain produced artificially or naturally by caspase cleavage.
Some transcriptional regulators have been shown to interact directly with STAT-1. These 
proteins include CBP (Zhang et al., 1996), BRCA-1 (Ouchi et al., 2000) and MCM5, a 
chromatin re-modeling factor (Zhang et al., 1998). Interaction of the C-terminal domain of 
STAT-1 with DNA-bound transcription factors such as CBP may lead to recruitment 
independently of the DNA binding domain of STAT-1. This co-activator type role for 
STAT-1 would allow the C-terminal domain to enhance cell death by activating specific 
target genes when present alone, or linked to the remainder of the STAT-1 molecule. The 
ability of STAT-3 to prevent induction of cell death by STAT-1 suggests that STAT-3 may 
negatively regulate STAT-1 by binding to the same DNA-bound factor as STAT-1 but 
such that binding does not induce enhanced cell death, as observed with STAT-1.
Recent data from the Chatterjee-Kishore study (Chatterjee-Kishore et al., 2000) has shown 
that some STAT-1 dependent genes are still activated when the tyrosine 701 amino acid 
residue is mutated to a phenylalanine that cannot be phosphorylated. In other studies, 
phosphorylation on the serine 727 amino acid residue is essential for interaction of STAT- 
1 with MCM5 or BRCA-1 (Zhang et al., 1998; Ouchi et al., 2000). Following stress, 
phosphorylation of serine 727 is not coupled to prior tyrosine 701 phosphorylation 
(Kovarik et al., 2001). Therefore, testing this effect in the U3A cells showed that
148
phosphorylation of both tyrosine 701 and serine 727 is essential for stress-induced 
apoptosis. In contrast, in U3A cells that are treated with TNF-a the tyrosine 701 to 
phenylalanine mutant is still able to induce enhanced apoptosis whereas the serine 727 to 
alanine mutant is not able to induce enhanced apoptosis (Kumar et al., 1997). In addition, 
cardiac cells that are exposed to simulated ischaemia/re-oxygenation following transfection 
of wild type STAT-1 or the tyrosine 701 to phenylalanine mutant displayed enhanced 
apoptosis. However, this was not observed when cardiac cells were exposed to simulated 
ischaemia/re-oxygenation following transfection of the serine 727 to alanine mutant 
(Stephanou et al., 2001).
The pattern of STAT-1 phosphorylation observed in our study and in the studies by Kumar 
et al. (1997) and Stephanou et al. (2001) may be due to use of TNFa rather than thermal or 
simulated ischaemic stress, and also the cells that were used in the other studies were 
primary cardiac neonatal cardiac myocytes, that become terminally differentiated rapidly 
and stop dividing. In contrast, the fibroblast cells that were used in our study were stably 
transformed cell lines. Therefore, the differences in phosphorylation of residues within the 
C-terminal domain of STAT-1 could be due to differences in cell type, which would also 
involve differences in signals that lead to STAT-1 phosphorylation.
Therefore, this data shows that the presence of STAT-1 results in enhanced sensitivity 
upon exposure to thermal or simulated ischaemic stress compared to cells where it is 
absent, and also demonstrates that the C-terminal activation domain of STAT-1 is 
necessary and sufficient for the enhanced apoptotic effect observed.
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Regulation of Heat Shock Proteins by the STAT Family of
Transcription Factors
4.0 INTRODUCTION
Extracellular stresses such as elevated temperature and ischaemia /reperfusion are known 
to induce the heat shock proteins (Hsps) (Lindquist, 1988). Other stimuli such as cytokines 
including Interferon y (IFN y) and Cardiotrophin-1 (CT-1) are also able to induce Hsp 
expression via Jak-STAT-1 or Jak-STAT-3 pathways respectively (Stephanou et al., 1998; 
Stephanou et al., 1999).
The mechanism of Hsp induction has been well established for example, exposure of cells 
to elevated temperature leads to activation of the latent monomeric transcription factor 
called Heat Shock Factor (HSF)-1, leading to homo-trimerisation followed by translocation 
to the nucleus to bind specific HSE sequences within Hsp gene promoters (Morimoto, 
1993). Thus, during stress, normally expressed genes are down regulated, and an increase 
in Hsp gene activity occurs and this mechanism is generally accepted for many other stress 
conditions of the cell.
Other mechanisms of Hsp induction also exist but are not activated in response to stresses 
such as elevated temperature. For example, recent studies have shown that Hsps are 
induced in response to cytokine stimulation, and that different transcription factors are also 
involved.
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Sludies have shown that IL-6, a pleiotropic cytokine, is able to stimulate the liver to induce 
synthesis of acute-phase proteins. IL-6 stimulation of cells leads to activation of two 
separate signalling pathways namely the MAPKinase pathway, and the Jak/STAT pathway 
(Akira and Kishimoto, 1992; Akira et al., 1994). Further studies on IL-6 have shown that 
this cytokine can induce Hsps. IL-6 has been shown to be elevated in systemic lupus 
erythematosis (SLE), rheumatoid arthritis and juvenile chronic arthritis (Eastgate et al., 
1988; De Benedetti et al., 1991; Linker-Israeli et al., 1991). Interestingly, Hsp90 levels 
have been shown to be elevated in peripheral blood mononuclear cells (PBMCs) from a 
specific subset of SLE patients (Latchman and Isenberg, 1994). Stephanou et al (1997) 
demonstrated that IL-6 was able to induce accumulation of Hsp90 in both liver cells and 
PBMCs, and that it was the Hsp90(3 promoter that was activated in response to IL-6 
(Stephanou et al., 1997). Morover, this effect was mediated by activation of the NFIL-6 
transcription factor (Stephanou et al., 1998a).
CT-1 is also able to induce expression of Hsp90 and Hsp70 in neonatal cardiac myocytes 
and protects against exposure to severe thermal or ischaemic stress (Stephanou et al., 
1998b). Furthermore, STAT-3 (which is activated by CT-1 or IL-6) is able to induce 
activation of Hsp90|3 promoter, and NFIL-6 and STAT-3 synergize in activating the 
Hsp90p promoter (Stephanou et al., 1998a). In addition, it has been demonstrated by 
Stephanou et al. (1998) that both NFIL-6 and STAT-3 are able to interact differently with 
HSF-1 or heat shock. Over-expression of NF-IL6 and HSF-1 (or heat shock) co-operate 
and enhance activity of Hsp90p promoter, while over-expressed STAT-3 and/ HSF-1 (or 
heat shock) antagonise each other (Stephanou et al., 1998).
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Other cyokines have also been shown to produce induction of Hsps in different cell types, 
for example IL-lp can induce expression of Hsp90 and Hsp70 in rat islet pancreatic cells 
(Helquest et al., 1991).
IFNy is a multi-functional cytokine that has anti-viral, anti-tumour properties (Darnell et 
al., 1994), and specifically activates STAT-1 (Schindler et al., 1995). IFNy has been shown 
to enhance Hsp70 levels in granulosa-luteal cells and HepG2 cells (Kim et al., 1996). 
Over-expressed STAT-1 enhances Hsp90f3 and Hsp70 promoter activity. IFNy was not 
able to induce expression of Hsp90p or Hsp70 promoters in the STAT-1 deficient cell line 
U3A. However, when STAT-1 was re-introduced, Hsp90p and Hsp70 promoter activity 
was stimulated (Stephanou et al., 1999). Stephanou et al (1999) demonstrated that both 
STAT-1 and HSF-1 were able to produce an additive effect on Hsp90p and Hsp70 
promoter activity, and that a direct protein-protein interaction occurs between STAT-1 and 
HSF-1. Moreover, a composite response element was also identified in this study that was 
able to integrate HSF-mediated heat shock response with IL-6 and IFNy signalling to 
mediate differential regulation of HSPs.
In previous studies it has been shown that various cytokines can activate and enhance Hsp 
promoter activity. For example, CT-1 (an IL-6 like cytokine) can induce Hsp expression 
via the JAK/STAT-3 pathway. IFNy can induce expression of Hsps via the JAK/STAT-1 
pathway specifically (Darnell et al., 1994). IFNa can activate STAT-1 and STAT-2 and 
hence mediate expression of IFNa specific genes. IFNa and IFNy both display
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overlapping transcriptional signalling pathways (Darnell et al., 1994; Schindler et al., 
1995). Induction of Hsps by IFNa has not been investigated previously, and it is possible 
that IFNa can also induce expression of Hsps like IFNy in the absence and presence of 
heat shock (Stephanou et al., 1999). Therefore, in this chapter, the protein-protein 
interaction of STAT-1 and HSF-1, and the effect of STATs on Hsp90 induction by IFNa,
IFNy and heat stress were investigated. The effect on hsp protein induction was also 
investigated.
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4.1 In vitro protein-protein interaction of STAT-1 and HSF-1
Stephanou et al (1999) have previously demonstrated that a direct protein-protein 
interaction occurs between STAT-1 and HSF-1 in vivo. Therefore, the in vitro protein- 
protein interaction of STAT-1 and HSF-1 was investigated by in vitro translating STAT-1
or
(and incorporating S as a label) and expressing HSF-1 in bacterial cells (for methods, see 
Chapter 2). The autoradiograph can be seen in figure 4.1:
1 2 3 4 5 6 7
Figure 4.1 In vitro protein-protein interaction of STAT-1 and HSF-1. Lane: 
STAT-l+HSF-1; Lane 2: T7 Luciferase control+HSF-1; Lane 3:ERa+Bm3b 
(+ve control); Lane 4:ERa+GST; Lane 5: STAT-1 radiolabelled in vitro 
translated product; Lane 6: T7 Luciferase radiolabelled in vitro translated 
product (control); Lane 7: ERa radiolabelled in vitro translated product. The 
experiment was repeated 3 times.
In this experiment a protein-protein interaction was not observed between STAT-1 and 
HSF-1.
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4.2 Effect of IFNs on the Hsp90 promoter and Hsp90 protein
The Hsp90p full length promoter (figure 4.2) was transfected into 2fTGH and U3A cell 
lines. Cells were then left untreated or stimulated with IFNa, IFNy or IFNa+IFNy 
(50ng/ml of IFNa or IFNy) for four hours, and then maintained at 37°C or heat shocked at 
43°C for 30 minutes. 18 hours later, cells were harvested and CAT assays were performed 
to measure promoter activity. Cells were co-transfected with an RSVpromoter driven 
p-galactosidase expression vector as a control for transfection efficiency. The results 
presented as CAT assays are representatives from 3 experiments with similar results.
HSF STAT
NFIL-6 /  NFIL-6 NFIL-6-1052 NFIL-6 NFIL-6
STAT STAT
-643 GCCTGGAAACTGCTGGAAAT -623 
HSF HSF HSF
Figure 4.2. A diagrammatic representation of the transcription factor binding sites within 
the Hsp90p promoter. The sequence shows overlap of transcription factor binding sites for 
STAT and also HSF.
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Western blots presented here are representative of 3 experiments showing similar results 
and were quantified by densitometry and equalised for actin. The results are presented as 
bar graphs with standard error bars. Wilcoxon signed rank test was used to test for 
statistical significance.
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4.3 IFNa and IFNy have different effects in 2fTGH and U3A cells which are likely to 
be due to STAT-1
In the next set of experiments, the effects of IFNa and IFNy were investigated in 2fTGH 
and U3A cell lines. 2fTGH is the parental cell line in which STAT-1 is functional, 
whereas in U3A cells STAT-1 is knocked out (Darnell et al., 1992).
IFNa treatment was able to activate Hsp90p promoter activity in the absence of heat stress 
in 2fTGH cells. However, very slight Hsp90p promoter activity was observed when 
2fTGH cells were treated with IFNy (Figure 4.3). Both IFNa and IFNy together did not 
have any effect on Hsp90P promoter activity, therefore, both IFNa and IFNy together had 
an antagonistic effect on the promoter.
Under conditions of heat stress, both IFNs did not have any effect on Hsp90p promoter 
activity since the heat shock treatment alone had the same effect. IFNa and IFNy 
treatments together did not have any effect on Hsp90P promoter activity and this was 
reduced compared to either IFNa/HS or IFNy/HS treatment alone.
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IF N : NT IFNa IFNy IFNa+ NT IFNa IFNy IFNa+
IFNy IFNy
HS: - - + + + +
Figure 4.3 Assay of CAT activity of the Hsp90p promoter in 2fTGH cells. 
Cells were treated with IFNa or IFNy, or both. Some cells were subjected to 
heat shock at 43°C for 30 minutes, or left in an incubator at 37°C. A p- 
galactosidase assay was performed to check for transfection efficiency, p- 
galactosidase values were constant in each experiment. The experiment was 
repeated 3 times. Western blots were performed on the lysate for each treatment.
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In U3A cells, the pattern of Hsp90p promoter activation was found to be distinct from that 
of 2fTGH cells (figure 4.4). Treatment with IFNa did not have any effect on 
Hsp90P promoter activity. In addition, Hsp90p promoter activation by IFNa observed in 
2fTGH cells was not observed in U3A cells. Both IFNa and IFNy together did not have 
any effect on Hsp90p promoter activity. No Hsp90P promoter activity was observed when 
U3A cells were given a mild heat stress after IFN treatment, and no increased Hsp90p 
promoter activity was observed when heat stress was applied after both IFNa and IFNy 
treatments together (figure 4.4).
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IF N : NT IFNa IFNy IFNa+ NT IFNa IFNy IFNa+
IFNy IFNy
HS: + + + +
Figure 4.4 Assay of CAT activity of the Hsp90p promoter in U3A cells. Cells 
were treated with IFNa or IFNy, or both. Some cells were subjected to heat 
shock at 43°C for 30 minutes, or left in an incubator at 37°C. A P-galactosidase 
assay was performed to check for transfection efficiency, p-galactosidase values 
were constant in each experiment. The experiment was repeated 3 times. 
Western analysis was performed on the lysate for each treatment.
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At the protein level, in 2fTGH cells IFN treatments had little effect on Hsp90 protein levels 
in the absence of heat stress (Figure 4.5). However, with a mild heat stress in addition to 
IFNa treatment, Hsp90p protein was lower compared to control cells. Enhancement of 
Hsp90p protein was observed when heat stress was applied in addition to IFNy treatment 
(p<0.05), and enhancement of Hsp90p protein was also observed when heat stress was 
applied in addition to IFNa and IFNy treatments together (p<0.05) (figure 4.6).
HS: - + + + +
IFN: NT IFNa IFNy IFNa NT IFNa IFNy IFNa 
+IFNy +IFNy
Actin
Figure 4.5 Western blot analysis of Hsp90P protein 
in 2fTGH cells. Blots were stripped and re-probed 
with actin antibody.
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HS + + + +
Figure 4.6 Hsp90(3 protein levels in 2fTGH cells. The values for Hsp90(3 
protein were obtained from densitometric analysis, and were divided by 
densitometric values for actin. The values indicate the mean of 3 
determinations for each treatment (n=3) whose standard error is shown by the 
bars. *p<0.05 treatment vs control, determined by Wilcoxon signed rank test.
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In U3A cells an enhancement of Hsp90p protein was observed when treated with 
IFNa (p<0.05) or IFNy (p<0.05), or both IFNa and IFNy together (figure 4.7). However, 
when heat stress was applied, Hsp90|3 protein levels were reduced after IFNa (p<0.05) 
treatment (figure 4.8). This effect was also observed in IFNy treated U3A cells.
IFN: NT IFNa IFNy EFNa NT IFNa IFNy IFNa
+IFNy +IFNy
HS: . + + + +
Actin
Figure 4.7 Western blot analysis in U3A cells of Hsp90 protein. Cells were left 
untreated (NT) or treated with IFNa or IFNy, or both together for 4 hours. Some 
cells were given heat shock at 43°C for 30 minutes, and then returned to the 
incubator. Cells were harvested after 18 hours and lysates used for Western blot 
analysis using an antibody for Hsp90. Blots were stripped and re-probed for actin.
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HS - - + + + +
Figure 4.8 Hsp90(3 protein levels in U3A cells. The values for Hsp90(3 
following various treatments were obtained from densitometric analysis, 
and were divided by densitometric values for actin. The values indicate the 
mean of 3 determinations for each treatment, whose standard error is 
shown by the bars. *p<_0.05.treatment vs control determined by Wilcoxon 
signed rank test.
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Therefore, these results demonstrate that IFNy activated Hsp90p promoter activity is 
affected by the lack of STAT-1 in U3A cells and IFNa treatment has a negative effect on 
FIsp90|3 promoter activity in the presence of heat stress.
Taken together, these results demonstrate that IFNs a  and y have different effects on 
Hsp90 in different cell types. In addition, by using a cell line that lacks a functional 
STAT-1 protein, it is possible that STAT-1 may be required for the effects observed both 
in the absence and presence of heat shock. A summary table for both Hsp90 protein 
induction and Hsp90 promoter activity are represented in table 4.1 and table 4.2.
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Table 4.1 Summary table to show the effect of IFNa and IFNy and heat shock on Hsp90 levels
Cell Type No Treatment IFNa IFNy IFNa+
IFNy
Heat
shock
IFNa+ 
Heat shock
IFNy+
Heat shock
IFNa+IFNy 
+Heat shock
21TGH
(n=3)
+ ++ ++ ++ ++ ++ +++ ++++
U3A
(n=3)
+ +++ ++ ++ ++ ++ +++ ++++
+ = Hsp90 levels of protein induction 
- = No Hsp90 protein induction
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Table 4.2 Summary table to show the effect of IFNa and IFNy and heat shock on Hsp90 promoter activity
Cell
Type
No
Treatment
IFNa IFNy IFNa+IFNy Heat
shock
IFNa+ 
Heat shock
IFNy+
Heat shock
IFNa+IFNy 
+Heat shock
2fTGH
(n=3)
+ + + + + + +
U3A
(n=3)
+ + +
+ = Hsp90 promoter activity 
- = No Hsp90 promoter activity
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4.4 D iscussion
Previous studies have demonstrated that IFNy has antiviral and anti-tumour properties by 
inducing specific IFNy responsive genes (Pestfa et al., 1987; Darnell et al., 1994). INFy 
activates the STAT-1 signalling pathway via the JAKs (Schindler et al., 1995). IFNy is 
also able to induce expression of Hsp90 in HepG2 cells (Stephanou et al., 1999). In 
addition, over-expression of STAT-1 enhanced the activity of the Hsp90p promoter 
whereas in U3A cells, IFNy was not able to activate the Hsp90P promoter. However, re- 
introduction of STAT-1 into the cell line restored Hsp90p promoter responsiveness to 
IFNy (Stephanou et al., 1999). In the same study, HSF-1 and STAT-1 protein-protein 
interaction was also demonstrated, however, in this thesis, a protein-protein interaction in 
vitro was not found. Therefore, the effect of IFNa as well as IFNy was studied on the 
Hsp90p promoter since this had not been demonstrated previously. IFNa is known to 
activate the JAK/STAT pathway via STAT-1 and STAT-2, which form heterodimers. 
Thus, using the 2fTGH and U3A cell lines, the responsiveness of Hsp90 to IFNa was 
investigated.
A different effect on Hsp90p promoter and protein levels was observed in the 2fTGH and 
U3A cell types. The U3A cell type lacks a functional STAT-1 protein whereas the 2fTGH 
cells are the parental cell line in which a functional STAT-1 protein is present (Darnell et 
al., 1992). This cell line is ideal to study the effect of STAT-1 in response to the 
stimulatory treatments given by IFNa and IFNy. In these two cell lines, the effects of
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IFNa or IFNy were more apparent when a heat stress was applied subsequent to IFN 
stimulation.
In U3A cells, lack of STAT-1 reduced levels of Hsp90p in all IFN treatments at the 
promoter level. This effect would suggest that STAT-1 is likely to be required for IFN 
mediated Hsp90p expression. STAT-1 is not only essential for activation by IFNy, but 
also for activation by IFNa. The lack of STAT-1 reduces Hsp90p activity and IFNa 
stimulation, suggesting that STAT-1 is required for the formation of the ISGF3 DNA 
complex. The effects of STAT-1 on the ISGF3 binding site were not studied due to time 
limitations.
Other studies have shown that in the absence of STAT-1, STAT-2 phosphorylation is 
abolished, and that STAT-1 phosphorylation is required for STAT-l/STAT-2 dimer 
formation. Therefore, in this case IFNa has a negative regulatory effect on Hsp90p 
promoter and protein levels, whereas IFNy has a synergistic effect with heat stress.
IFNy stimulation of all cell types leads to potent activation of Hsp90p at both promoter and 
protein levels. In this chapter it can be inferred that the effects observed on IFNy 
stimulation is due to STAT-1. This effect is also observed after heat shock treatment of 
IFNy treated cells, which further suggests that an interaction between HSF-1 and STAT-1 
may occur. STAT-1 and HSF-1 do not form a protein-protein interaction in vitro. This 
effect does not complement the results observed by Stephanou et al (1999). The study by 
Stephanou (1999) has demonstrated that a HSF-1 binding site is contained within the
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STAT binding site in the short region of the Hsp70 and Hsp90p promoters. In addition, 
IFNy treatment induces the expression of Hsp70 and Hsp90 in a STAT-1-dependent 
manner. HSF-1 and STAT-1 expression vectors have also been used in this study to show 
an interaction of STAT-1 and HSF-1 in transfection studies, which show that presence of 
both STAT-1 and HSF-1 have an additive effect in activating Hsp70 and Hsp90p 
promoters. In co-immunoprecipitation experiments, Stephanou et al. (1999) have shown a 
direct protein-protein interaction between STAT-1 and HSF-1 by using an anti-STAT-1 
polyclonal antibody endogenous STAT-1 immunoprecipitate followed by a specific anti- 
HSF-1 polyclonal antibody on the same blot.
In this thesis, an in vitro approach to observing a protein -protein interaction between 
STAT-1 and HSF-1 was taken. The STAT-1 mammalian expression vector was added to a
35rabbit reticulocyte lysate, S , and T7 polymerase mix for translation of STAT-1. HSF-1 
was expressed by ITPG induction in bacterial cells. HSF-1 protein was purified from 
bacterial lysate by using His tagged beads which bind to His residues fused to the HSF-1 
insert. Both STAT-1 and HSF-1 proteins were incubated together in order for the 
interaction to take place. The interaction was visualised on SDS PAGE gel for 
autoradiography. Unfortunately, a band was not observed for the two proteins, which 
shows that in vitro STAT-1 and HSF-1 do not interact under these conditions.
The main difference between these two methods is that the Stephanou study uses whole 
cell lysate in which endogenous STAT-1 is already present, therefore, by using an antibody 
specific to STAT-1 it is easier to identify interaction with HSF-1. However, in an in vitro
171
condition, all components are separate, ie STAT-1 is expressed in a different system,
whereas HSF-1 is expressed in a bacterial system and it may be possible that a “co-
chaperone” exists in vivo that aids the interaction of STAT-1 and HSF-1 and this is
probably not present in the in vitro reticulocyte lysate system.
Protein ‘X ’STAT-1
In addition, if the concentration of HSF-1 protein is extremely low, then it may not be 
possible to observe an interaction. An alternative would be to use a different bacterial 
expression vector to enhance HSF-1 protein levels after IPTG induction. Unfortunately, 
due to time limitations this has not been possible.
Reduction of Hsp90p by IFNa and IFNy together upon heat shock treatment could be due 
to the presence of STAT-l/STAT-2 dimers. It is known that STAT-1(3 can also form a 
dimer with STAT-2 (Qureshi et al., 1996). Therefore, STAT-ip/STAT-2 may behave as a 
negative regulator in Hsp90p expression by IFNa. These effects are more clearly 
observed in U3A cells. Lack of STAT- 1 in this cell type reduces Hsp90p levels in all 
treatments, showing that STAT-1 is required for Hsp90p stimulation by IFNy. In addition, 
lack of induction by IFNa suggests that STAT-1 is likely to be required for formation of
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the ISGF3 DNA complex. Absence of STAT-1 does not promote phosphorylation of 
STAT-2 thus preventing heterodimer formation (Qureshi et ah, 1996). Therefore, in order 
to prove that indeed STAT-1 is required for the effects observed, it is essential that further 
transfection experiments are carried out in U3A cells by re-introducing STAT-1 into the 
cell line and subject STAT-1 transfected cells with IFNs in the absence or presence of heat 
shock.
In ND7 cells when IFNa or IFNy are administered, upon heat stress Hsp90p promoter 
activity is significantly increased with IFNa or IFNy treatment alone. Interestingly, heat 
stress causes a synergistic effect when IFNa and IFNy are administered together followed 
by heat stress. It has been shown by Stephanou et al (1999), that STAT-1 and HSF-1 
together do have an additive effect on the HSp90p promoter, and that this effect is specific 
to IFNy treatment (Stephanou et al., 1999). It is not known, however, if the STAT-1/ 
STAT-2 dimer, interacts with HSF-1, or whether an interaction occurs between STAT- 
1/STAT-l and HSF-1. STAT-1 homodimers can be formed after IFNa treatment, but not 
as readily as after IFNy treatment. IFNy treatment also leads to formation of STAT-la or 
STAT-1 p and STAT-2 heterodimers (Schindler et al., 1992; Qureshi et al., 1995; Shuai et 
al., 1994). Therefore, it is a possibility that there are more STAT-1 homodimers present 
after IFNa and IFNy treatment, therefore, enhancing activation of the Hsp90p promoter or 
there is a preference for STAT-1/STAT-1 dimers over STAT-1/STAT-2 dimers. This 
would need to be studied further.
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At the protein level, no distinct changes in levels of Hsp90p were discovered with IFN 
treatments alone, however, an increase in protein levels was observed in combined 
treatment with IFNa and IFNy together without heat stress, which was also observed at the 
promoter level. It is not known why a synergistic effect is observed but it is possible that 
both STAT-l/STAT-1 dimers and STAT-l/STAT-2 dimers could contribute to the effect, 
or the effect is specific to the cell type.
Hsp90p activity was not enhanced in HepG2 cells treated with IFNa but was stimulated 
with IFNy treatment alone, which is in accordance with previous published data 
(Stephanou et al., 1999). Upon heat stress, IFNa was able to stimulate Hsp90p promoter 
activity, and IFNy strongly enhanced Hsp90p promoter activity in the presence of heat 
stress, suggesting that the presence of STAT-1 and HSF-1 had an effect on activation of 
the Hsp90p promoter. Interestingly, when both IFNa and IFNy were administered, 
followed by heat stress, activity of the Hsp90p promoter was significantly reduced 
compared to either IFN a  or IFNy treatment alone.
At the protein level, similar results were also observed, where IFNy treatment increased 
Hsp90 protein, in the absence of heat stress and also in the presence of heat stress. In 
addition, protein levels were reduced when IFNa and IFNy were administered together 
followed by heat stress, suggesting that IFNy strongly stimulates Hsp90p promoter 
activity, with activity being enhanced when heat stress is given whereas IFNa does not. 
IFNa seems to have a negative regulatory effect on the Hsp90p promoter in the presence 
of heat stress and reduces the effect of IFNy on the promoter and also protein levels. This
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could be due to competition between STAT-l/STAT-2 dimers and STAT-l/STAT-1 
dimers for DNA binding.
To conclude, the results demonstrated in this chapter are preliminary. STATs modulate 
genes depending upon the stimulus. It is known that regulatory sequences in eukaryotic 
genes contain multiple transcription factor binding sites which provide different 
combinations of interactions between many transcription factors to mediate integration of 
multiple signals. It is therefore, apparent that the Hsp90p promoter contains composite 
response elements that are able to integrate multiple signals and allow interaction of 
transcription factors with each other to have either a stimulatory or inhibitory effect on 
geneexpression.
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CHAPTER 5.
The Cardioprotective Agent 
Urocortin Induces 
Expression of Cardiotrophin-1
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The C ardioprotective A gent Urocortin Induces Expression o f CT-1
5.0 Introduction
In the previous two chapters, extracellular stress such as simulated ischaemia or elevated 
temperature were used to investigate the role of the STAT-1 transcription factor and Hsp90 
respectively in order to understand the mechanisms and importantly to consider them as 
important factors in cell survival. In this chapter, simulated hypoxic stress has been used 
to investigate the induction of expression of cardiotrophin-1 (CT-1), which is known to be 
cardioprotective, by urocortin (an unrelated peptide that is also cardioprotective via the 
same signaling pathway as CT-1). The identification of cardioprotective agents and an 
understanding of the mechanism by which they act is likely to be of considerable 
importance in understanding the processes which occur during cardiac stress and in their 
ultimate modulation for therapeutic benefit.
We previously identified two agents, cardiotrophin-1 (CT-1) and Urocortin (Ucn), both of 
which are able to protect the heart against the damaging effects of cardiac ischaemia 
followed by reperfusion by reducing the levels of apoptotic cell death (Latchman, 1999; 
Latchman, 2000; Latchman, 2001; Latchman, 2002). In particular, the protective effect of 
both these agents in either cultured cardiac cells or in the intact heart can be demonstrated 
when they are added following the ischaemic episode prior to reperfusion, as well as when 
they are added before the ischaemic event itself (Brar et al, 2001; Liao et al, 2002; Brar et 
al, 2000). Hence, these agents or their derivatives could potentially be utilised 
therapeutically at reperfusion following an ischaemic episode.
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Despite the differences in the nature of these two factors, common signaling pathways 
appear to mediate their protective effects. Thus, both CT-1 and Ucn have been shown to 
activate the p42/p44 mitogen activated protein kinase (MAPK) pathway and inhibition of 
this pathway either by chemical inhibitors or by dominant negative mutants of the enzymes 
involved inhibits the protective effect of CT-1 or Ucn (Brar et al, 2001, Liao et al, 2002; 
Brar et al, 2000 Sheng et al, 1997). In contrast, neither of these agents activates the p38 
MAPK or JNK pathway and inhibition of these pathways has no effect on the protective 
abilities of Ucn or CT-1. Interestingly, however, both CT-1 and Ucn are also able to 
activate the PI-3 kinase/Akt pathway and inhibition of this pathway also prevents the 
cardioprotective effect of both these agents (Brar et al, 2001; Brar et al, 2002).
Ucn and CT-1 do differ however, in their requirement for protein synthesis to produce their 
protective effects. Thus, while new protein synthesis is necessary for the protective effect 
of Ucn, which can be blocked by the protein synthesis inhibitor cylohexamide (Brar et al, 
2002), this is not the case for CT-1 whose protective effect is extremely rapid and is 
insensitive to inhibitors of protein synthesis (Brar et al, 2001, Railson et al, 2000). In 
addition, both CT-1 and Ucn are able to induce Hsps (Brar et al., 2002). In view of this, 
and the similarities between the pathways activated by these two diverse protective agents, 
it has been hypothesized here that Ucn induces the expression of CT-1.
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5.1 Urocortin induces expression of CT-1 at the messenger RNA 
level
Previous studies by Brar et al (1999) have shown that Ucn can induce cardio-protection in 
cardiac myocytes against lethal ischaemic injury. In this study, the aim was to investigate 
whether Ucn can induce the expression of CT-1, another cardio-protective agent. 
Therefore, initial experiments involved exposing cardiac neonatal myocytes to Ucn for 
various periods of time in order to test the possibility that Ucn could induce the expression 
of CT-1 by detecting changes in the CT-1 messenger RNA (mRNA) levels. Cells were 
treated for 4 hours, 16 hours, or 24 hours with Ucn, and then harvested to prepare mRNA 
to be hybridised with a CT-1 complementary DNA (cDNA) probe (figure 5.1a).
C 4 16 24
wmr*: CT-1
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Figure 5.1a. RNA slot blot to show time course (hours) of CT-1 
mRNA levels and control Cyclophilin in cardiac cells treated 
with Urocortin (10'7M)
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Hybridisation of CT-1 probes to total mRNA showed that CT-1 expression was induced by 
treatment with Ucn, and the induction of CT-1 increased with time, with induction being 
greatest at 24 hours of Ucn treatment, which was approximately 3.5-fold compared to 
control cells.
In the next set of experiments, cardiac myocytes were also exposed to hypoxia or hypoxia/ 
re-oxygenation, which was also able to clearly enhance induction of CT-1 expression by 
2.5-fold compared to control (figure 5.1b).
c H H/R a-h
m m m m - m m
*MPP* mmmm mnn Cyclophilin
Figure 5.1b. RNA slot blot to show levels of CT-1 mRNA and control 
cyclophilin mRNA in cardiac cells in control cells (C), cells exposed to 
simulated hypoxia (H) for 4 hours, or cells exposed to simulated hypoxia 
followed by re-oxygenation (H/R), or to hypoxia in the presence of a-helical 
CRH (a-h) (107 M). a  -helical CRH was added 10 minutes before simulated 
hypoxic treatment.
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Enhancement of induction of CT-1 expression by Ucn was blocked when a-helical CRH, 
which blocks Ucn binding to its receptor, was added (figure 5.1c).
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Figure 5.1c. RNA slot blot to show levels of CT-1 mRNA in cardiac 
cells in control cells (C), or in cellstreated with Urocortin 
(Ucn) and/or a-helical CRH (a-h) (10’7M). a-helical CRH was added 
10 minutes before Ucn (107M)
Interestingly, a similar inhibition of CT-1 induction was also observed when a-helical 
CRH was added during simulated hypoxia (figure 5.1b). These results suggest that Ucn 
may mediate induction of CT-1 by hypoxia. Ucn mRNA expression increases during 
simulated hypoxia or simulated ischaemia (Okosi et al, 1998; Brar et al, 1999) and may 
mediate the induction of CT-1 by simulated hypoxia.
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5.2Urocortin induces enhancement of CT-1 protein
In order to confirm that the enhanced CT-1 mRNA levels induced by Ucn were paralleled 
at the protein level, assays of CT-1 were carried out to detect levels of CT-1 protein in the 
medium of cells treated with Ucn or left untreated (figure 5.2).
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Figure 5.2 CT-1 level in the medium of cardiac myocytes exposed to 
indicated treatment. Values are the mean of 5 determinations carried 
out in duplicate ,whose standard error is shown by the bars.
Single Factor ANOVA showedsignificant differences between 
groups, P<0.0001. Post-hoc Bonferroni tests were performed between 
pairs of data, with a significance level of P<0.05 Control.
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In these experiments, cells that were treated with Ucn clearly showed increase in CT-1 
protein, although this effect was not as dramatic as observed at the mRNA level. 
Interestingly, an increase in CT-1 protein was also observed when cells were exposed to 
hypoxia/re-oxygenation. Moreover, the CT-1 levels in cells exposed to hypoxia and also 
treated with Ucn were higher than those in cells exposed to either treatment alone. The 
CT -1 protein detected in supernatants was significantly different across the four conditions 
tested (P<0.008). CT-1 levels in Ucn and hypoxia treated supernatants were significantly 
elevated compared to control cells (P<0.003), although the elevation with either Ucn or 
hypoxia alone did not reach significance (P<0.06). These results therefore demonstrate 
that treatment of cardiac cells with Ucn results in enhanced CT-1 mRNA levels and 
increased CT-1 protein levels.
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5.3 Ucn activates the CT-1 gene promoter
In the following experiments, it was investigated whether the enhanced CT-1 mRNA and 
protein levels induced by Ucn were produced by activation of the CT-1 gene promoter by 
Ucn. In order to do this, a reporter construct in which the CT-1 promoter (from -99 to 
+ 19) relative to the transcriptional start site) was fused to the luciferase reporter gene was 
used (Funamoto et al., 2000). This construct was transfected into neonatal cardiac 
myocytes and the response to various stimuli of this promoter construct was tested, for 
example, with CT-1 or Ucn in the presence or absence of hypoxia (figure 5.3).
m  No Treatment CH Hypoxia
Figure 5.3 Activity of the wild type CT-1 promoter-luciferase reporter construct 
following transfection into cardiac myocytes and subsequent exposure to indicated 
treatment. Values are the mean of 6 determinations (corrected to Renilla) whose 
standard error is shown by the bars. Single Factor ANOVA was carried out and 
showed significant differences between treatment groups (P<0.0001). Post-hoc 
Bonferroni tests were carried out and significance levels compared to control 
are depicted as follows: *<0.05, **<0.01, ***<0.0001.
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This construct showed a two-fold response to hypoxia, paralleling the response at the 
mRNA level and protein level. Interestingly, this promoter was not responsive to CT-1 
itself, however, it showed a two-fold activation upon treatment with Ucn. In addition, a 
stronger induction of approximately three-fold relative to control was observed in cells that 
were treated with Ucn and also exposed to hypoxia. These results demonstrate, therefore, 
that the response of CT-1 mRNA and protein levels to Ucn are paralleled by activation of 
the promoter, indicating that Ucn treatment has a direct effect on the CT-1 promoter 
activity rather than, for example, stabilising the CT-1 mRNA, leading to enhanced mRNA 
and protein levels.
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5,4 The C/EBPp transcription factor binding site is required 
lor CT-1 promoter activity induced bv Ucn
Previous studies have localised a number of transcription factor binding sites within the 
CT-1 promoter, one of which mediates its induction by norepinephrine for example 
(Funamoto et al, 2000;Erdmann et al, 1998). However, all of these binding sites are 
located upstream of the region of the promoter which has been shown to confer 
responsiveness to Ucn onto a heterologous gene. Upon examination of this sequence 
(Figure 5.4a) using the Transfac 4.0 program, a potential binding site for the C/EBPp/NF- 
IL6 transcription factor was identified (Figure 5.4b).
-99 c tg a a c ta tg  a ttg g ccg a g  cccgagccac  gcccctagcc c t t tc c c c c t  t t t t c c c c c t  
g a c ttg a ta c  ta a ccg g ctc  g g g ctcg g tg  cggggatcgg  gaaaggggga aaaaggggga
t t t t c c c c c t  c c c c t c c t c c  t c c c c c g g a g  g g g tgtgt tg aggaacctgg  
aaaaggggga ggggaggagg agggggcc tc cccskcacaac t cc t t g  gacc
a t a a g c c t g g  g g c c a g c a t g  ag +19  
t a t t c g g a c c c c g g t c g t a c  tc
Figure 5.4a CT-1 minimal promoter sequence with the 
C/EBPp transcription factor binding site in italics.
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V$TCFll 01 } 1 ( — 1 1 0.807 I 0.873 ATCAtagttcaga
V$NFY 01 1 6 {-) I 1.000 I 0.965 ctcggCCAAtcatagt
fc'V$NFY_C I 8 (+) 1 1.000 I 0.875 tatgATTGGccgag
V$NFY 06 1 9 (-> f 1.000 1 0.940 cggCCAAtcat
V$CAAT 01 1 10 (-) t 1.0Q0 f 0.972 ctcggCCAAtca
tV$NFl 06 1 11 (+) ) 1.000 } 0.931 gatTGGCcgagcccgagc
V$NF1 06 ! 16 (-) j 1.000 i 0.854 gcgTGGCtcgggctcggc
V$GC 01 [ 25 ( - )  1 1.000 1 0.900 taggGGCGtggctc
V$AHRARNT 01 1 26 ( - )  } 1.000 I 0.869 ggctaggggCGTGgct
V?SP1_Q6 I 26 (~) I 1.0Q0 1 0.854 taggGGCGtggct
V$NFAT 06 f 40 (-} j 1.000 I 0.907 aggggGAAAggg
v m . i _ . o i } 40 (-) | 1.000 } 0.863 aaggGGGAaaggg
V$GKLF 01 i 40 (") 1 1.000 I 0.939 aaagggggaaAGGG
V$GKLF 01 1 41 {-) | 0.937 I 0.918 aaaagggggaAAGG
V$IK2 01 I 41 M  1 1.000 1 0.906 aaggGGGAaagg
V$MZF1 01 1 45 {-) | 1.000 I 0.969 aagGGGGa
V$GKLF 01 \ 46 {-) ! 0.951 I 0.879 ggggaaaaagGGGG
V$GKLF 01 1 47 ( - )  ; 0.951 I 0.888 gggggaaaaaGGGG
V$GKLF_01 1 48 {-) | 1.000 \ 0.890 agggggaaaaAGGG
V$GKLF 01 1 49 (-) 1 0.937 I 0.863 gagggggaaaAAGG
V$NFAT 06 1 50 (-) i 1.000 f 0.948 aggggGAAAaag
V$IK1 01 I 50 1.000 1 0-871 gaggGGGAaaaag
V$IK2 01 1 51 (-) | 1.000 1 0.918 gaggGGGAaaaa
V$GC 01 1 54 ( - )  ( 0.877 I 0.890 gaggGGAGggggaa
V$MZiT..01 I 55 ( - )  1 1.000 ! 0.965 gagGGGGa •«
V$SP1 06 1 55 I 0.845 I 0.902 gaggGGAGgggga
V$GKLF 01 1 57 ( - )  | 0.951 I 0.897 gaggaggggaGGGG
V$IK2 01 i 57 ( - )  | 1.000 1 0.863 ggagGGGAgggg
Y£GKLF_01 1 58 (-1 ( 1.000 I 0.892 ggaggaggggAGGG
V$MZF1 01 1 61 {-} | 1.000 { 0.982 ggaGGGGa
V$GKLF 01 1 62 ( - )  1 0.951 I 0.864 gggaggaggaGGGG
V$GKLF 01 1 63 ( - )  J i .oocf I 0.853 ggggaggaggAGGG
V$GC 01 I 65 ( - )  1 0. 877 | 0.872 cgggGGAGgaggag
V$SP1 06 I 66 (~d 1 0.845 1 0.870 cgggGGAGgagga
V$IK2 01 I 68 {-) | 1.000 ! 0.865 ccggGGGAggag
V$MZF1 01 1 72 (~) 1 1.000 t 0.953 ccgGGGGa
«r¥$AF2 06 1\ t J i "*■/ t 7 nAA J- * vuu i A nr r| U * OJO ccCCCGgagggg
«V$CETS1P54 01 1 75 (+) 1 1.000 1 0.893 ccCGGAgggg__
rV$CEBPB 01 1 86 (+) 1 0.873 I 0.924 qta.ttj^ aGGAAC.Ct ">
|V$GATA1 03 1 96 (+) 1 1.000 t 0.944 a cc t gwTAagce t
*V$GATA1 02 1 96 (+) 1 1.000 I 0.927 acctgGATAagcct
tV$GATAl 04 1 97 <+) 1 1.000 f 0.917 cctgGATAagcct
‘V$GATA3 02 1 98 (+> | 1.000 J 0.859 ctgGATAagc
fV$GATA2 02 1 98 (+} 1 1.000 I 0.919 ctgGATAagc
rV$GATAl 06 1 98 1+) j 1.000 f 0.887 ctgGATAagc
;V$GATA1 05 { 98 (+1 \ 1.000 I 0.892 ctgGATAagc
>V$LM02C0M 02 1 99 (+) | 1.000 1 0.927 tgGATAagc
#V$GATA C 1 100 {+) 1 1.000 I 0.969 gGATAAgcctg
-V$NF1_Q6 1 102 ( - )  t 1.000 I 0.875 tgcTGGCcccaggcttat
V$CP2 01 I 108 (—) i 1.000 I 0.853 gctggccCCAG
Figure 5.4b Analysis of the CT-1 minimal promoter sequence (-99 to
+19) for potential transcription factor binding sites using the
Matlnspector V2.2 based on TRANSFAC 4.0
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The C/EBPp transcription factor binding site was chosen in this study since previous 
studies have shown that simulated ischaemia can increase C/EBP transcription factor 
expression in cardiomyocytes (Yan et al., 1997). Moreover, cardioprotective effects of 
CT-1 are mediated via MAPKinases and C/EBPp/NFIL-6 (Sheng et al., 1997). In 
addition, NFIL-6/C/EBPp is a potent transactivator of the CRH gene in neuronal cells and 
lymphoblastoid cells (Stephanou et al., 1997). Brar et al (1999) have shown that simulated 
ischaemia increases expression of urocortin mRNA partly through increased expression of 
C/EBP transactivators (Brar et al., 1999). Therefore, in order to investigate whether the 
C/EBPP/NF-IL6 transcription factor binding site is required, the CT-1 promoter/luciferase 
reported construct was transfected together with expression vector encoding the wild type 
C/EBPp/NF-IL6 or a dominant negative mutant of C/EBPp/NF-IL6 (Figure 5.5).
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Figure 5.5 Activity of the wild type CT-1 promoter-luciferase reporter construct 
following co-transfection into cardiac myocytes with empty expression vector 
or the same vector expressing wild type or dominant negative (dn) C/EBPp and 
exposure to the indicated treatment. Values are the mean of 
6 determinations whose standard error is shown by the bars. Single Factor 
ANOVA was carried out and showed significant differences between 
treatment groups (PcO.OOOl). Post-hoc Bonferroni tests were carried out 
and significance levels compared to control are depicted as follows:
*<0.05, **<0.01, ***<0.0001.
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In these experiments, wild type C/EBPJ3/NF-IL6 produced a small enhancement of CT-1 
promoter activity both in the absence and presence of Ucn. Interestingly, transfection of 
dominant negative C/EBPp/NF-IL6 reduced the basal activity of the CT-1 promoter, and 
its induction by Ucn. These results demonstrate that inhibition of C/EBPp/NF-IL6 with a 
dominant negative C/EBPP mutant can block the response of the CT-1 promoter to Ucn, 
and that C/EBPp is therefore likely to be required for this effect.
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5.5 Inactivation of the C/EBPp/NF-IL6 transcription factor 
binding site does not reduce CT-1 promoter activity in response 
to Ucn
Since the previous experiments demonstrated that the C/EBP(3/NF-IL6 transcription factor 
binding site was important for activation of the CT-1 promoter, the next set of experiments 
were carried out to investigate whether mutation of this binding site would reduce the 
activity of the CT-1 promoter in response to Ucn. Therefore, four mutations were 
introduced into the C/EBPp binding site by site directed mutagenesis (figure 5.6), and this 
promoter construct was co-transfected into cardiac myocytes with C/EBPp/NF-IL6, or 
dominant negative C/EBP (3/NF-IL6 expression vectors in the presence or absence of Ucn 
(figure 5.7).
-99 c tgaacta tg  a t tg g ccg a g  cccgagccac  gcccctagcc  c t t t c c c c c t  t t t t c c c c c t  
gact tgatac  taa ccg g c tc  gggctcggtg  cggggatcgg gaaaggggga aaaaggggga
gg cc
t t t t c c c c c t  c c c c t c c t c c  t c c c c c g g a g  g g g tgtgt tg aggaacctgg  
aaaaggggga ggggaggagg  agggggcc tc c c c acacaac tcctt  g gacc
ataagcctgg  g g c c a g c a t g  ag +19  
t a t t c g g a c c c c g g t c g t a c  tc
Figure 5.6 Sequence of CT-1 -99 to + 19 promoter region 
showing the C/EBP|3 transcription factor binding site (italics) and 
mutations (red)
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Figure 5.7 Activity of a mutant CT-1 promoter-luciferase reporter construct 
following co-transfection into cardiac myocytes with empty expression vector 
or the same vector expressing wild type or dominant negative (dn) C/EBPp and 
exposure to the indicated treatment. Values are the mean of 6 
determinations whose standard error is shown by the bars. Single Factor 
ANOVA was carried out and showed significant differences between 
treatment groups (P<0.0001). Post-hoc Bonferroni tests were carried out 
and significance levels compared to control are depicted as follows:
*<0.05, **<0.01, ***<0.0001.
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Surprisingly, this mutant CT-1 promoter was still able to respond to Ucn even in the 
absence of C/EBPp expression vector. Moreover, the CT-1 promoter was still able to 
respond to Ucn in the presence of C/EBPp. However, the response of this mutant 
promoter to Ucn could still be inhibited by dominant negative C/EBPp/NF-IL6. In 
addition, the mutant promoter was able to strongly respond to functional C/EBPP even in 
the absence of Ucn. These results demonstrate that C/EBPp/NF-IL6 is involved in CT-1 
promoter activation, but the potential binding site in the promoter is not essential for the 
response to Ucn or to C/EBPp/NF-IL6.
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5.6 Discussion
This study was carried out to investigate the induction of CT-1 expression by the 
cardioprotective agent Ucn. Findings from this study indicate that Ucn, acting via the 
C/EBPp transcription factor, is able to activate the CT-1 promoter resulting in enhanced 
CT-1 mRNA and CT-1 protein levels. In addition, C/EBPp is important in the response of 
the CT-1 promoter to Ucn because blocking its activity on both the wild-type and mutant 
promoters blocks Ucn induction, while its over-expression induces the promoter.
It is likely, therefore, that other binding sites for C/EBPp must exist in the minimal 
promoter in addition to the single C/EBPp site that was mutated because mutation of this 
site does not abolish the responsiveness to either Ucn or C/EBPp. Indeed, the stronger 
activation of the mutant compared to the wild type promoter by Ucn suggests that the 
single site that was mutated may have an inhibitory effect rather than an activating effect.
Ucn may mediate its effect on cardioprotection, at least in part, via inducing the synthesis 
of the cardioprotective CT-1 protein. This would explain the similar signaling pathways 
that are involved in cardioprotection mediated by Ucn and CT-1 despite the distinct protein 
families to which they belong (Brar et al, 2001; Liao et al, 2002; Brar et al, 2000,Sheng et 
al., 1997;Brar et al., 2001). Similarly, the need to induce CT-1 synthesis would explain 
why Ucn requires protein synthesis for its cardioprotective effect (Brar et al., 2002). In 
contrast, CT-1 itself may act by inducing, for example, post-translational modifications of 
other proteins, therefore explaining why new protein synthesis is not necessary for its 
cardioprotective effect.
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It should be noted however, that we have also identified a number of other genes whose 
expression is induced by Ucn (Lawrence et al., 2002) and some of these are likely to also 
play a role in its protective effects, which are not therefore likely to be mediated 
exclusively by CT-1. Interestingly, one of the induced genes is that for the epsilon isoform 
of PKC and this enzyme is also activated by Ucn. It is possible therefore that PKCe or 
other Ucn-activated kinases may modify C/EBP{3 and thereby activate CT-1 gene 
expression. Clearly, it would be of interest to determine the effect on the protective effect 
of Ucn, of specifically blocking activation of CT-1 by Ucn. The mechanisms discussed 
here were not investigated further due to time limitations to finish the project.
As well as responding to Ucn, the data presented here also indicates that the CT-1 is 
activated in cardiac cells exposed to simulated hypoxia/reoxygenation resulting in 
enhanced mRNA and protein levels, a-helical CRH is able to block the effect of simulated 
hypoxia on the CT-1 promoter. It is possible therefore, that Ucn also plays a role in this 
effect.
Thus, previously it has been demonstrated that Ucn is released from cardiac cells exposed 
to simulated hypoxia (Okosi et al., 1998; Brar et al., 1999). Hence, endogenous Ucn 
released in response to simulated hypoxia could be responsible for the effect of simulated 
hypoxia on the CT-1 promoter and CT-1 mRNA/protein levels.
Although further studies will be required to determine whether Ucn is indeed involved in 
the response of CT-1 to simulated hypoxia, it is clear that Ucn treatment is able to directly
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activate the CT-1 promoter in cardiac myocytes resulting in enhanced mRNA and protein 
levels of the cardioprotective agent CT-1.
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CHAPTER 6.
DISCUSSION
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CHAPTER 6. DISCUSSION
The aim of this thesis was to investigate the regulation of gene expression and survival in 
cellular stress. The results presented in Chapter 3 show that the C-terminal domain of the 
STAT-1 transcription factor is required for apoptosis induced by lethal stresses including 
heat shock and simulated ischemia.
In this study, lethal heat stress or ischemic stress caused significant cell death, with the 
effects being more severe after ischemic stress. Parental 2fTGH cells were more sensitive 
compared to their mutant counterpart U3A cells. Re-introduction of STAT-1 into the U3A 
cell line confirmed that STAT-1 was causing the sensitivity to stress since STAT-1 
transfected U3A cells became more sensitive to stress compared to untransfected U3A 
cells. This effect is in agreement with other work in our laboratory (Stephanou et al., 
2002).
The U3A cell line was ideal to study effects of STAT-1 since no functional STAT-1 was 
present in this cell line. Thus, comparison of STAT-1 with STAT-3 showed that indeed 
the enhanced apoptotic effects that were observed were due to the presence of STAT-1. 
STAT-3 transfected U3A cells were more resistant to stress, suggesting that STAT-3 has 
an anti-apoptotic function compared to STAT-1 (Bromberg et al., 1999; Ram et al., 2000). 
Effects of chimeras containing different regions of STAT-1 and STAT-3 indicated that the 
N-terminal domain of STAT-1 was dispensable for the apoptotic effects observed. Other 
studies have shown that the N-terminal domain is required for interactions with other 
proteins (Zhang et al., 1996); however, in this case, stress-induced apoptosis does not
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require an N-terminal domain. The DNA binding domain of STAT-1 was also dispensable 
lor the apoptotic effects observed as demonstrated using STAT-l/STAT-3 chimeras. 
Moreover, this is the first demonstration that even the isolated C-terminal domain of 
STAT-1 can cause apoptosis in the absence of the DNA binding domain.
STAT-1 is known to interact with other regulatory proteins such as CBP, BRCA1, and the 
chromatin remodelling factor MCM5 (Zhang et al., 1996; Ouchi et al., 2000; Zhang et al 
1998). Moreover, serine phosphorylation of STAT-1 has been shown to be critical for its 
ability to interact with such molecules (Da Fonesca et al., 2001; Ouchi et al., 2000) and it 
is possible that the C-terminal domain of STAT-1 requires interaction with other pro- 
apoptotic regulatory factors to mediate its apoptotic effects.
Recent studies have shown that STAT-1 is cleaved at position 694 by caspase 3, leading to 
release of the C-terminal fragment of STAT-1, which may be required for down-regulating 
cellular responses to cell death (King and Goodboum, 1998). However, in this thesis, a 
mutation at the caspase cleavage site of STAT-1 did not have any preventative effect on 
apoptosis, and would suggest that cleavage of STAT-1 to release a free C-terminal 
fragment is not essential for stress-induced apoptosis and hence the C-terminal domain can 
produce apoptotic effects either within an intact molecule or as an isolated domain 
produced artificially or naturally by caspase cleavage in the cell type studied.
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IFNy or ischemic treatment of cardiac cells leads to induction of caspase-1 and fas/fasL 
gene expression, and this is dependent upon STAT-1 activation. Also, over expression of 
STAT-1 inhibits expression of antiapoptotic BC12 and BCLX, whereas STAT-3 enhances 
expression of these anti-apoptotic genes (Stephanou et al., 2000a). It is possible that if 
pro-apoptotic signals outweigh anti-apoptotic signals, then STAT-1 may intervene to make 
sure that the cell undergoes apoptosis, and also to make sure that the commitment phase of 
apoptosis is irreversible.
In past studies it has been shown that IFNy activated apoptosis and caspase activation is 
dependent upon STAT-1 and is defective in STAT-1 deficient U3A cells (Chin et al.,
1997). It is possible that a full length STAT-1 molecule is involved in upstream caspase 
activation, resulting in cleavage of STAT-1 at the same time as caspase cleavage. 
Cleavage of STAT-1 results in the release of the C-terminal trans-activating domain (TAD) 
and also the N-terminal domain containing the DNA binding domain. Release of the 
STAT-1 TAD could lead to its interaction with other factors containing a DNA binding 
domain required for activation of pro-apoptotic genes and perpetuation and amplification 
of the apoptotic signal. Such an explanation is plausible, since STAT-1 is known to have 
its potent apoptotic effect in later stages of apoptosis in cardiac cells exposed to 
ischaemia/reperfusion (Stephanou et al., 2002). The remaining N-terminal domain could 
behave as a negative regulator of full length STAT-1 or even anti-apoptotic genes or 
survival pathways that may be down-regulated during apoptosis (Figure 6.1).
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Figure 6.1 Possible Mechanism of the STAT-1 C-terminal TAD Leading to 
Apoptosis
It is likely that STAT-1 exerts its effects at various levels of the apoptotic pathway to 
ensure that cell survival is not possible. In a recent study by Townsend (2003) STAT-1 
has also been shown to interact with the important tumour suppressor p53. Interestingly, 
this interaction requires the C-terminal domain of STAT-1, which is critical for its 
apoptotic effect in response to stress (Townsend et al., 2003). Therefore, STAT-1 behaves 
as a negative regulator of cell proliferation and displays tumour suppressor qualities like 
p53.
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The results presented in chapter 3 therefore, show a novel mechanism for stress-induced 
apoptosis by STAT-1, and demonstrates that the C-terminal domain is sufficient and 
necessary for the effects observed.
Hsps are required for cell protection against stress, and predominantly act as negative 
regulators of the apoptotic pathway. Although Hsp27 and Hsp70 have not been studied in 
this thesis, the information obtained from other studies show that these two proteins have 
anti-apoptotic properties in the cell death pathway, since over expression in tumour cells 
increases their tumourigenicity (Garrido et al., 19981 Bruey et al., 2000), and can protect 
against apoptosis induced by hyperthermia, oxidative stress, Fas death receptor ligation, 
and cytotoxic drugs (Garrido et al., 1998; Garrido et al., 1996; Mehlen et al., 1996). Hsp27 
may prevent activation of pro-caspase-9 and pro-caspase-3 (Garrido et al., 1997) by 
interaction with cytochrome c (Bruey et al., 2000). Hsp70 reduces or blocks caspase 
activation to suppress mitochondrial damage and nuclear fragmentation (Buzzard et al.,
1998). Hsp70 also inhibits apoptosis downstream of the release of cytochrome c and 
upstream of caspase-3 activation (Li et al., 2000). In addition, Hsp70 also prevents 
recruitment of procaspase- 9 to the apoptosome by binding directly to APAF-1 (Saleh et 
al., 2000; Beere et al., 2000).
Hsp90 appears to display pro-apoptotic as well as anti-apoptotic characteristics. Over - 
expression of Hsp90 in U937 cells increases the rate of apoptosis upon TNFa induction 
(Galea-Lauri et al., 1996). However, Hsp90 can directly bind to APAF-1 to inhibit its
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oligomerisation and further recruitment of procaspase-9 (Pandey et al., 2000). Therefore, 
it appears that the role of Hsp90 in the apoptotic pathway could be dependent on the type 
of stimulus that the cell is subjected to. In this thesis it seems that if STAT-1 is activated 
then the likely path that Hsp90 will activate would be that of a pro-apoptotic nature rather 
than an anti-apoptotic one. It is possible that the STAT-1/HSF-1 interaction observed by 
Stephanou et al. (1999) could be required for this effect. If this is the case, then it would 
be interesting to know whether the C-terminal construct of STAT-1 used in chapter 3 (691- 
750) could also activate Hsp90 promoter activity.
Previous work in our laboratory has shown that cytokines as well as stress can induce 
expression of Hsps. For example, IL-6 can induce expression of HSp90p in hepatoma 
cells and also in peripheral blood mononuclear cells (Stephanou et al., 1997; Stephanou et 
al., 1998). IL-6 is a multifunctional cytokine with pleiotropic activities on various cell 
types (Akira et al., 1992). This property of IL-6 is dependent upon the IL-6 receptor and 
the receptor subunit gpl30 that is shared among other cytokine receptors belonging to the 
IL-6 receptor super family (LIF, IL-11, OM, CT-1) (Kishimoto et al., 1995).IL-6 
stimulation leads to activation of STAT-3 and also C/EBPp (Stephanou et al., 1998). 
STAT-3 and C/EBP(3 have been shown to interact differentially with HSF-1 (Stephanou et 
al., 1998).
IFNy has antiviral and antitumour properties by inducing specific INF-y dependent genes, 
one of which is Hsp90p (Darnell et al.„ 1994; Schindler and Darnell, 1994). IFN-y 
induces expression of Hsp90|3 directly via activation of STAT-1 (Stephanou et al., 1999).
203
Interestingly, in this study STAT-1 and HSF-1 were found to interact directly via protein- 
protein interaction (Stephanou et al., 1999). Therefore, the effects of IFNy and also IFNa 
on the Hsp90p promoter were investigated in chapter 4.
IFNy alone can activate Hsp90p gene expression, but in the presence of heat shock, 
Hsp90|3 promoter activity is enhanced further. IFNa was also able to activate the Hsp90p 
promoter but the effect was much lower compared to IFNy. These results suggest that 
although differences in activation of STATs are apparent, both IFNs are able to activate the 
Hsp90(3 promoter directly with the effect of IFNy being more potent than IFNa and that in 
some cell types the pattern of Hsp90p expression is different to other cell types. 
Hypothetically, STAT-l/STAT-2 dimers activated by IFNa may have a negative effect on 
the Hsp90p promoter in the presence of IFNy in HepG2 cells. It has been demonstrated in 
other studies that STAT-2 contains a highly potent transcriptional activation domain at the 
C-terminal region which could lead to STAT-2 being more dominant over STAT-1 in 
interferon-a-induced interferon stimulated gene factor-3 (ISGF-3) mediated antiviral and 
antiproliferative effects of IFNa (Bromberg et al., 1996; Horvath and Darnell, 1996). 
Therefore it is possible that for this reason, STAT-l/STAT-2 dimers predominantly reduce 
activity of Hsp90p by competing for STAT binding sites within Hsp90p promoter, and 
also interaction with HSF-1. It would be interesting to investigate the heterodimer 
interaction with HSF-1.
Both IFNa and IFNy are multifunctional and elicit many biological responses from target 
cells, and are also capable of inducing many unique responses (Stark et al., 1998). The
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II Ns display overlapping pathways leading to transcriptional regulation of different sets of 
genes with overlap of functions (Der et al., 1998). Further work would need to be carried 
out to investigate similar responses with other Hsps.
Other cytokines and hormones have been shown to induce Hsps and also activate STATs 
lor their effects on cells. CT-1, a member of the IL-6 family of cytokines, induces Hsp70 
and Hsp90 in cardiac cells (Latchman, 1998). Hypertrophic effects of CT-1 are mediated 
via activation of STAT-3 (Railson et al., 2002). CT-1 protection is achieved via the 
p42/p44 MAPKinase pathway, and this has also been observed for Ucn, a peptide hormone 
which mediates the endocrine response to stress (Sheng et al., 1997; Brar et al., 2000; Chen 
et al.,1993).
The work presented in chapter 5 showed that the cardioprotective agent Ucn was able to 
induce expression of another cardioprotective agent CT-1. Such studies are of 
considerable importance in understanding protective mechanisms that are activated due to 
hypoxic stress followed by reperfusion and an ultimate modulation for therapeutic benefit.
CT-1 and Ucn have been previously identified to be protective agents and can protect the 
heart against damaging effects of cardiac ischemia/reperfusion (Brar et al., 2001; Liao et 
al., 2002; Brar et al., 2000). Both agents protect by activating the p42/p44 MAPK 
pathway. Dominant negative mutants of the p42/p44 enzymes inhibit the protective effects 
by these two proteins (Sheng et al., 1997).
205
All hough CT-1 and Ucn belong to different protein families, in this chapter, the results 
demonstrated that CT-1 expression was induced by Ucn. Time course experiments of CT- 
1 expression in Ucn treated cells showed that CT-1 expression was more apparent at 16 
hours-24 hours. This suggests that CT-1 expression is not instant and rapid and it is 
probable that at this time point CT-1 is more important in exerting its protective effects.
The results in chapter 5 also indicate that CT-1 is activated in cardiac cells exposed to 
hypoxia/reoxygenation, resulting in enhanced CT-1 mRNA and protein levels. It is 
possible; however, that Ucn plays a role in mediating this effect. Previous studies in our 
laboratory have demonstrated that Ucn is released from cardiac cells exposed to hypoxia 
(Okosi et al., 1998; Brar et al., 1999). Endogenous Ucn released in response to hypoxia 
could be responsible for the effect of hypoxia on the CT-1 promoter and CT-1 mRNA and 
protein levels. It is clear that Ucn treatment is able to directly activate the CT-1 promoter, 
resulting in enhanced mRNA and protein levels of cardioprotective CT-1. Further studies 
would require determining whether Ucn is involved in the response to hypoxia since 
exposure of cells to hypoxia/reoxygenation leads to enhanced CT-1 levels which could be 
blocked by a  helical CRH. Furthermore, a  helical CRH also blocked enhanced CT-1 
levels in Ucn treated cells under hypoxic conditions (Okosi et al., 1998; Brar et al., 1999).
An enhanced level of CT-1 was also detected in the media of Ucn and hypoxia treated 
cells, suggesting that Ucn enhances mRNA levels and protein levels of CT-1. To our 
knowledge, this is a novel effect by which Ucn is able to induce expression of CT-1. Ucn 
also has a direct effect on the CT-1 promoter rather than stabilising CT-1 mRNA. In
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addition, Ucn induced CT-1 expression is mediated, in part, by C/EBPp. C/EBPp is 
known to be activated by CT-1 and other members of the IL-6 family of cytokines 
(Nakajima et al., 1993). Dominant negative C/EBPp has a negative effect on the CT-1 
promoter, suggesting that the effect of Ucn on the CT-1 promoter requires activation of 
C/EBPp.
Mutation of the C/EBPp site does not block activation of CT-1 by Ucn therefore, is likely 
that other transcription factor binding sites must exist in the minimal CT-1 promoter that 
are required for the effect observed. Cardio-protective effects of Ucn may be mediated by 
inducing synthesis of CT-1, which would explain the similar signalling pathways involved 
in cardio-protection by these different factors (Sheng et al., 1997; Brar et al., 2001). 
Induction of CT-1 by Ucn could lead to induction of other cell protective proteins; for 
example, Ucn can increase expression of Hsp90 protein. Synthesis required for protection 
of cardiac cells by Ucn, which could be due to a need to induce CT-1 protein (Brar et al., 
2002). Interestingly, Ucn also induces expression of the K a t p  channel gene to mediate its 
cardioprotective effect (Lawrence et al., 2002). The gene for PKCc , also activated by 
Ucn, could modify C/EBPp and activate CT-1 expression. It would be interesting to 
determine whether blocking PKCs can block the effect of Ucn on CT-1.
The work presented in this thesis opens up new and interesting avenues for research. In 
particular, an investigation of the interaction of other proteins with STAT-1 could be of 
interest since the mechanism could be targeted for therapeutic purposes. The effect of the
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C-terminal domain of STAT-1 presented here highlights a potentially important role for 
this protein in understanding the mechanism of apoptotic cell death.
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6.1 Future W ork
The work presented here opens up many questions about the events that take place when 
cells are exposed to stress. In chapter 3, the role of the STAT-1 transcription factor in 
stress-induced apoptosis led to the conclusion that other factors that contain DNA binding 
domains are likely to be involved in apoptotic processes that require the C-terminal 
activation domain of STAT-1. With these factors acting by recruiting STAT-1 to the DNA 
the next step in this project is to unravel which factors may interact with STAT-1 in a pro- 
apoptotic manner, and can be achieved by mapping the candidate promoter region needed 
for a STAT-1 response and ideally the DNA binding function. Protein-protein interaction 
studies (in vitro) can also be carried out to see whether STAT-1 interacts with candidate 
pro-apoptotic transcription factors.
In the IFN study, there was no conclusive evidence that STAT-1 was required for Hsp90 
induction, and this could not be studied further due to time restrictions. However, further 
experiments would involve transfection studies ie, to re-introduce STAT-1 into the U3A 
cell line (which lacks functional STAT-1) with Hsp90 promoter constructs and subject 
transfected cells to IFN and heat shock treatments as carried out in this thesis. In addition, 
the effect at the protein level in these cells would be tested by Western blotting. It would 
also be of importance to extend the study to other Hsps including Hsp70, Hsp47 and 
Hsp27 as this has not been tested so far. The interaction of the STAT-l/STAT-2 
heterodimer with HSF-1 needs to be investigated, and can be achieved by protein protein 
interaction in vitro.
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Further experiments for Ucn induced CT-1 activity would also be required. This thesis 
demonstrated that other transcription factor binding sites are present in the minimal CT-1 
promoter as well as the binding site for C/EBPp. It would be necessary to further 
investigate the C/EBPp transcription factor binding site within the CT-1 minimal promoter 
and to test whether C/EBPp binds elsewhere in the promoter. In this thesis only four 
mutations were made in this site (2x thymine to guanine, and 2x adenine to cytosine). 
Therefore, further site directed mutagenesis of this binding site is required. In addition, it 
would be of importance to also mutate amino acid residues of other transcription factor 
binding sites in the CT-1 promoter by site directed mutagenesis to determine whether they 
are also involved in activating the CT-1 promoter in response to Ucn.
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